documents incorporated reference document part proxy statement annual meeting shareholders held may filed part iii securities exchange commission within days close fiscal year covered reporttable contents table contents part item business item risk factors cautionary factors may affect future results item b unresolved staff comments item properties item legal proceedings item mine safety disclosures executive officers registrant part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data afinancial statements notes consolidated financial statements report independent registered public accounting firm bsupplementary data item changes disagreements accountants accounting financial disclosure item controls procedures managements report item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules item summary signatures table contents part item business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include four operating segments pharmaceutical animal health healthcare services alliances segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities animal health segment discovers develops manufactures markets animal health products including pharmaceutical vaccine products prevention treatment control disease major livestock companion animal species company sells veterinarians distributors animal producers healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients alliances segment primarily includes results companys relationship astrazeneca lp related sales nexium prilosec concluded company incorporated new jersey product service marks appearing type form different surrounding text trademarks service marks owned licensed promoted distributed merck subsidiaries affiliates except noted trademarks services marks respective owners product sales total company sales including sales companys top pharmaceutical products well sales animal health products follows millions total sales pharmaceutical keytruda januviajanumet gardasilgardasil proquadmmr iivarivax zetiavytorin isentressisentress hd bridion pneumovax nuvaring simponi animal health livestock companion animals revenues revenues primarily comprised healthcare services segment revenue thirdparty manufacturing sales miscellaneous corporate revenues including revenue hedging activities table contents pharmaceutical pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders human health vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices certain products within companys franchises follows oncology keytruda pembrolizumab companys antipd programmed death receptor therapy monotherapy treatment certain patients nonsmallcell lung cancer nsclc melanoma classical hodgkin lymphoma chl urothelial carcinoma head neck squamous cell carcinoma hnscc gastric gastroesophageal junction adenocarcinoma microsatellite instabilityhigh msih mismatch repair deficient cancer combination chemotherapy certain patients nsclc keytruda also used united states monotherapy treatment certain patients cervical cancer primary mediastinal large bcell lymphoma pmbcl hepatocellular carcinoma merkel cell carcinoma combination chemotherapy patients squamous nsclc emend aprepitant prevention chemotherapyinduced postoperative nausea vomiting temodar temozolomide marketed temodal outside united states treatment certain types brain tumors addition company recognizes alliance revenue related sales lynparza olaparib oral poly adpribose polymerase parp inhibitor certain types ovarian breast cancer lenvima lenvatinib certain types thyroid cancer hepatocellular carcinoma combination certain patients renal cell carcinoma vaccines gardasil human papillomavirus quadrivalent types vaccine recombinantgardasil human papillomavirus valent vaccine recombinant vaccines help prevent certain diseases caused certain types human papillomavirus hpv proquad measles mumps rubella varicella virus vaccine live pediatric combination vaccine help protect measles mumps rubella varicella mmr ii measles mumps rubella virus vaccine live vaccine help prevent measles mumps rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infants children zostavax zoster vaccine live vaccine help prevent shingles herpes zoster hospital acute care bridion sugammadex injection medication reversal two types neuromuscular blocking agents used surgery noxafil posaconazole prevention invasive fungal infections invanz ertapenem sodium treatment certain infections cubicin daptomycin injection iv antibiotic complicated skin skin structure infections bacteremia caused designated susceptible organisms cancidas caspofungin acetate antifungal product primaxin imipenem cilastatin sodium antibacterial product zerbaxa ceftolozane tazobactam currently approved united states treatment adult patients complicated urinary tract infections caused certain susceptible gramnegative microorganisms also indicated combination metronidazole treatment adult patients complicated intraabdominal infections caused certain susceptible gramnegative grampositive microorganisms immunology simponi golimumab oncemonthly subcutaneous treatment certain inflammatory diseases remicade infliximab treatment inflammatory diseases company markets europe russia turkey neuroscience belsomra suvorexant orexin receptor antagonist indicated treatment insomnia characterized difficulties sleep onset andor sleep maintenance virology isentressisentress hd raltegravir hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection zepatier elbasvir grazoprevir treatment adult patients chronic hepatitis c virus hcv genotype gt gt infection ribavirin certain patient populations table contents cardiovascular zetia ezetimibe marketed ezetrol countries outside united states vytorin ezetimibesimvastatin marketed inegy outside united states atozet ezetimibe atorvastatin marketed certain countries outside united states rosuzet ezetimibe rosuvastatin marketed certain countries outside united states cholesterol modifying medicines adempas riociguat cardiovascular drug treatment pulmonary arterial hypertension diabetes januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabetes womens health nuvaring etonogestrelethinyl estradiol vaginal ring vaginal contraceptive product implanon etonogestrel implant singlerod subdermal contraceptive implantnexplanon etonogestrel implant single radiopaque rodshaped subdermal contraceptive implant animal health animal health segment discovers develops manufactures markets animal health products including pharmaceutical vaccine products prevention treatment control disease major livestock companion animal species principal products segment include livestock products nuflor florfenicol antibiotic range use cattle swine bovilisvista vaccine lines infectious diseases cattle banamine flunixin meglumine bovine swine antiinflammatory estrumate cloprostenol sodium treatment fertility disorders cattle matrix altrenogest fertility management swine resflor florfenicol flunixin meglumine combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zuprevo tildipirosin bovine respiratory disease zilmax zilpaterol hydrochloride revalor trenbolone acetate estradiol improve production efficiencies beef cattle safeguard fenbendazole dewormer cattle mpac mycoplasma hyopneumoniae bacterin swine pneumonia vaccine porcilis lawsonia intracellularis baterin circumvent porcine circovirus vaccine type killed baculovirus vector vaccine lines infectious diseases swine nobilisinnovax live mareks disease vector vaccine lines poultry paracox coccivac coccidiosis vaccines exzolt systemic treatment poultry red mite infestations slice emamectin benzoate parasiticide sea lice salmon aquavac avirulent live culturenorvax vaccines bacterial viral disease fish compact pd vaccine salmon aquaflor florfenicol antibiotic farmraised fish companion animal products bravecto fluralaner line oral topical products kills fleas ticks dogs cats weeks nobivac vaccine lines flexible dog cat vaccination otomax gentamicin sulfate usp betamethasone valerate usp clotrimazole usp ointmentmometamax gentamicin sulfate usp mometasone furoate monohydrate clotrimazole usp otic suspensionposatex orbifloxacin mometasone furoate monohydrate posaconazole suspension ear ointments acute chronic otitis caninsulinvetsulin porcine insulin zinc suspension diabetes mellitus treatment dogs cats panacur fenbendazolesafeguard fenbendazole broadspectrum anthelmintic dewormer use many animals regumate altrenogest fertility management horses prestige vaccine line horses scalibor deltamethrinexspot protecting bites fleas ticks mosquitoes sandflies discussion sales companys products see item managements discussion analysis financial condition results operations table contents product approvals set forth summary significant product approvals received company product date approval japanese ministry health labor welfare jmhlw approved keytruda three expanded uses december unresectable advanced recurrent nsclc one malignant melanoma well new indication high microsatellite instability solid tumors us food drug administration fda approved keytruda treatment adult pediatric december patients recurrent locally advanced metastatic merkel cell carcinoma european commission ec approved keytruda adjuvant treatment adults stage iii december melanoma lymph node involvement undergone complete resection fda approved keytruda treatment patients hepatocellular carcinoma november previously treated sorafenib fda approved keytruda combination carboplatin either paclitaxel nabpaclitaxel first october line treatment patients metastatic squamous nonsmall cell lung cancer nsclc ec approved keytruda combination pemetrexed platinum chemotherapy firstline september treatment metastatic nonsquamous nsclc adults whose tumors egfr alk positive keytruda mutations ec approved keytruda treatment recurrent metastatic head neck squamous cell carcinoma september hnscc adults whose tumors express pdl tps progressing platinum containing chemotherapy fda approved keytruda combination pemetrexed platinum chemotherapy firstline august treatment metastatic nonsquamous nsclc patients egfr alk genomic tumor aberrations china national drug administration cnda approved keytruda treatment adult patients july unresectable metastatic melanoma following failure one prior line therapy june fda approved keytruda treatment adult pediatric patients refractory primary mediastinal large bcell lymphoma pmbcl relapsed two prior lines therapy fda approved keytruda treatment patients recurrent metastatic cervical cancer june disease progression chemotherapy whose tumors express pdl determined fda approved test fda approved lynparza use maintenance treatment certain patients advanced ovarian december fallopian tube primary peritoneal cancer complete partial response firstline platinum based chemotherapy july jmhlw approved lynparza use patients unresectable recurrent brcamutated human epidermal growth factor receptor hernegative breast cancer received prior chemotherapy lynparza ec approved lynparza use maintenance therapy patients platinumsensitive relapsed high may grade epithelial ovarian fallopian tube primary peritoneal cancer response complete partial platinum based chemotherapy regardless brca mutation status fda approved lynparza use patients brcamutated hernegative metastatic breast cancer january previously treated chemotherapy january jmhlw approved lynparza use maintenance therapy patients platinumsensitive relapsed ovarian cancer regardless brca mutation status table contents september cnda approved lenvima treatment certain patients hepatocellular carcinoma august fda approved lenvima treatment certain patients hepatocellular carcinoma lenvima august ec approved lenvima treatment certain patients hepatocellular carcinoma march jmhlw approved lenvima treatment certain patients unresectable hepatocellular carcinoma october fda approved gardasil expanded age indication use women men ages gardasil prevention certain cancers diseases caused nine hpv types covered vaccine april cnda approved gardasil use girls women ages ec approved delstrigo doravirine lamivudine tenofovir disoproxil fumarate treatment adults november infected human immunodeficiency virus hiv without past present evidence resistance delstrigo nonnucleoside reverse transcriptase inhibitor nnrti class lamivudine tenofovir fda approved delstrigo treatment hiv infection adult patients prior antiretroviral august treatment experience ec approved pifeltro doravirine combination antiretroviral medicinal products november treatment adults infected hiv without past present evidence resistance nnrti class pifeltro fda approved pifeltro treatment hiv infection adult patients prior antiretroviral august treatment experience ec approved isentress extension existing indication cover treatment neonates isentress isentress march indicated combination antiretroviral medicinal products treatment hiv infection prevymis january ec approved prevymis letermovir prophylaxis cytomegalovirus cmv reactivation disease adult cmvseropositive recipients r allogeneic hematopoietic stem cell transplant ec approved steglatro ertugliflozin steglujan ertugliflozin sitagliptin segluromet ertugliflozin steglatro steglujan metformin hydrochloride treatment adults aged years older type diabetes segluromet march mellitus adjunct diet exercise improve glycaemic control monotherapy patients use metformin considered inappropriate due intolerance contraindications addition medicinal products treatment diabetes fda approved vaxelis diphtheria tetanus toxoids acellular pertussis adsorbed inactivated vaxelis december poliovirus haemophilus b conjugate meningococcal protein conjugate hepatitis b recombinant vaccine use children weeks years age prior th birthday july merck astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza march merck eisai co ltd announced strategic collaboration worldwide codevelopment cocommercialization eisais lenvima merck pfizer inc announced entered worldwide collaboration except japan codevelopment copromotion ertugliflozin competition health care environment competition markets company conducts business pharmaceutical industry general highly competitive highly regulated companys competitors include worldwide researchbased pharmaceutical companies smaller research companies limited therapeutic focus generic drug manufacturers animal health care companies companys operations may adversely affected generic biosimilar competition companys products mature well technological advances competitors industry consolidation table contents patents granted competitors competitive combination products new products competitors generic availability competitors branded products new information clinical trials marketed products postmarketing surveillance addition patent rights increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products could result payment royalties recognition impairment charge respect intangible assets associated certain products competitive pressures intensified pressures industry grown pharmaceutical competition involves rigorous search technological innovations ability market innovations effectively long standing emphasis research development company wellpositioned compete search technological innovations additional resources required meet market challenges include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products external alliances licensing arrangements collaborations refining sales marketing efforts address changing industry conditions however introduction new products processes competitors may result price reductions product displacements even products protected patents example number compounds available treat particular disease typically increases time result slowed sales growth reduced sales companys products therapeutic category highly competitive animal health business affected several factors including regulatory legislative issues scientific technological advances product innovation quality price companys products effective promotional efforts frequent introduction generic products competitors health care environment government regulation global efforts toward health care cost containment continue exert pressure product pricing market access united states federal state governments many years also pursued methods reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities hospitals serving disproportionate share low income uninsured patients backdrop united states enacted major health care reform legislation patient protection affordable care act aca various insurance market reforms since advanced state federal insurance exchanges launched respect effect law pharmaceutical industry law increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program law also requires pharmaceutical manufacturers pay point service discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole approximately million million million recorded merck reduction revenue respectively related donut hole provision beginning point service discount increase point service discount coverage gap result balanced budget act addition point service discount extended biosimilar products also pharmaceutical manufacturers required pay annual nontax deductible health care reform fee total annual industry fee billion decrease billion currently planned remain amount thereafter fee assessed company proportion share prior year branded pharmaceutical sales certain government programs medicare medicaid company recorded million million million costs within selling general administrative expenses respectively annual health care reform fee february centers medicare medicaid services cms issued medicaid rebate final rule implements provisions aca effective april rule provides comprehensive guidance calculation average manufacturer price best price two metrics utilized determine rebates drug manufacturers required pay state medicaid programs impact changes resulting issuance rule material merck time however company still awaiting guidance cms two aspects rule deferred later implementation include definition constitutes product line extension delay participation us territories medicaid drug rebate program april company evaluate financial impact two elements become effective table contents significant uncertainty future aca particular health care laws general united states company participating debate monitoring proposed changes could affect business company unable predict likelihood changes aca depending nature repeal replacement aca actions could material adverse effect companys business cash flow results operations financial position prospects number states passed pharmaceutical price cost transparency laws laws typically require manufacturers report certain product price information financial data state case california law manufacturers also required provide advance notification price increases company expects states continue focus pharmaceutical price transparency focus continue exert pressure product pricing company also faces increasing pricing pressure globally managed care organizations government agencies programs could negatively affect companys sales profit margins united states include practices managed care organizations federal state exchanges institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act aca changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures example health care reform contributing increase number patients medicaid program sales pharmaceutical products subject substantial rebates addition effort contain us federal deficit pharmaceutical industry could considered potential source savings via legislative proposals debated enacted types revenue generating cost saving proposals include additional direct price controls medicare prescription drug program part addition congress may consider proposals allow certain conditions importation medicines countries remains uncertain proposals may included part future federal budget deficit reduction proposals would directly indirectly affect company us private sector consolidation integration among health care providers major factor competitive marketplace pharmaceutical products health plans pharmacy benefit managers consolidating fewer larger entities thus enhancing purchasing strength importance private thirdparty insurers well governments increasingly employ formularies control costs negotiating discounted prices exchange formulary inclusion failure obtain timely adequate pricing formulary placement mercks products obtaining placement unfavorable pricing could adversely impact revenue addition formulary tier copay differentials private health insurance companies selfinsured employers raising co payments required beneficiaries particularly branded pharmaceuticals biotechnology products private health insurance companies also increasingly imposing utilization management tools clinical protocols requiring prior authorization branded product generic product available requiring patient first fail one generic products permitting access branded medicine management tools also used treatment areas payer taken position multiple branded products therapeutically comparable us payer market concentrates drugs become available generic form pharmaceutical companies may face greater pricing pressure private thirdparty payers order provide information companys pricing practices company annually posts website pricing transparency report united states report provides companys average annual list price net price increases across companys us portfolio dating back efforts toward health care cost containment also remain intense european countries company faces competitive pricing pressure resulting generic biosimilar drugs addition majority countries europe attempt contain drug costs engaging reference pricing authorities examine predetermined markets published prices drugs brand authorities use price data markets set new local prices brandname drugs including companys guidelines examining reference pricing usually set local markets changed pursuant local regulations table contents addition japan pharmaceutical industry subject governmentmandated biennial price reductions pharmaceutical products certain vaccines occurred furthermore government order repricings classes drugs determines appropriate applicable rules certain markets outside united states also implemented cost management strategies health technology assessments hta require additional data reviews administrative processes increase complexity timing costs obtaining product reimbursement exert downward pressure available reimbursement united states htas also used government private payers companys focus emerging markets continued governments many emerging markets also focused constraining health care costs enacted price controls related measures compulsory licenses aim put pressure price pharmaceuticals constrain market access company anticipates pricing pressures market access challenges continue varying degrees emerging markets beyond pricing market access challenges conditions emerging market countries affect companys efforts continue grow markets including potential political instability changes trade sanctions embargoes significant currency fluctuation controls financial crises limited changing availability funding health care developments may adversely impact business environment company company may engage thirdparty agents assist operating emerging market countries may affect ability realize continued growth may also increase companys risk exposure addressing cost containment pressures company engages public policy advocacy policymakers continues work demonstrate medicines provide value patients pay health care company advocates government policymakers encourage longterm approach sustainable health care financing ensures access innovative medicines disproportionately target pharmaceuticals source budget savings markets historically low rates health care spending company encourages governments increase investments adopt market reforms order improve citizens access appropriate health care including medicines operating conditions become challenging global pressures competition industry regulation cost containment efforts although one predict effect factors companys business company continually takes measures evaluate adapt improve organization business practices better meet customer needs believes wellpositioned respond evolving health care environment market forces pharmaceutical industry also subject regulation regional country state local agencies around world focused standards processes determining drug safety effectiveness well conditions sale reimbursement particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals cases fda requirements practices increased amount time resources necessary develop new products bring market united states time fda committed expediting development review products bearing breakthrough therapy designation accelerated regulatory review process medicines designation fda also undertaken efforts bring generic competition market efficiently timely manner european union eu adopted directives legislation concerning classification labeling advertising wholesale distribution integrity supply chain enhanced pharmacovigilance monitoring approval marketing medicinal products human use provide mandatory standards throughout eu may supplemented implemented additional regulations eu member states companys policies procedures already consistent substance directives consequently believed material effect companys business companys business china grown rapidly past years importance china companys overall pharmaceutical vaccines business increased accordingly continued growth companys business china dependent upon ongoing development favorable environment innovative pharmaceutical products vaccines sustained access companys current inline products absence table contents trade impediments adverse pricing controls recent years chinese government introduced implemented number structural reforms accelerate shift innovative products reduce costs since multiple new policies introduced government improve access new innovation reduce complexity regulatory filings accelerate review approval process led significant expansion new products approved year additionally government updated national reimbursement drug list first time eight years mechanism drugs added list evolves likely future inclusion require price negotiation could impact outlook market selected brands pricing pressure always existed china health care reform led acceleration generic substitution pilot tendering process mature products generic substitutes generic quality consistency evaluation approval company believes continue able conduct operations including launching new drugs regulatory environment see research development discussion regulatory approval process access medicines global health care company mercks primary role discover develop innovative medicines vaccines company also recognizes important role play helping improve access products around world companys efforts regard wideranging include set principles company strives embed operations business strategies guide companys worldwide approach expanding access health care addition company many farreaching philanthropic programs merck patient assistance program provides medicines adult vaccines free people united states prescription drug health insurance coverage without companys assistance afford merck medicine vaccines merck launched merck mothers longterm effort global health partners end preventable deaths complications pregnancy childbirth merck also provided funds merck foundation independent organization partnered variety organizations dedicated improving global health privacy data protection company subject significant number privacy data protection laws regulations globally many place restrictions companys ability transfer access use personal data across business legislative regulatory landscape privacy data protection continues evolve increased attention privacy data protection issues developed emerging markets potential affect directly companys business including new eu general data protection regulation went effect may imposes penalties global revenue additional laws regulations enacted united states europe asia latin america increases enforcement litigation activity united states developed markets increases regulatory cooperation among privacy authorities globally company adopted comprehensive global privacy program manage evolving risks certified compliant approved asia pacific economic cooperation crossborder privacy rules system euus privacy shield program binding corporate rules eu distribution company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccines sold primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value companys pharmaceutical vaccine products health care professionals private practice group practices hospitals managed care organizations company sells animal health products veterinarians distributors animal producers raw materials raw materials supplies generally available multiple sources purchased worldwide normally available quantities adequate meet needs companys business table contents patents trademarks licenses patent protection considered aggregate material importance companys marketing products united states major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products protection individual products extends varying periods accordance legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage food drug administration modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity united states indications new currently marketed drugs certain agreed upon pediatric studies completed applicant current us patent law provides additional patent term periods patented product regulatory review fda eu also provides additional six months pediatric market exclusivity attached products supplementary protection certificate spc japan provides additional term pediatric studies attached market exclusivity unrelated patent rights patent portfolios developed products introduced company normally provide market exclusivity company following key patent protection united states eu japan including potential patent term extensions pte spcs indicated following marketed products table contents product year expiration us year expiration eu year expiration japan emend expired emend injection noxafil na vaxelis method making spcs marketed januvia janumet na janumet xr na na isentress simponi na na lenvima pending pte patents spcs adempas bridion pending pte nexplanon device device marketed bravecto pending pte patents spcs gardasil expired gardasil patents spcs na keytruda patents spcs lynparza pending pte patents spcs pending pte zerbaxa pending pte patents spcs na sivextro patents spcs pending pte belsomra na prevymis pending pte patents spcs pending pte steglatro pending pte patents spcs na steglujan pending pte patents spcs na segluromet pending pte patents spcs na delstrigo pending pte na pifeltro pending pte na na currently marketing approval note compound patent unless otherwise noted certain products listed may subject patent litigation see item financial statements supplementary data note contingencies environmental liabilities eu date represents expiration date following five countries france germany italy spain united kingdom major eu markets spc applications filed granted major eu markets patent expiry date spc expiry date listed eligible months pediatric exclusivity pte system japan allows patent extended provided later approval directed different indication previous approval may result multiple pte approvals given patent expiration date commercialized usbased joint partnership sanofi pasteur spcs granted four major eu markets pending one based patent expired company marketing rights us japan includes pediatric exclusivity granted four major eu markets pending one developed commercialized global strategic oncology collaboration eisai commercialized worldwide collaboration bayer ag developed commercialized global strategic oncology collaboration astrazeneca developed promoted worldwide except japan collaboration pfizer spc applications filed may expiration product patent normally results loss market exclusivity covered pharmaceutical product commercial benefits may continue derived latergranted patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv united states certain countries market exclusivity may available relevant law effect product patent expiration pharmaceutical products also depends upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries additions market exclusivity sought united states countries relevant laws including laws increasing patent life benefits increases patent life partially offset table contents increase number incentives use generic products additionally improvements intellectual property laws sought united states countries reform patent relevant laws implementation international treaties company following key us patent protection drug candidates review united states fda additional patent term may provided pipeline candidates based patent term restoration pediatric exclusivity currently anticipated review us year expiration us v ebola vaccine mka relebactam imipenemcilastatin company also following key us patent protection drug candidates phase development currently anticipated phase drug candidate year expiration us mk vericiguat mk gefapixant v pneumoconjugate vaccine developed worldwide clinical development collaboration bayer ag unless otherwise noted patents charts compound patents patent subject future patent term restoration five years six month pediatric market exclusivity either may available addition depending circumstances surrounding final regulatory approval compound may listed patents patent applications pending could relevance product finally approved relevance application would depend upon claims ultimately may granted nature final regulatory approval product also regulatory exclusivity tied protection clinical data complementary patent protection cases may provide effective longer lasting marketing exclusivity compounds patent estate united states data protection generally runs five years first marketing approval new chemical entity extended seven years orphan drug indication years first marketing approval biological product information respect companys patents see item risk factors item financial statements supplementary data note contingencies environmental liabilities worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely royalty income patent knowhow licenses rights amounted million merck also incurred royalty expenses amounting billion patent knowhow licenses holds research development companys business characterized introduction new products new uses existing products strong research development program december approximately people employed companys research activities company prioritizes research development efforts focuses candidates believes represent breakthrough science make difference patients payers company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources candidates company believes capable providing unambiguous promotable advantages patients payers delivering maximum value approved medicines vaccines new indications new formulations merck pursuing emerging product opportunities independent therapeutic area modality small molecule biologics vaccines building biologics capabilities company committed ensuring externally sourced programs remain important table contents component pipeline strategy focus supplementing internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well access new technologies company also reviews pipeline examine candidates may provide value outlicensing company continues evaluate certain latestage clinical development platform technology assets determine outlicensing sale potential companys clinical pipeline includes candidates multiple disease areas including cancer cardiovascular diseases diabetes infectious diseases neurosciences obesity pain respiratory diseases vaccines development human health products industry practice government regulations united states foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug vaccine may marketed united states recorded data preclinical clinical experience included new drug application nda drug biologics license application bla vaccine biologic submitted fda required approval companys scientists discover new small molecule compound biologic believe promise treat medical condition company commences preclinical testing compound preclinical testing includes laboratory testing animal safety studies gather data chemistry pharmacology immunogenicity toxicology pending acceptable preclinical data company initiate clinical testing accordance established regulatory requirements clinical testing begins phase studies designed assess safety tolerability pharmacokinetics preliminary pharmacodynamic activity compound humans favorable additional larger phase studies initiated determine efficacy compound affected population define appropriate dosing compound well identify adverse effects could limit compounds usefulness situations clinical program incorporates adaptive design methodology use accumulating data decide modify aspects ongoing clinical study continues without undermining validity integrity trial one type adaptive clinical trial adaptive phase ab trial design twostage trial design consisting phase proofofconcept stage phase b doseoptimization finding stage data phase trials satisfactory company commences largescale phase trials confirm compounds efficacy safety another type adaptive clinical trial adaptive phase trial design study includes interim analysis adaptation changes trial features common phase study eg multiple dose groups design similar phase trial adaptive phase trial design reduces timelines eliminating activities would required start separate study upon completion phase trials satisfactory company submits regulatory filings appropriate regulatory agencies around world product candidate approved marketing assurance compound result particular program obtain regulatory approvals necessary marketed vaccine development follows general pathway drugs preclinical testing focuses vaccines safety ability elicit protective immune response immunogenicity premarketing vaccine clinical trials typically done three phases initial phase clinical studies conducted normal subjects evaluate safety tolerability immunogenicity vaccine candidate phase studies doseranging studies finally phase trials provide necessary data effectiveness safety successful company submits regulatory filings appropriate regulatory agencies united states fda review process begins complete nda bla submitted received accepted review agency within days receipt fda determines application sufficiently complete permit substantive review fda also assesses time whether application granted priority review standard review pursuant prescription drug user fee act v pdufa fda review period target ndas original blas either six months priority review ten months standard review time application deemed sufficiently complete review timelines determined fda generally act upon application within timelines unless major amendment submitted either companys initiative fdas request pending application occurs fda may extend review period allow review new information three months extensions review period communicated company fda act application either issuing approval letter issuing complete response letter crl stating application approved present form describing deficiencies fda identified company wish pursue application receiving table contents crl resubmit application information addresses questions issues identified fda order support approval resubmissions subject review period targets vary depending underlying submission type content resubmission fda four program designations fast track breakthrough therapy accelerated approval priority review facilitate expedite development review new drugs address unmet medical needs treatment serious lifethreatening conditions fast track designation provides pharmaceutical manufacturers opportunities frequent interactions fda reviewers products development ability manufacturer rolling submission ndabla rolling submission allows completed portions application submitted reviewed fda ongoing basis breakthrough therapy designation provides manufacturers features fast track designation well intensive guidance implementing efficient development program product commitment fda involve senior managers experienced staff review accelerated approval designation allows fda approve product based effect surrogate intermediate endpoint reasonably likely predict products clinical benefit generally requires manufacturer conduct required postapproval confirmatory trials verify clinical benefit priority review designation means fdas goal take action ndabla within six months compared ten months standard review addition generating antibiotic incentives act fda may grant qualified infectious disease product qidp status antibacterial antifungal drugs intended treat serious life threatening infections including caused antibiotic antifungal resistant pathogens novel emerging infectious pathogens qualifying pathogens qidp designation offers certain incentives development qualifying drugs including priority review nda filed eligibility fast track designation fiveyear extension applicable exclusivity provisions food drug cosmetic act primary method company uses obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part marketing authorization application maa european medicines agency ema ema evaluates maa provides recommendation ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states outside united states eu company submits marketing applications national regulatory authorities examples pharmaceuticals medical devices agency japan health canada agncia nacional de vigilncia sanatria brazil korea food drug administration south korea therapeutic goods administration australia china food drug administration country separate independent review process timeline many markets approval times longer regulatory authority requires approval major market united states eu issuance certificate pharmaceutical product market initiating local review process research development update company currently several candidates regulatory review united states internationally keytruda approved antipd therapy clinical development expanded indications different cancer types february fda accepted granted priority review supplemental bla keytruda combination inlyta axitinib tyrosine kinase inhibitor firstline treatment patients advanced renal cell carcinoma supplemental bla based findings phase keynote trial demonstrated keytruda combination axitinib compared sunitinib significantly improved overall survival os progressionfree survival pfs firstline treatment advanced renal cell carcinoma data presented american society clinical oncology asco genitourinary cancers symposium table contents february supplemental bla also included supporting data phase b keynote trial fda set pdufa date june merck filed data keynote regulatory authorities worldwide february committee medicinal products human use ema adopted positive opinion recommending keytruda combination carboplatin either paclitaxel nabpaclitaxel firstline treatment metastatic squamous nsclc adults recommendation based results pivotal phase keynote trial enrolled patients regardless pdl tumor expression status trial showed significant improvement os pfs patients taking keytruda combination chemotherapy carboplatin either paclitaxel nabpaclitaxel compared chemotherapy alone approved would mark first approval europe antipd therapy combination chemotherapy adults metastatic squamous nsclc october fda approved keytruda combination carboplatinpaclitaxel nabpaclitaxel firstline treatment metastatic squamous nsclc regardless pdl expression december fda extended action date supplemental bla seeking approval keytruda monotherapy firstline treatment locally advanced metastatic nsclc patients whose tumors express pdl tps without egfr alk genomic tumor aberrations supplemental bla based results phase keynote trial keytruda monotherapy demonstrated significant improvement os compared chemotherapy patient population company submitted additional data analyses fda constituted major amendment extended pdufa date three months april merck continues work closely fda review supplemental bla february fda accepted granted priority review supplemental bla keytruda monotherapy treatment patients advanced smallcell lung cancer sclc whose disease progressed two lines prior therapy supplemental bla seeking accelerated approval new indication based data sclc cohorts phase keynote phase b keynote trials fda set pdufa date june keytruda also studied combination chemotherapy ongoing phase keynote study patients newly diagnosed extensive stage sclc february fda accepted supplemental bla keytruda monotherapy combination platinum fluorouracil chemotherapy firstline treatment patients recurrent metastatic hnscc supplemental bla based part data pivotal phase keynote trial keytruda demonstrated significant improvement os compared standard care monotherapy patients whose tumors expressed pdl combined positive score cps cps combination chemotherapy total patient population data presented european society medical oncology esmo congress fda granted priority review supplemental bla set pdufa date june keynote also serves confirmatory trial keynote phase b study supported previous accelerated approval keytruda monotherapy treatment patients recurrent metastatic hnscc disease progression platinumcontaining chemotherapy november merck announced phase keynote trial investigating keytruda monotherapy secondline treatment advanced metastatic esophageal esophagogastric junction carcinoma met primary endpoint os patients whose tumors expressed pdl cps pivotal study treatment keytruda resulted statistically significant improvement os compared chemotherapy paclitaxel docetaxel irinotecan patients cps regardless histology primary endpoint os also evaluated patients squamous cell histology entire intentionto treat study population directionally favorable statistical significance os met two patient groups per statistical analysis plan key secondary endpoints pfs objective response rate orr formally tested os reached full intentiontotreat study population results presented january asco gastrointestinal cancers symposium submitted regulatory review additionally keytruda received breakthrough therapy designation fda treatment highrisk earlystage triplenegative breast cancer combination neoadjuvant chemotherapy fdas breakthrough therapy designation intended expedite development review candidate planned use alone combination treat serious lifethreatening disease condition preliminary clinical evidence indicates drug may demonstrate substantial improvement existing therapies one clinically significant endpoints table contents october merck announced first presentation results interim analysis keynote phase trial evaluating keytruda previously treated patients highrisk nonmuscle invasive bladder cancer interim analysis studys primary endpoint showed complete response rate nearly three months keytruda patients whose disease unresponsive bacillus calmettegurin therapy current standard care disease ineligible refused undergo radical cystectomy results well study findings presented esmo congress february merck announced pivotal phase keynote trial evaluating keytruda plus best supportive care treatment patients advanced hepatocellular carcinoma previously treated systemic therapy meet coprimary endpoints os pfs compared placebo plus best supportive care final analysis study improvement os patients treated keytruda compared placebo however os results meet statistical significance per prespecified statistical plan results pfs also directionally favorable keytruda arm compared placebo reach statistical significance key secondary endpoint orr formally tested since superiority reached os pfs results presented upcoming medical meeting shared fda discussion keytruda clinical development program consists clinical trials including trials combine keytruda cancer treatments studies encompass cancer types including bladder cervical colorectal esophageal gastric head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma melanoma mesothelioma nasopharyngeal nsclc ovarian pmbcl prostate renal smallcell lung triplenegative breast many currently phase clinical development trials planned cancers lynparza oral parp inhibitor currently approved certain types ovarian breast cancer july merck astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza multiple cancer types april merck astrazeneca announced ema validated review maa lynparza use patients deleterious suspected deleterious brcamutated hernegative metastatic breast cancer previously treated chemotherapy neoadjuvant adjuvant metastatic setting first regulatory submission parp inhibitor breast cancer europe lynparza tablets also review eu maintenance treatment patients newlydiagnosed brcamutated advanced ovarian cancer complete partial response following firstline standard platinumbased chemotherapy submission based positive results pivotal phase solo trial trial showed statisticallysignificant clinicallymeaningful improvement pfs lynparza compared placebo reducing risk disease progression death patients newlydiagnosed brcamutated advanced ovarian cancer complete partial response platinumbased chemotherapy december merck astrazeneca announced positive results randomized openlabel controlled phase solo trial lynparza tablets patients relapsed ovarian cancer two lines treatment trial conducted postapproval commitment agreement fda results trial showed brcamutated advanced ovarian cancer patients treated lynparza following two prior lines chemotherapy demonstrated statistically significant clinically meaningful improvement primary endpoint orr key secondary endpoint pfs compared chemotherapy merck astrazeneca plan discuss results fda mka combination relebactam investigational betalactamase inhibitor imipenemcilastatin approved carbapenem antibiotic february merck announced fda accepted priority review nda mka treatment complicated urinary tract infections complicated intraabdominal infections caused certain susceptible gramnegative bacteria adults limited alternative therapies available pdufa date july april merck announced pivotal phase study mka demonstrated favorable overall response treatment certain imipenemnonsusceptible bacterial infections primary endpoint lower treatmentemergent nephrotoxicity kidney toxicity secondary endpoint compared colistin colistimethate sodium plus imipenemcilastatin regimen fda previously designated combination qualified infectious disease product designated fast track status treatment hospital table contents acquired bacterial pneumonia ventilatorassociated bacterial pneumonia complicated intraabdominal infections complicated urinary tract infections v rvsvgzebovgp live attenuated investigational ebola zaire disease vaccine candidate studied large scale phase clinical trials december merck announced application emergency use assessment listing eual v accepted review world health organization according eual process designed expedite availability vaccines needed public health emergencies another outbreak ebola decision grant v eual status based data regarding quality safety efficacyeffectiveness well riskbenefit analysis emergency use eual designation allows emergency use vaccine remains investigational yet licensed commercial distribution july merck announced fda granted v breakthrough therapy designation ema granted vaccine candidate prime priority medicines status november merck announced started submission rolling bla fda v rolling submission made pursuant fdas breakthrough therapy designation merck expects rolling submission bla completed company also intends file v ema february merck announced fda accepted priority review supplemental nda zerbaxa treat adult patients nosocomial pneumonia including ventilatorassociated pneumonia caused certain susceptible gramnegative microorganisms pdufa date june zerbaxa also review indication ema zerbaxa currently approved united states treatment adult patients complicated urinary tract infections caused certain susceptible gramnegative microorganisms also indicated combination metronidazole treatment adult patients complicated intraabdominal infections caused certain susceptible gramnegative grampositive microorganisms addition candidates regulatory review company several drug candidates phase clinical development addition keytruda programs discussed mk gefapixant selective nonnarcotic orallyadministered pxreceptor agonist investigated phase trials treatment refractory chronic cough phase trial treatment women endometriosisrelated pain lenvima orally available tyrosine kinase inhibitor currently approved certain types thyroid cancer hepatocellular carcinoma combination certain patients renal cell carcinoma march merck eisai entered strategic collaboration worldwide codevelopment cocommercialization lenvima agreement merck eisai develop commercialize lenvima jointly monotherapy combination keytruda per agreement companies jointly initiate clinical studies evaluating keytrudalenvima combination support potential indications six types cancer endometrial cancer nsclc hepatocellular carcinoma head neck cancer bladder cancer melanoma well basket trial targeting multiple cancer types fda granted breakthrough therapy designation keytruda combination lenvima potential treatment patients advanced andor metastatic renal cell carcinoma potential treatment certain patients advanced andor metastatic nonmicrosatellite instability highproficient mismatch repair endometrial carcinoma mk vericiguat investigational treatment heart failure studied patients suffering chronic heart failure reduced ejection fracture phase clinical trial chronic heart failure preserved ejection fracture phase clinical trial development vericiguat part worldwide strategic collaboration merck bayer v investigational polyvalent conjugate vaccine prevention pneumococcal disease june merck initiated first phase study adult population prevention invasive pneumococcal disease currently five phase adult studies ongoing including studies healthy adults years age older adults risk factors pneumococcal disease infected hiv recipients allogeneic hematopoietic stem cell transplant october merck began first phase study pediatric population currently three studies ongoing including studies healthy infants children afflicted sickle cell disease january merck announced v received breakthrough therapy designation fda prevention invasive pneumococcal disease caused vaccine serotypes pediatric patients weeks years age table contents result changes herpes zoster vaccine environment merck ending development v investigational vaccine prevention shingles immunocompromised patients chart reflects companys research pipeline february candidates shown phase include specific products date candidate entered phase development candidates shown phase include advanced compound specific mechanism listed compounds mechanism currently intended commercialization given therapeutic area small molecules biologics given mknumber designations vaccine candidates given vnumber designations except otherwise noted candidates phase additional indications therapeutic area respect cancer certain indications additional claims line extensions formulations inline products shown phase phase phase entry date review cancer cancer new molecular entitiesvaccines mk keytruda mk keytruda bacterial infection advanced solid tumors breast october mka relebactamimipenemcilastatin cutaneous squamous cell carcinoma cervical october eu us prostate colorectal november ebola vaccine mk lenvima esophageal december v us biliary tract gastric may eu nonsmallcell lung hepatocellular may eu certain supplemental filings v cavatak mesothelioma may cancer melanoma nasopharyngeal april mk keytruda mk ovarian december firstline advanced renal cell carcinoma colorectal renal october eu keynote us mk lynparza smallcell lung may eu firstline metastatic squamous nonsmall advanced solid tumors mk lenvima cell lung cancer keynote eu cytomegalovirus vaccine endometrial june firstline metastatic nonsmallcell lung v mk lynparza cancer keynote us eu diabetes mellitus pancreatic december thirdline advanced smallcell lung mk prostate april cancer keynote us hiv infection cough firstline head neck cancer mk mk gefapixant march keynote us pediatric neurofibromatosis type heart failure alternative dosing regimen mk selumetinib mk vericiguat september qw eu respiratory syncytial virus pneumoconjugate vaccine mk lynparza mk v june secondline metastatic breast cancer eu schizophrenia firstline advanced ovarian cancer eu mk habpvabp mka zerbaxa us footnotes developed collaboration developed combination keytruda development currently hold rolling submission habp hospitalacquired bacterial pneumonia vabp ventilatorassociated bacterial pneumonia employees december company approximately employees worldwide approximately employed united states including puerto rico approximately worldwide employees company represented various collective bargaining groups restructuring activities company commenced actions global restructuring programs designed streamline cost structure actions programs include elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research table contents development sites consolidation office facilities company also continues reduce global real estate footprint improve efficiency manufacturing supply network since inception programs december merck eliminated approximately positions comprised employee separations well elimination contractors vacant positions company substantially completed actions programs environmental matters company believes compliance issues associated applicable environmental laws regulations would material adverse effect company company also remediating environmental contamination resulting past industrial activity certain sites expenditures remediation environmental liabilities million estimated million aggregate years amounts consider potential recoveries parties company taken active role identifying accruing costs managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures material adverse effect companys financial position results operations liquidity capital resources year merck believes climate change could present risks business potential impacts climate change business include increased operating costs due additional regulatory requirements physical risks companys facilities water limitations disruptions supply chain potential risks integrated companys business planning including investment reducing energy water use greenhouse gas emissions company believe risks material business time geographic area information companys operations outside united states conducted primarily subsidiaries sales worldwide subsidiaries outside united states percentage total company sales sales sales sales companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions merck operations countries located latin america middle east africa eastern europe asia pacific business developing areas sometimes less stable offers important opportunities growth time available information companys internet website address wwwmerckcom company make available free charge investors portion website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act amended soon reasonably practicable reports electronically filed furnished us securities exchange commission sec address website httpwwwsecgov addition company provide without charge copy annual report including financial statements schedules upon written request shareholder office secretary merck co inc galloping hill road k kenilworth nj usa companys corporate governance guidelines charters board directors four standing committees available companys website wwwmerckcomaboutleadership information available print shareholder requests company table contents item risk factors investors carefully consider information set forth including following risk factors deciding invest companys securities risks ones company faces additional risks currently known company company presently deems immaterial may also impair business operations companys business financial condition results operations prospects could materially adversely affected risks also contains forwardlooking statements involve risks uncertainties companys results could materially differ anticipated forwardlooking statements result certain factors including risks faces described elsewhere see cautionary factors may affect future results company dependent patent rights patent rights invalidated circumvented business would adversely affected patent protection considered aggregate material importance companys marketing human health animal health products united states major foreign markets patents covering products introduced normally provide market exclusivity important successful marketing sale products company seeks patents covering products markets intends sell products meaningful patent protection available even company succeeds obtaining patents covering products third parties government authorities may challenge seek invalidate circumvent patents patent applications important companys business defend successfully patent rights provide market exclusivity products company often involved patent disputes relating challenges patents claims third parties infringement company company defends patents within outside united states including filing claims infringement parties see item financial statements supplementary data note contingencies environmental liabilities particular manufacturers generic pharmaceutical products time time file abbreviated ndas fda seeking market generic forms companys products prior expiration relevant patents owned licensed company company normally responds defending patent including filing lawsuits alleging patent infringement patent litigation challenges companys patents costly unpredictable may deprive company market exclusivity patented product cases thirdparty patents may prevent company marketing selling product particular geographic area additionally certain foreign governments indicated compulsory licenses patents may granted case national emergencies circumstances could diminish eliminate sales profits regions negatively affect companys results operations court decisions relating companies patents potential legislation relating patents well regulatory initiatives may result general weakening intellectual property protection one important products lose patent protection profitable markets sales products likely decline significantly result generic versions products becoming available companys results operations may adversely affected lost sales unless company successfully launched commercially successful replacement products addition products measured fair value capitalized connection acquisitions experience difficulties market negatively affect product cash flows company may recognize material noncash impairment charges respect value products chart listing patent protection certain companys marketed products us patent protection candidates review phase clinical development set forth item business patents trademarks licenses companys products lose market exclusivity company generally experiences significant rapid loss sales products company depends upon patents provide exclusive marketing rights products period time loss patent protection one companys products typically leads significant rapid loss sales product lower priced generic versions drug become available case products contribute significantly companys sales loss market exclusivity material adverse effect table contents companys business cash flow results operations financial position prospects example pursuant agreement generic manufacturer manufacturer launched united states generic version zetia december addition company lost us patent protection vytorin april result company experienced significant rapid loss sales zetia vytorin united states continued furthermore patents provide us eu market exclusivity noxafil expire july december respectively company anticipates significant decline us eu noxafil sales thereafter key products generate significant amount companys profits cash flows events adversely affect markets leading products could material negative impact results operations cash flows companys ability generate profits operating cash flow depends largely upon continued profitability companys key products keytruda januvia janumet gardasilgardasil bridion result companys dependence key products event adversely affects products markets products could significant adverse impact results operations cash flows events could include loss patent protection increased costs associated manufacturing generic overthecounter availability companys product competitive product discovery previously unknown side effects results postapproval trials increased competition introduction new effective treatments discontinuation removal market product reason events could material adverse effect sales products example sales zepatier materially unfavorably affected increasing competition declining patient volumes sales zostavax also materially unfavorably affected due competition company expects competition continue adversely affect sales products companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequence company may able replace sales successful products lost patent protection like major pharmaceutical companies order remain competitive company must continue launch new products expected declines sales products loss market exclusivity mean companys future success dependent pipeline new products including new products may develop collaborations joint ventures products able obtain license acquisition accomplish company commits substantial effort funds resources research development dedicated resources various collaborations third parties high rate failure inherent research development process new drugs result high risk funds invested company research programs generate financial returns risk profile compounded fact research long investment cycle bring pharmaceutical compound discovery phase market may take decade failure occur point process including later process significant funds invested description research development process see item business research development phase testing highly regulated phase substantial risk company encounter serious obstacles achieve goals therefore company may abandon product invested substantial amounts time resources risks encountered research development process include following preclinical testing new compound may yield disappointing results competing products manufacturers may reach market first clinical trials new drug may successful new drug may effective may harmful side effects new drug may approved regulators intended use may possible obtain patent new drug payers may refuse cover reimburse new product sales new product may disappointing company state certainty whether products development approved launched whether able develop license otherwise acquire compounds product candidates products whether products launched commercially successful company must maintain continuous flow successful new products successful new indications brand extensions existing products table contents sufficient cover substantial research development costs replace sales lost profitable products lose market exclusivity displaced competing products therapies failure short term long term would material adverse effect companys business results operations cash flow financial position prospects companys success dependent successful development marketing new products subject substantial risks products appear promising development may fail reach market fail succeed numerous reasons including following findings ineffectiveness superior safety efficacy competing products harmful side effects clinical preclinical testing failure receive necessary regulatory approvals including delays approval new products new indications anticipated labeling uncertainties time required obtain regulatory approvals benefitrisk standards applied regulatory agencies determining whether grant approvals failure certain markets obtain reimbursement commensurate level innovation clinical benefit presented product lack economic feasibility due manufacturing costs factors preclusion commercialization proprietary rights others future certain pipeline programs cancelled company believes commercial prospects reduced company may recognize material noncash impairment charges programs measured fair value capitalized connection acquisitions certain collaborations failure successfully develop market new products short term long term would material adverse effect companys business results operations cash flow financial position prospects companys products including products development marketed unless company obtains maintains regulatory approval companys activities including research preclinical testing clinical trials manufacturing marketing products subject extensive regulation numerous federal state local governmental authorities united states including fda foreign regulatory authorities including eu japan china united states fda administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states regulation outside united states also primarily focused drug safety effectiveness many cases reduction cost drugs fda foreign regulatory authorities substantial discretion require additional testing delay withhold registration marketing approval otherwise preclude distribution sale product even company successful developing new products able market products unless obtained required regulatory approvals jurisdiction proposes market new products obtained company must maintain approval long plans market new products jurisdiction approval required companys failure obtain approval significant delays approval process failure maintain approval jurisdiction prevent selling products jurisdiction company would able realize revenues new products jurisdiction approval developments following regulatory approval may adversely affect sales companys products even product reaches market certain developments following regulatory approval may decrease demand companys products including following results postapproval phase trials studies table contents rereview products already marketed recall loss marketing approval products already marketed changing government standards public expectations regarding safety efficacy labeling changes greater scrutiny advertising promotion past several years clinical trials postmarketing surveillance certain marketed drugs company competitors within industry raised concerns led recalls withdrawals adverse labeling marketed products clinical trials postmarketing surveillance certain marketed drugs also raised concerns among prescribers patients relating safety efficacy pharmaceutical products general negatively affected sales products addition increased scrutiny outcomes clinical trials led increased volatility market reaction matters often attract litigation even basis litigation groundless considerable resources may needed respond addition following wake product withdrawals significant safety issues health authorities fda ema japans pharmaceutical medical device agency increased focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications rereviewing select products already marketed adding uncertainties regulatory processes also greater regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising previously unknown side effects discovered increase negative publicity regarding known side effects companys products could significantly reduce demand product require company take actions could negatively affect sales including removing product market restricting distribution applying labeling changes current environment pharmaceutical companies operate company risk product liability consumer protection claims civil criminal governmental actions related products research andor marketing activities company faces intense competition lower cost generic products general company faces increasing competition lowercost generic products patent rights protect products varying strengths durations addition countries patent protection significantly weaker united states eu united states eu political pressure reduce spending prescription drugs led legislation measures encourage use generic biosimilar products although companys policy actively protect patent rights generic challenges companys products arise time companys patents may prevent emergence generic competition products loss patent protection product typically followed promptly generic substitutes reducing companys sales product availability generic substitutes companys drugs may adversely affect results operations cash flow addition proposals emerge time time united states countries legislation encourage early rapid approval generic drugs proposal enacted law could worsen substantial negative effect companys sales potentially business cash flow results operations financial position prospects company faces intense competition competitors products companys products face intense competition competitors products competition may increase new products enter market event competitors products may safer effective convenient use better insurance coverage reimbursement levels effectively marketed sold companys products alternatively case generic competition including generic availability competitors branded products may equally safe effective products sold substantially lower price companys products result company fails maintain competitive position could material adverse effect business cash flow results operations financial position prospects addition products measured fair value capitalized connection acquisitions experience table contents difficulties market negatively impact product cash flows company may recognize material noncash impairment charges respect value products company faces continued pricing pressure respect products company faces continued pricing pressure globally particularly mature markets managed care organizations government agencies programs could negatively affect companys sales profit margins united states include practices managed care groups institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act aca iii state activities aimed increasing price transparency including new laws noted item competition health care environment health care environment government regulations changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures addition us larger customers may future ask receive higher rebates drugs certain highly competitive categories company must also compete placed formularies managed care organizations exclusion product formulary lead reduced usage managed care organization order provide information companys pricing practices company annually posts website pricing transparency report united states report provides companys average annual list price net price increases across companys us portfolio dating back outside united states numerous major markets including eu japan china pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine products consequently markets company subject government decision making budgetary actions respect products company expects pricing pressures continue future health care industry united states continue subject increasing regulation political action company believes health care industry continue subject increasing regulation well political legal action future proposals reform health care system considered executive branch congress state legislatures united states enacted major health care reform legislation form aca various insurance market reforms advanced state federal insurance exchanges launched respect effect law pharmaceutical industry law increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program law also requires pharmaceutical manufacturers pay point service discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole companys revenue reduced million due requirement beginning point service discount increase point service discount coverage gap result balanced budget act addition point service discount extended biosimilar products also pharmaceutical manufacturers required pay annual nontax deductible health care reform fee total annual industry fee billion billion fee assessed company proportion share prior year branded pharmaceutical sales certain government programs medicare medicaid company recorded million costs annual fee centers medicare medicaid services cms issued medicaid rebate final rule implements provisions aca effective april rule provides comprehensive guidance calculation average manufacturer price best price two metrics utilized determine rebates drug manufacturers required pay state medicaid programs impact changes resulting issuance rule material merck time however company still awaiting guidance cms two aspects rule deferred later implementation include definition constitutes product line extension delay table contents participation us territories medicaid drug rebate program april company evaluate financial impact two elements become effective company predict likelihood future changes health care industry general pharmaceutical industry particular impact may companys business cash flow results operations financial position prospects company increasingly dependent sophisticated software applications computing infrastructure company experienced network cyberattack led disruption worldwide operations including manufacturing research sales operations company could target future cyberattacks company increasingly dependent sophisticated software applications complex information technology systems computing infrastructure collectively systems conduct critical operations disruption degradation manipulation systems intentional accidental means could impact key business processes cyberattacks companys systems could result exposure confidential information modification critical data andor failure critical operations misuse systems could result disclosure sensitive personal information theft trade secrets intellectual property confidential business information company continues leverage new innovative technologies across enterprise improve efficacy efficiency business processes use create new risks company experienced network cyberattack led disruption worldwide operations including manufacturing research sales operations due cyberattack company unable fulfill orders certain products certain markets unfavorable effect sales approximately million addition company recorded manufacturingrelated expenses primarily unfavorable manufacturing variances cost sales well expenses related remediation efforts selling general administrative expenses research development expenses aggregated million net insurance recoveries approximately million due residual backlog orders sales unfavorably affected certain markets approximately million cyberattack company insurance coverage insuring costs resulting cyberattacks received proceeds however disputes certain insurers availability insurance coverage claims related cyberattack company implemented variety measures enhance modernize systems guard similar attacks future also pursuing enterprisewide effort enhance company 's resiliency future cyberattacks including incidents similar attack objective efforts protect future cyberattacks also improve speed companys recovery attacks enable continued business operations greatest extent possible recovery period although aggregate impact cyberattacks network disruptions including cyberattack companys operations financial condition material date company continues target events nature expects continue company monitors data information technology personnel usage company systems reduce risks continues ongoing basis current potential threats assurance companys efforts protect data systems successful preventing disruptions operations including manufacturing research sales operations disruption could result loss revenue loss critical sensitive information companys companys third party providers databases systems could also result financial legal business reputational harm company potentially substantial remediation costs company subject variety us international laws regulations company currently subject number government laws regulations future could become subject new government laws regulations costs compliance laws regulations negative results noncompliance could adversely affect business cash flow results operations financial position prospects company laws regulations include additional healthcare reform initiatives united states countries including additional mandatory discounts fees ii us foreign corrupt practices act antibribery corruption laws iii new laws regulations judicial governmental table contents decisions affecting pricing drug reimbursement access marketing within across jurisdictions iv changes intellectual property laws v changes accounting standards vi new increasing data privacy regulations enforcement particularly eu united states vii legislative mandates preferences local manufacturing pharmaceutical vaccine products viii emerging new global regulatory requirements reporting payments value transfers healthcare professionals ix environmental regulations x potential impact importation restrictions embargoes trade sanctions legislative andor regulatory changes uncertainty global economic conditions together costreduction measures taken certain governments could negatively affect companys operating results uncertainty global economic geopolitical conditions may result slowdown global economy could affect companys business reducing prices drug wholesalers retailers hospitals government agencies managed health care providers may able willing pay companys products reducing demand companys products could turn negatively impact companys sales result material adverse effect companys business cash flow results operations financial position prospects global efforts toward health care cost containment continue exert pressure product pricing market access united states pricing pressures continue many companys products several international markets governmentmandated pricing actions reduced prices generic patented drugs company anticipates pricing actions continue negatively affect revenue performance credit economic conditions worsen resulting economic currency impacts affected markets globally could material adverse effect companys results company significant global operations expose additional risks adverse event could material negative impact companys results operations extent companys operations outside united states significant risks inherent conducting global business include changes medical reimbursement policies programs pricing restrictions key markets multiple regulatory requirements could restrict companys ability manufacture sell products key markets trade protection measures import export licensing requirements including imposition trade sanctions similar restrictions united states governments foreign exchange fluctuations diminished protection intellectual property countries possible nationalization expropriation addition may changes companys business political position instability disruption destruction significant geographic region regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm disease example companys lone manufacturing plant puerto rico negatively affected hurricane maria united kingdom uk held referendum voters approved exit eu commonly referred brexit result referendum british government process negotiating terms uks future relationship eu company taken actions made certain contingency plans scenarios uk eu reach mutually satisfactory understanding relationship possible time predict whether understanding understanding reached whether terms vary ways result greater restrictions imports exports uk eu countries increased regulatory complexities andor cross border labor issues could materially adversely impact companys business operations uk table contents failure attract retain highly qualified personnel could affect companys ability successfully develop commercialize products companys success largely dependent continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical research development governmental regulation commercialization competition qualified personnel pharmaceutical industry intense company sure able attract retain quality personnel costs materially increase past company experienced difficulties delays manufacturing certain products including vaccines merck past experienced difficulties manufacturing certain products including vaccines addition network cyberattack experienced company june led disruption companys operations including manufacturing operations company may future experience difficulties delays inherent manufacturing products failure company vendors suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing ii construction delays related construction new facilities expansion existing facilities including intended support future demand companys products iii manufacturing distribution problems including changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could impact continuous supply addition company could experience difficulties delays manufacturing products caused natural disasters hurricanes manufacturing difficulties result product shortages leading lost sales reputational harm company company may able realize expected benefits investments emerging markets company taking steps increase sales emerging markets however guarantee companys efforts expand sales markets succeed countries within emerging markets may especially vulnerable periods global financial instability may limited resources spend health care order company successfully implement emerging markets strategy must attract retain qualified personnel company may also required increase reliance thirdparty agents within less developed markets addition many countries currencies fluctuate substantially currencies devalue company offset devaluations companys financial performance within countries could adversely affected companys business china grown rapidly past years importance china companys overall pharmaceutical vaccines business outside united states increased accordingly continued growth companys business china dependent upon ongoing development favorable environment innovative pharmaceutical products vaccines sustained access companys currently marketed products absence trade impediments adverse pricing controls noted healthcare environment pricing pressure china increased chinese government taking steps reduce costs including implementing healthcare reform led acceleration generic substitution available addition company anticipates reported inquiries made various governmental authorities involving multinational pharmaceutical companies china may continue reasons sales within emerging markets carry significant risks however failure maintain companys presence emerging markets could material adverse effect companys business cash flow results operations financial position prospects company exposed market risk fluctuations currency exchange rates interest rates company operates multiple jurisdictions virtually sales denominated currencies local jurisdiction additionally company entered enter business development transactions borrowings financial transactions may give rise currency interest rate exposure table contents since company certainty foresee mitigate adverse fluctuations fluctuations currency exchange rates interest rates inflation could negatively affect companys business cash flow results operations financial position prospects order mitigate adverse impact market fluctuations company time time enter hedging agreements hedging agreements currency options forwards interest rate swaps may limit exposure exchange rate interest rate fluctuations attempts mitigate risks may costly always successful company subject evolving complex tax laws may result additional liabilities may affect results operations company subject evolving complex tax laws jurisdictions operates significant judgment required determining companys tax liabilities companys tax returns periodically examined various tax authorities company believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions tax authorities however due complexity tax contingencies ultimate resolution tax matters may result payments greater less amounts accrued addition company may affected changes tax laws new tax laws affecting example tax rates andor revised tax law interpretations domestic foreign jurisdictions pharmaceutical products develop unexpected safety efficacy concerns unexpected safety efficacy concerns arise respect marketed products whether scientifically justified leading product recalls withdrawals declining sales well product liability consumer fraud andor claims including potential civil criminal governmental actions reliance thirdparty relationships outsourcing arrangements could adversely affect companys business company depends third parties including suppliers alliances pharmaceutical biotechnology companies thirdparty service providers key aspects business including development manufacture commercialization products support information technology systems failure third parties meet contractual regulatory obligations company development factors materially disrupt relationships company third parties could material adverse effect companys business negative events animal health industry could negative impact future results operations future sales key animal health products could adversely affected number risk factors including certain risks specific animal health business example outbreak disease carried animals bovine spongiform encephalopathy mad cow disease could lead widespread death precautionary destruction well reduced consumption demand animals could adversely impact companys results operations also outbreak highly contagious diseases near companys main production sites could require company immediately halt production vaccines sites force company incur substantial expenses procuring raw materials vaccines elsewhere risks specific animal health include epidemics pandemics government procurement pricing practices weather global agribusiness economic events animal health segment companys business becomes significant impact events future results operations would also become significant biologics vaccines carry unique risks uncertainties could negative impact future results operations successful development testing manufacturing commercialization biologics vaccines particularly human animal health vaccines long complex expensive uncertain process unique risks uncertainties biologics vaccines including may limited access supply normal diseased tissue samples cell lines pathogens bacteria viral strains biological materials addition government regulations multiple table contents jurisdictions united states eu could result restricted access transport use materials company loses access sufficient sources materials tighter restrictions imposed use materials company may able conduct research activities planned may incur additional development costs development manufacturing marketing biologics vaccines subject regulation fda ema regulatory bodies regulations often complex extensive regulations applicable pharmaceutical products example united states bla including preclinical clinical trial data extensive data regarding manufacturing procedures required human vaccine candidates fda approval generally required release manufactured commercial lot manufacturing biologics vaccines especially large quantities often complex may require use innovative technologies handle living microorganisms lot approved biologic vaccine must undergo thorough testing identity strength quality purity potency manufacturing biologics requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures necessary slight deviations anywhere manufacturing process including filling labeling packaging storage shipping quality control testing may result lot failures product recalls spoilage changes made manufacturing process company may required provide preclinical clinical data showing comparable identity strength quality purity potency products changes biologics vaccines frequently costly manufacture production ingredients derived living animal plant material biologics vaccines made synthetically particular keeping demand vaccines may difficult due complexity producing vaccines use biologically derived ingredients lead variability manufacturing process could lead allegations harm including infections allergic reactions allegations would reviewed standard investigation process could lead closure product facilities due possible contamination events could result substantial costs product liability insurance products may limited cost prohibitive unavailable result number factors product liability insurance become less available cost increased significantly company subject substantial number product liability claims see item financial statements supplementary data note contingencies environmental liabilities information companys current product liability litigation respect product liability company selfinsures substantially risk availability commercial insurance become restrictive company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance certain product liabilities effective august including liability legacy merck products first sold date company continually assess efficient means address risk however guarantee insurance coverage obtained obtained sufficient fully cover product liabilities may arise social media platforms present risks challenges inappropriate andor unauthorized use certain media vehicles could cause brand damage information leakage could lead legal implications including improper collection andor dissemination personally identifiable information addition negative inaccurate posts comments company products social networking platforms could damage companys reputation brand image goodwill disclosure non public companysensitive information companys workforce others external media channels could lead information loss although internal company social media policy guides employees appropriate personal professional use social media company processes place may completely secure protect information identifying new points entry social media continues expand also presents new challenges table contents cautionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning negative variations foregoing one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement company cautions place undue reliance forwardlooking statements although possible predict identify factors may include following competition generic andor biosimilar products companys products lose patent protection increased brand competition therapeutic areas important companys longterm business performance difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures united states abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general changes government laws regulations including laws governing intellectual property enforcement thereof affecting companys business efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales significant changes customer relationships changes behavior spending patterns purchasers health care products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing health care insurance coverage legal factors including product liability claims antitrust litigation governmental investigations including tax disputes environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products cyberattacks companys information technology systems could disrupt companys operations lost market opportunity resulting delays uncertainties approval process fda foreign regulatory authorities increased focus privacy issues countries around world including united states eu legislative regulatory landscape privacy data protection continues evolve table contents increasing amount focus privacy data protection issues potential affect directly companys business including recently enacted laws majority states united states requiring security breach notification changes tax laws including changes related taxation foreign earnings changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board sec adverse company economic factors company control including changes inflation interest rates foreign currency exchange rates list considered exhaustive statement potential risks uncertainties see risk factors item b unresolved staff comments none item properties companys corporate headquarters located kenilworth new jersey companys us commercial operations headquartered upper gwynedd pennsylvania companys us pharmaceutical business conducted divisional headquarters located upper gwynedd pennsylvania kenilworth new jersey companys vaccines business conducted divisional headquarters located upper gwynedd pennsylvania mercks animal health headquarters located madison new jersey principal us research facilities located rahway kenilworth new jersey west point pennsylvania palo alto california boston massachusetts south san francisco california elkhorn nebraska animal health principal research facilities outside united states located switzerland china mercks manufacturing operations headquartered whitehouse station new jersey company also production facilities human health products nine locations united states puerto rico outside united states subsidiaries company owns interest manufacturing plants properties japan singapore south africa countries western europe central south america asia capital expenditures billion billion billion united states amounted billion billion billion abroad expenditures amounted billion million million company subsidiaries principal facilities manufacturing plants titles consider satisfactory company believes properties good operating condition machinery equipment well maintained plants manufacture products suitable intended purposes capacities projected capacities adequate current projected needs existing company products capacity plants converted needed modification requirements newly introduced future products addition october company announced plans invest approximately billion new capital projects focus investment primarily increasing manufacturing capacity across mercks key businesses item legal proceedings information called item incorporated herein reference item financial statements supplementary data note contingencies environmental liabilities item mine safety disclosures applicable table contents executive officers registrant ages february officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer persons name age offices business experience kenneth c frazier chairman president chief executive officer since december sanat chattopadhyay executive vice president president merck manufacturing division since march senior vice president operations merck manufacturing division november march frank clyburn executive vice president chief commercial officer since january president global oncology business unit october december president primary care womens health business line september october robert davis executive vice president global services chief financial officer since april executive vice president chief financial officer april april corporate vice president president medical products baxter international inc october march richard r deluca jr executive vice president president merck animal health since september julie l gerberding executive vice president chief patient officer strategic communications global public policy population health since july executive vice president strategic communications global public policy population health january july president merck vaccines january january rita karachun senior vice president finance global controller since march assistant controller november march steven c mizell executive vice president chief human resources officer human resources since october executive vice president chief human resources officer december october executive vice president human resources monsanto company august december michael nally executive vice president chief marketing officer since january president global vaccines global human health september january managing director united kingdom ireland global human health january september managing director sweden global human health november january roger perlmutter md phd executive vice president president merck research laboratories since april jim scholefield executive vice president chief information digital officer since october chief information officer nike inc july october chief technology officer cocacola company november june executive vice president general counsel since april partner covington burling llp jennifer zachary january march table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities principal market trading companys common stock new york stock exchange nyse symbol mrk january approximately shareholders record companys common stock issuer purchases equity securities three months ended december follows issuer purchases equity securities millions total number average price approximate dollar value shares shares paid per may yet purchased period purchased share plans programs october october november november december december total shares purchased period made part plan approved board directors november purchase billion merck shares october board directors authorized additional purchases billion mercks common stock treasury shares approximated amount includes billion held back pending final settlement accelerated share repurchase agreements discussed table contents performance graph following graph assumes investment december reinvestment dividends companys common shares sp index composite peer group major pharmaceutical companies abbvie inc amgen inc astrazeneca plc bristolmyers squibb company johnson johnson eli lilly company glaxosmithkline plc novartis ag pfizer inc roche holding ag sanofi sa comparison fiveyear cumulative total return merck co inc composite peer group sp index end period value cagr merck peer grp sp merck peer grp sp compound annual growth rate peer group average calculated market cap weighted basis performance graph deemed incorporated reference filing securities act securities exchange act except extent company specifically incorporates reference addition performance graph deemed soliciting material filed sec subject regulation c provided regulation sk liabilities section securities exchange act except extent company specifically requests information treated soliciting material specifically incorporates reference filing securities act exchange act table contents item selected financial data following selected financial data read conjunction item managements discussion analysis financial condition results operations consolidated financial statements notes thereto contained item financial statements supplementary data report merck co inc subsidiaries millions except per share amounts results year sales cost sales selling general administrative research development restructuring costs income expense net income taxes taxes income net income less net loss income attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders cash dividends declared cash dividends declared per common share capital expenditures depreciation average common shares outstanding millions average common shares outstanding assuming dilution millions yearend position working capital property plant equipment net total assets longterm debt total equity yearend statistics number stockholders record number employees amounts include charge related formation collaboration eisai co ltd amounts recast result adoption january new accounting standard related classification certain defined benefit plan costs impact net income result adopting new accounting standard amounts include provisional net tax charge related enactment us tax legislation charge related formation collaboration astrazeneca amounts include charge related settlement worldwide patent litigation related keytruda amounts include net charge related settlement vioxx shareholder class action litigation foreign exchange losses related venezuela gains dispositions businesses assets favorable benefit certain tax items amounts reflect divestiture mercks consumer care business october including gain sale well gain recognized option exercise astrazeneca gains dispositions businesses assets loss extinguishment debt table contents item managements discussion analysis financial condition results operations description mercks business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include four operating segments pharmaceutical animal health healthcare services alliances segments pharmaceutical animal health segments reportable segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities december merck sanofi pasteur sa sanofi terminated equallyowned joint venture sanofi pasteur msd spmsd developed marketed vaccines europe merck began recording vaccine sales incurring costs result operating vaccines business european markets previously part spmsd joint venture accounted equity method affiliate animal health segment discovers develops manufactures markets animal health products including pharmaceutical vaccine products prevention treatment control disease major livestock companion animal species company sells veterinarians distributors animal producers healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients alliances segment primarily includes activity companys relationship astrazeneca lp related sales nexium prilosec concluded see note consolidated financial statements overview companys performance demonstrates execution innovation strategy revenue growth oncology vaccines hospital acute care animal health focused investment research development pipeline disciplined allocation resources additionally merck completed several business development transactions expanded capital expenditures program primarily increase future manufacturing capacity returned capital shareholders worldwide sales billion increase compared strong growth oncology franchise reflects performance keytruda well alliance revenue related lynparza lenvima resulting mercks business development activities also contributing revenue growth higher sales vaccines driven primarily gardasilgardasil growth hospital acute care franchise largely attributable bridion noxafil higher sales animal health products reflecting increases companion animal livestock products inline recently launched products also contributed revenue growth growth areas partially offset competitive pressures zepatier zostavax well ongoing effects generic biosimilar competition resulted sales declines products including zetia vytorin remicade augmenting mercks portfolio pipeline external innovation remains important component companys overall strategy merck continued executing strategy entering strategic collaboration eisai co ltd eisai worldwide codevelopment cocommercialization lenvima lenvima orally available tyrosine kinase inhibitor discovered eisai approved certain types thyroid cancer hepatocellular carcinoma combination certain patients renal cell carcinoma agreement merck eisai develop commercialize lenvima jointly monotherapy combination keytruda addition merck acquired viralytics limited viralytics company focused oncolytic immunotherapy treatments range cancers also company announced agreement acquire antelliq group antelliq leader digital animal identification traceability monitoring solutions table contents company advanced leadership oncology focused commercial execution achievement important regulatory milestones presentation clinical data keytruda continues global launch multiple new indications across several tumor types including approval us food drug administration fda treatment certain patients cervical cancer primary mediastinal large bcell lymphoma pmbcl type nonhodgkin lymphoma hepatocellular carcinoma merkel cell carcinoma combination chemotherapy treatment certain patients squamous nonsmallcell lung cancer nsclc also european commission ec approved keytruda treatment certain patients head neck squamous cell carcinoma hnscc adjuvant treatment melanoma combination chemotherapy firstline treatment certain patients nonsquamous nsclc first approval europe antipd therapy combination chemotherapy also keytruda approved china treatment certain patients melanoma additionally merck recently announced receipt five new approvals keytruda japan including three expanded uses advanced nsclc one adjuvant melanoma well new indication advanced microsatellite instabilityhigh msih tumors keytruda also continues launch many international markets lynparza developed collaboration astrazeneca plc astrazeneca received fda approval use certain patients metastatic breast cancer previously treated chemotherapy use maintenance treatment adult patients certain types advanced ovarian fallopian tube primary peritoneal cancer complete partial response chemotherapy additionally lenvima approved united states european union eu japan china treatment certain patients hepatocellular carcinoma fda ec also approved two new hiv medicines delstrigo oncedaily fixeddose combination tablet doravirine lamivudine tenofovir disoproxil fumarate pifeltro doravirine new nonnucleoside reverse transcriptase inhibitor administered combination antiretroviral medicines merck continues invest pipeline emphasis leader immunooncology expanding areas vaccines hospital acute care addition recent regulatory approvals discussed company continued advance latestage pipeline several regulatory submissions keytruda review united states combination axitinib tyrosine kinase inhibitor firstline treatment patients advanced renal cell carcinoma granted priority review fda eu firstline treatment certain patients metastatic squamous nsclc united states eu monotherapy firstline treatment certain patients locally advanced metastatic nsclc united states monotherapy treatment certain patients advanced smallcell lung cancer sclc united states monotherapy combination chemotherapy firstline treatment certain patients recurrent metastatic hnscc granted priority review fda additionally mka combination relebactam imipenemcilastatin accepted priority review fda treatment complicated urinary tract infections complicated intraabdominal infections caused certain susceptible gramnegative bacteria adults limited alternative therapies available merck also started submission rolling biologics license application bla fda v investigational ebola zaire disease vaccine candidate companys phase oncology programs include keytruda therapeutic areas breast cervical colorectal esophageal gastric hepatocellular mesothelioma nasopharyngeal ovarian renal smallcell lung cancers lynparza pancreatic prostate cancer lenvima combination keytruda endometrial cancer additionally company candidates phase clinical development several therapeutic areas including v investigational polyvalent conjugate vaccine prevention pneumococcal disease received breakthrough therapy designation fda prevention invasive pneumococcal disease caused vaccine serotypes pediatric patients weeks years age mk gefapixant selective nonnarcotic orallyadministered pxreceptor agonist developed treatment refractory chronic cough mk vericiguat investigational treatment heart failure developed collaboration see research development company allocating resources effectively support commercial opportunities near term making necessary investments support longterm growth research development expenses reflect higher clinical development spending investment discovery early drug development table contents october mercks board directors approved increase companys quarterly dividend raising per share per share companys outstanding common stock also october mercks board directors approved billion share repurchase program company entered billion accelerated share repurchase asr agreements company returned billion shareholders dividends share repurchases earnings per common share assuming dilution attributable common shareholders eps compared eps years reflect impact acquisition divestiturerelated costs well restructuring costs certain items certain items include charge related formation collaboration eisai include provisional net tax charge related enactment us tax legislation charge related formation collaboration astrazeneca nongaap eps exclude items see nongaap income nongaap eps pricing global efforts toward health care cost containment continue exert pressure product pricing market access worldwide united states pricing pressure continues many companys products changes us health care system part health care reform well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries contributed pricing pressure several international markets governmentmandated pricing actions reduced prices generic patented drugs addition companys revenue performance negatively affected costreduction measures taken governments thirdparties lower health care costs company anticipates actions continue negatively affect revenue performance cyberattack june company experienced network cyberattack led disruption worldwide operations including manufacturing research sales operations due backlog orders certain products result cyberattack company unable fulfill orders certain products certain markets unfavorable effect sales approximately million million respectively addition company recorded manufacturingrelated expenses primarily unfavorable manufacturing variances cost sales well expenses related remediation efforts selling general administrative expenses research development expenses aggregated approximately million net insurance recoveries approximately million costs immaterial referenced company insurance coverage insuring costs resulting cyberattacks received insurance proceeds however disputes certain insurers availability insurance coverage claims related incident operating results sales worldwide sales billion increase compared sales growth driven primarily higher sales oncology franchise reflecting strong growth keytruda well alliance revenue related lynparza lenvima also contributing revenue growth higher sales vaccines driven primarily human papillomavirus hpv vaccine gardasilgardasil well higher sales hospital acute care franchise largely attributable bridion noxafil higher sales animal health products also drove revenue growth sales growth partially offset declines virology franchise driven primarily lower sales hepatitis c virus hcv treatment zepatier well lower sales shingles herpes zoster vaccine zostavax ongoing effects generic biosimilar competition cardiovascular products zetia vytorin immunology product remicade well lower sales products within diversified brands franchise also partially offset revenue growth diversified brands franchise includes certain products approaching expiration marketing exclusivity longer protected patents developed markets sales united states billion growth compared increase driven primarily higher sales keytruda gardasilgardasil nuvaring bridion well alliance revenue table contents lynparza lenvima higher sales animal health products growth partially offset lower sales zepatier zetia vytorin zostavax januvia janumet invanz products within diversified brands franchise international sales billion increase compared increase primarily reflects growth keytruda gardasilgardasil januvia janumet atozet well higher sales animal health products sales growth partially offset lower sales zepatier remicade zetia vytorin products within diversified brands franchise international sales represented total sales worldwide sales billion increase compared sales growth driven primarily higher sales keytruda zepatier bridion additionally sales benefited december termination spmsd marketed vaccines major european markets merck began recording vaccine sales markets previously part spmsd joint venture resulting incremental vaccine sales approximately million higher sales pneumovax adempas animal health products also contributed revenue growth increases largely offset effects generic competition certain products including zetia lost us market exclusivity december vytorin lost us market exclusivity april cubicin due us patent expiration june cancidas lost eu patent protection april revenue growth also offset continued biosimilar competition remicade ongoing generic erosion products including singulair nasonex collectively sales decline attributable products affected generic biosimilar competition billion lower sales products within diversified brands franchise well lower combined sales diabetes franchise januvia janumet declines sales isentressisentress hd also partially offset revenue growth additionally sales reduced million due borrowing company made us centers disease control prevention cdc pediatric vaccine stockpile doses gardasil discussed also company unable fulfill orders certain products certain markets due cyberattack unfavorable effect sales approximately million see note consolidated financial statements details sales companys products pharmaceutical segment oncology keytruda approved united states eu monotherapy treatment certain patients nsclc melanoma classical hodgkin lymphoma chl hnscc urothelial carcinoma type bladder cancer combination chemotherapy certain patients nonsquamous nsclc keytruda also approved united states monotherapy treatment certain patients gastric gastroesophageal junction adenocarcinoma msih mismatch repair deficient cancer addition fda recently approved keytruda treatment certain patients cervical cancer pmbcl hepatocellular carcinoma merkel cell carcinoma combination chemotherapy patients squamous nsclc see keytruda approved japan treatment certain patients nsclc monotherapy combination chemotherapy melanoma chl msih tumors urothelial carcinoma additionally keytruda approved china treatment certain patients melanoma keytruda also approved many international markets keytruda clinical development program includes studies across broad range cancer types see research development august fda approved expanded label keytruda combination pemetrexed platinum chemotherapy firstline treatment patients metastatic nonsquamous nsclc egfr alk genomic tumor aberrations based results keynote trial keytruda combination pemetrexed carboplatin first approved fdas accelerated approval process firstline treatment patients metastatic nonsquamous nsclc based tumor response rates progressionfree survival pfs data phase study keynote cohort g accordance accelerated approval process continued approval contingent upon verification description clinical benefit demonstrated keynote resulted fda converting accelerated approval full regular approval also september ec approved keytruda combination pemetrexed platinum chemotherapy firstline treatment metastatic nonsquamous nsclc adults whose tumors egfr alk positive mutations june fda approved keytruda treatment patients recurrent metastatic cervical cancer disease progression chemotherapy whose tumors express pdl determined fda table contents approved test also june fda approved keytruda treatment adult pediatric patients refractory pmbcl relapsed two prior lines therapy september ec approved keytruda monotherapy treatment recurrent metastatic hnscc adults whose tumors express pdl tumor proportion score tps progressed platinumcontaining chemotherapy based data phase keynote trial october fda approved keytruda combination carboplatin either paclitaxel nabpaclitaxel firstline treatment patients metastatic squamous nsclc based results keynote trial approval marks first time antipd regimen approved firstline treatment squamous nsclc regardless tumor pdl expression status november fda approved keytruda treatment patients hepatocellular carcinoma previously treated sorafenib based data keynote trial december fda approved keytruda treatment adult pediatric patients recurrent locally advanced metastatic merkel cell carcinoma based results cancer immunotherapy trials networks citnkeynote trial also december ec approved keytruda adjuvant treatment adults stage iii melanoma lymph node involvement undergone complete resection keytruda approved indication fda february approvals based data pivotal phase eortckeynote trial conducted collaboration european organisation research treatment cancer global sales keytruda billion billion billion yearoveryear increases driven volume growth company continues launch keytruda multiple new indications globally sales united states continue build across multiple approved indications particular treatment nsclc reflecting continued adoption keytruda firstline setting monotherapy patients metastatic nsclc whose tumors high pdl expression well uptake keytruda combination pemetrexed carboplatin commonly used chemotherapy regimen firstline treatment metastatic nonsquamous nsclc without pdl expression indications contributing sales growth include hnscc bladder melanoma recently approved indications including squamous nsclc msih cancer also contributed growth sales growth international markets reflects continued uptake treatment nsclc company secured reimbursement major markets sales growth international markets also includes contributions recently approved indications described including treatment hnscc bladder cancer combination chemotherapy treatment nsclc eu multiple new indications japan treatment melanoma china january merck entered settlement license agreement resolve worldwide patent infringement litigation related keytruda pursuant settlement company pay royalties net sales keytruda net sales keytruda global sales emend prevention chemotherapyinduced postoperative nausea vomiting million decline compared including favorable effect foreign exchange decline primarily reflects lower demand united states due competition worldwide sales emend million increase compared patent provided us market exclusivity emend expired patent provides market exclusivity major european markets expire may patent provides us market exclusivity emend injection expires september patent provides market exclusivity major european markets expires february although sixmonth pediatric exclusivity may extend date company anticipates sales emend markets decline significantly patent expiries lynparza oral poly adpribose polymerase parp inhibitor developed part collaboration astrazeneca entered july see note consolidated financial statements currently approved certain types ovarian breast cancer merck recorded alliance revenue million million related lynparza revenue increase reflects approval new indications well full year activity january fda approved lynparza use patients brcamutated human epidermal growth factor receptor hernegative metastatic breast cancer previously treated chemotherapy table contents triggering million capitalized milestone payment merck astrazeneca lynparza also approved japan july use patients unresectable recurrent brcamutated hernegative breast cancer received prior chemotherapy additionally lynparza approved use maintenance therapy patients platinumsensitive relapsed ovarian cancer regardless brca mutation status japan january eu may december fda approved lynparza use maintenance treatment adult patients deleterious suspected deleterious germline somatic brcamutated advanced epithelial ovarian fallopian tube primary peritoneal cancer complete partial response firstline platinumbased chemotherapy based results solo clinical trial triggering million capitalized milestone payment merck astrazeneca lenvima oral receptor tyrosine kinase inhibitor developed part collaboration eisai entered march see note consolidated financial statements approved certain types thyroid cancer hepatocellular carcinoma combination certain patients renal cell carcinoma merck recorded alliance revenue million related lenvima lenvima approved treatment certain patients hepatocellular carcinoma united states eu japan china triggering capitalized milestone payments million aggregate merck eisai vaccines december merck sanofi terminated equallyowned joint venture spmsd developed marketed vaccines europe accordingly vaccine sales include sales merck vaccines european markets previously part spmsd joint venture whereas sales periods prior prior vaccine sales european markets sold spmsd joint venture results reflected equity income affiliates included income expense net supply sales spmsd however included vaccine sales periods prior incremental vaccine sales resulting termination spmsd joint venture approximately million approximately million relate gardasilgardasil worldwide sales gardasilgardasil vaccines help prevent certain cancers diseases caused certain types hpv billion growth compared including favorable effect foreign exchange sales growth driven primarily higher sales asia pacific region particularly china reflecting continued uptake since launch well higher demand certain european markets sales increase also attributable replenishment doses borrowed cdc pediatric vaccine stockpile discussed april chinas food drug administration approved gardasil use girls women ages october fda approved expanded age indication use women men ages prevention certain cancers diseases caused nine hpv types covered vaccine company made request borrow doses gardasil cdc pediatric vaccine stockpile cdc granted companys decision borrow doses cdc driven part temporary shutdown resulting cyberattack occurred june well overall higher demand expected result borrowing company reversed sales related borrowed doses recognized corresponding liability company subsequently replenished portion doses borrowed stockpile net effect borrowing subsequent partial replenishment reduction sales million company replenished remaining borrowed doses resulting recognition sales million reversal related liability global sales gardasilgardasil billion growth compared sales growth driven primarily higher sales europe resulting termination spmsd joint venture noted well higher demand asia pacific region due part launch china partially offset lower sales united states lower sales united states reflect timing public sector purchases cdc stockpile borrowing described company party certain thirdparty license agreements respect gardasilgardasil pursuant company pays royalties worldwide gardasilgardasil sales royalties vary country range included cost sales global sales proquad pediatric combination vaccine help protect measles mumps rubella varicella million increase compared driven primarily higher volumes table contents pricing united states volume growth certain european markets worldwide sales proquad million increase compared million sales growth driven primarily higher pricing volumes united states well volume growth international markets particularly europe foreign exchange favorably affected global sales performance worldwide sales mmr ii vaccine help protect measles mumps rubella million increase compared driven primarily volume growth latin america global sales mmr ii million increase compared million sales growth largely attributable higher sales europe resulting termination spmsd joint venture foreign exchange favorably affected global sales performance unfavorably affected global sales performance global sales varivax vaccine help prevent chickenpox varicella million increase compared reflecting volume growth latin america asia pacific region along higher pricing united states largely offset volume declines turkey loss government tender due competition worldwide sales varivax million decline compared million sales decline driven primarily lower volumes brazil due loss government tender well lower sales united states reflecting lower demand partially offset higher pricing higher sales europe resulting termination spmsd joint venture partially offset sales decline worldwide sales pneumovax vaccine help prevent pneumococcal disease million increase compared sales growth driven primarily higher pricing united states volume growth europe global sales pneumovax million increase compared driven primarily higher demand pricing united states well higher sales europe resulting termination spmsd joint venture foreign exchange unfavorably affected sales performance global sales rotateq vaccine help protect rotavirus gastroenteritis infants children million increase compared driven primarily launch china worldwide sales rotateq million increase compared driven primarily higher sales europe resulting termination spmsd joint venture worldwide sales zostavax vaccine help prevent shingles herpes zoster adults years age older million decline compared driven lower volumes markets particularly united states lower demand united states reflects launch competing vaccine received preferential recommendation cdcs advisory committee immunization practices october prevention shingles zostavax declines partially offset higher demand certain european markets company anticipates competition continue adverse effect sales zostavax future periods global sales zostavax million decline compared including favorable effect foreign exchange sales decline driven primarily lower demand united states reflecting approval competing vaccine noted partially offset growth europe resulting termination spmsd joint venture volume growth asia pacific region fda approved vaxelis diphtheria tetanus toxoids acellular pertussis adsorbed inactivated poliovirus haemophilus b conjugate meningococcal protein conjugate hepatitis b recombinant vaccine use children weeks years age prior th birthday vaxelis currently marketed europe developed part jointpartnership merck sanofi merck sanofi working maximize production vaxelis allow sustainable supply meet anticipated us demand commercial supply available prior hospital acute care global sales bridion reversal two types neuromuscular blocking agents used surgery million growth compared driven primarily volume growth united states certain european markets worldwide sales bridion million growth compared driven strong global demand particularly united states table contents worldwide sales noxafil prevention invasive fungal infections million increase compared including favorable effect foreign exchange sales growth primarily reflects higher demand united states certain european markets china global sales noxafil million increase compared primarily reflecting higher demand pricing united states well volume growth europe patent provides us market exclusivity noxafil expires july additionally patent noxafil expire number major european markets december company anticipates sales noxafil markets decline significantly thereafter global sales invanz treatment certain infections million decline compared including unfavorable effect foreign exchange sales decline driven lower volumes united states patent provided us market exclusivity invanz expired november generic competition began second half company experiencing significant decline us invanz sales result generic competition expects decline continue worldwide sales invanz million increase compared driven primarily higher sales united states reflecting higher pricing partially offset lower demand well higher demand brazil global sales cubicin iv antibiotic complicated skin skin structure infections bacteremia caused designated susceptible organisms million decline compared including favorable effect foreign exchange worldwide sales cubicin million decline compared resulting generic competition united states following expiration us composition patent cubicin june global sales cancidas antifungal product sold primarily outside united states million decline compared million decline compared foreign exchange favorably affected global sales performance sales declines driven primarily generic competition certain european markets eu compound patent cancidas expired april accordingly company experiencing significant decline cancidas sales european markets expects decline continue immunology sales simponi oncemonthly subcutaneous treatment certain inflammatory diseases marketed company europe russia turkey million growth compared including favorable effect foreign exchange sales simponi million growth compared including favorable effect foreign exchange sales growth years driven higher demand europe company anticipates sales simponi unfavorably affected future periods recent launch biosimilars competing product sales remicade treatment inflammatory diseases marketed company europe russia turkey million decline compared million decline compared foreign exchange favorably affected sales performance company lost market exclusivity remicade major european markets longer market exclusivity marketing territories company experiencing pricing volume declines markets result biosimilar competition expects declines continue virology worldwide sales isentressisentress hd hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection billion decline compared billion decline compared foreign exchange favorably affected global sales performance sales declines primarily reflect competitive pressure united states europe august fda approved two new hiv medicines delstrigo oncedaily fixeddose combination tablet doravirine lamivudine tenofovir disoproxil fumarate pifeltro doravirine new nonnucleoside reverse transcriptase inhibitor administered combination antiretroviral medicines delstrigo pifeltro indicated treatment hiv infection adult patients prior antiretroviral treatment experience delstrigo pifeltro also approved ec november january fda accepted review supplemental new drug applications nda pifeltro delstrigo seeking approval table contents use patients living hiv switching stable antiretroviral regimen whose virus suppressed prescription drug user fee act pdufa date supplemental ndas september global sales zepatier treatment adult patients certain types chronic hepatitis c virus hcv infection million decline compared sales decline driven primarily unfavorable effects increasing competition declining patient volumes particularly united states europe japan company anticipates sales zepatier future continue adversely affected competition lower patient volumes worldwide sales zepatier billion compared million sales growth driven primarily higher sales europe united states japan following product launch cardiovascular combined global sales zetia marketed countries outside united states ezetrol vytorin marketed outside united states inegy well atozet rosuzet marketed certain countries outside united states medicines lowering ldl cholesterol billion decline compared including favorable effect foreign exchange sales decline driven primarily lower demand united states europe zetia vytorin lost market exclusivity united states december april respectively accordingly company experienced rapid substantial decline us zetia vytorin sales result generic competition lost nearly us sales products addition company lost market exclusivity major european markets ezetrol april also lost market exclusivity certain european markets inegy see note consolidated financial statements accordingly company experiencing significant sales declines markets result generic competition expects declines continue declines partially offset higher sales japan due part launch atozet combined worldwide sales ezetimibe family billion decline compared sales decline driven lower volumes pricing zetia vytorin united states result generic competition due loss us market exclusivity described pursuant collaboration bayer ag bayer see note consolidated financial statements merck lead commercial rights adempas cardiovascular drug treatment pulmonary arterial hypertension countries outside americas bayer lead rights americas including united states companies share profits equally collaboration merck began promoting distributing adempas europe transition bayer merck territories including japan continued revenue adempas includes sales mercks marketing territories well mercks share profits sale adempas bayers marketing territories merck recorded revenue related adempas million increase compared reflecting higher sales mercks marketing territories partially offset lower profit sharing bayer due part lower pricing united states revenue related adempas million increase compared reflecting higher sales mercks marketing territories well recognition higher profit sharing bayer foreign exchange favorably affected global sales performance diabetes worldwide combined sales januvia janumet medicines help lower blood sugar levels adults type diabetes billion essentially flat compared global combined sales januvia janumet billion decline compared foreign exchange favorably affected sales performance sales performance periods driven primarily ongoing pricing pressure particularly united states partially offset higher demand international markets company expects pricing pressure continue womens health worldwide sales nuvaring vaginal contraceptive product million increase compared including favorable effect foreign exchange sales growth driven primarily higher pricing united states patent provided us market exclusivity nuvaring expired april company anticipates significant decline us nuvaring sales future periods result generic competition global sales nuvaring million decline compared including favorable effect foreign exchange sales decline driven primarily lower sales united states reflecting lower volumes partially offset higher pricing lower demand europe table contents animal health segment global sales animal health products billion increase compared reflecting growth inline recently launched companion animal livestock products higher sales companion animal products reflect growth bravecto line products kill fleas ticks dogs cats weeks well higher sales companion animal vaccines growth livestock products reflects higher sales ruminant poultry swine products worldwide sales animal health products billion increase compared primarily reflecting higher sales companion animal products largely driven growth bravecto reflecting growth oral formulation continued uptake topical formulation launched animal health sales growth also driven higher sales ruminant poultry swine products december company signed agreement acquire antelliq leader digital animal identification traceability monitoring solutions see note consolidated financial statements costs expenses millions change change cost sales selling general administrative research development restructuring costs income expense net greater cost sales cost sales billion billion billion costs include million charge related termination collaboration agreement samsung bioepis co ltd samsung insulin glargine see note consolidated financial statements also company recorded million cumulative amortization expense amounts capitalized connection recognition liabilities potential future milestone payments related collaborations see note consolidated financial statements cost sales includes expenses amortization intangible assets recorded connection business acquisitions totaled billion billion billion costs also include intangible asset impairment charges million million respectively related marketed products intangibles recorded connection business acquisitions see note consolidated financial statements costs also include million intangible asset impairment charge related licensing agreement company may recognize additional noncash impairment charges future related intangible assets measured fair value capitalized connection business acquisitions charges could material also included cost sales expenses associated restructuring activities amounted million million million respectively primarily reflecting accelerated depreciation asset writeoffs related planned sale closure manufacturing facilities separation costs associated manufacturingrelated headcount reductions incurred reflected restructuring costs discussed gross margin compared yearoveryear improvements gross margin reflect lower net impact amortization intangible assets intangible asset impairment charges related business acquisitions well restructuring costs noted reduced gross margin percentage points percentage points percentage points gross margin improvement compared also reflects favorable effects product mix amortization unfavorable manufacturing variances recorded resulting part june cyberattack gross margin improvement partially offset charge associated termination collaboration agreement table contents samsung well unfavorable effects pricing pressure cumulative amortization expense potential future milestone payments related collaborations noted gross margin improvement compared also reflects favorable effects product mix manufacturingrelated costs associated cyberattack partially offset gross margin improvement selling general administrative selling general administrative sga expenses billion essentially flat compared reflecting higher administrative costs unfavorable effect foreign exchange offset lower selling promotional expenses sga expenses billion increase compared higher administrative costs including costs associated company operating vaccines business european markets previously part spmsd joint venture remediation costs related cyberattack higher promotional expenses related product launches partially offset lower restructuring acquisition divestiturerelated costs lower selling expenses favorable effect foreign exchange sga expenses include restructuring costs million related primarily accelerated depreciation facilities closed divested separation costs associated sales force reductions incurred reflected restructuring costs discussed sga expenses also include acquisition divestiturerelated costs million million million respectively consisting integration transaction certain costs related business acquisitions divestitures research development research development rd expenses billion decline compared decrease primarily reflects lower expenses upfront license option payments related formation oncology collaborations lower inprocess research development iprd impairment charges reduction expenses associated decrease estimated fair value measurement liabilities contingent consideration partially offset higher clinical development spending investment discovery early drug development well higher expenses related business development activities including charge acquisition viralytics rd expenses billion increase compared increase driven primarily charge related formation collaboration astrazeneca unfavorable effect changes estimated fair value measurement liabilities contingent consideration higher clinical development spending largely offset lower iprd impairment charges lower restructuring costs rd expenses comprised costs directly incurred merck research laboratories mrl companys research development division focuses human healthrelated activities billion billion billion also included rd expenses costs incurred divisions support rd activities including depreciation production general administrative well licensing activity certain costs operating segments including pharmaceutical animal health segments aggregate billion billion billion respectively additionally rd expenses include billion charge related formation collaboration eisai see note consolidated financial statements well million charge acquisition viralytics see note consolidated financial statements rd expenses include billion charge related formation collaboration astrazeneca see note consolidated financial statements rd expenses also include iprd impairment charges million million billion respectively see note consolidated financial statements company may recognize additional noncash impairment charges future related cancellation delay pipeline programs measured fair value capitalized connection business acquisitions charges could material addition rd expenses include expense income related changes estimated fair value measurement liabilities contingent consideration recorded connection acquisitions company recorded net reduction expenses million million respectively decrease estimated fair value liabilities contingent consideration related discontinuation delay certain programs see note consolidated financial statements company recorded charges million increase estimated fair value liabilities contingent consideration rd expenses also reflect million accelerated depreciation asset abandonment costs associated restructuring activities table contents restructuring costs company commenced actions global restructuring programs designed streamline cost structure actions programs include elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities company also continues reduce global real estate footprint improve efficiency manufacturing supply network restructuring costs primarily representing separation related costs associated restructuring activities million million million respectively separation costs million million million respectively incurred associated actual headcount reductions well estimated expenses existing severance programs headcount reductions probable could reasonably estimated merck eliminated approximately positions positions positions related restructuring activities also included restructuring costs asset abandonment shutdown related costs well employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation plan costs segment reporting restructuring costs unallocated expenses additional costs associated companys restructuring activities included cost sales selling general administrative research development discussed company recorded aggregate pretax costs million million billion related restructuring program activities see note consolidated financial statements company substantially completed actions programs income expense net income expense net million income million income million expense details components income expense net see note consolidated financial statements segment profits millions pharmaceutical segment profits animal health segment profits nonreportable segment profits income taxes pharmaceutical segment profits comprised segment sales less standard costs well sga rd expenses directly incurred segment animal health segment profits comprised segment sales less cost sales well sga rd expenses directly incurred segment internal management reporting presented chief operating decision maker merck allocate remaining cost sales included segment profits described research development expenses incurred mrl general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits also excluded determination segment profits acquisition divestiturerelated costs amortization purchase accounting adjustments intangible asset impairment charges expense income related changes estimated fair value measurement liabilities contingent consideration restructuring costs portion equity income additionally segment profits reflect expenses corporate manufacturing cost centers miscellaneous income expense unallocated items including charge related termination collaboration agreement samsung insulin glargine loss extinguishment debt charge related settlement worldwide keytruda patent litigation gains divestitures reflected table also included miscellaneous corporate profits losses well operating profits losses related thirdparty manufacturing sales first quarter company adopted new accounting standard related classification certain defined benefit plan costs resulted change measurement segment profits see note consolidated financial statements prior period amounts recast conform new presentation table contents pharmaceutical segment profits grew compared primarily reflecting higher sales lower selling promotional costs pharmaceutical segment profits grew compared primarily reflecting higher sales favorable effects product mix animal health segment profits grew driven primarily higher sales partially offset increased selling promotional costs taxes income effective income tax rates reflect impacts acquisition divestiturerelated costs restructuring costs beneficial impact foreign earnings effective income tax rate includes measurementperiod adjustments provisional amounts recorded associated enactment us tax legislation known tax cuts jobs act tcja including million related transition tax see note consolidated financial statements addition effective income tax rate reflects unfavorable impacts billion pretax charge recorded connection formation collaboration eisai million pretax charge related termination collaboration agreement samsung tax benefits recognized effective income tax rate includes provisional net charge billion related enactment tcja effective income tax rate also reflects unfavorable impact billion pretax charge recorded connection formation collaboration astrazeneca tax benefit recognized partially offset favorable impact net tax benefit million related settlement certain federal income tax issues see note consolidated financial statements benefit million related settlement state income tax issue net loss income attributable noncontrolling interests net loss income attributable noncontrolling interests million compared million million loss primarily reflects portion goodwill impairment charges related certain business healthcare services segment attributable noncontrolling interests net income earnings per common share net income attributable merck co inc billion billion billion eps nongaap income nongaap eps nongaap income nongaap eps alternative views companys performance merck providing management believes information enhances investors understanding companys results permits investors understand management assesses performance nongaap income nongaap eps exclude certain items nature items impact analysis underlying business performance trends excluded items considered nonrecurring consist acquisition divestiturerelated costs restructuring costs certain items excluded items significant components understanding assessing financial performance nongaap income nongaap eps important internal measures company senior management receives monthly analysis operating results includes nongaap eps management uses measures internally planning forecasting purposes measure performance company along metrics senior managements annual compensation derived part using nongaap income nongaap eps since nongaap income nongaap eps measures determined accordance gaap standardized meaning prescribed gaap therefore may comparable calculation similar measures companies information nongaap income nongaap eps considered addition substitute superior net income eps prepared accordance generally accepted accounting principles united states gaap table contents reconciliation gaap financial measures nongaap financial measures follows millions except per share amounts income taxes reported gaap increase decrease excluded items acquisition divestiturerelated costs restructuring costs items charge related formation oncology collaboration eisai charge related termination collaboration samsung charge acquisition viralytics charge related formation oncology collaboration astrazeneca charge related settlement worldwide keytruda patent litigation nongaap income taxes taxes income reported gaap estimated tax benefit excluded items net tax charge related enactment tcja net tax benefit settlement certain federal income tax issues tax benefit related settlement state income tax issue nongaap taxes income nongaap net income less net loss income attributable noncontrolling interests reported gaap acquisition divestiturerelated costs attributable noncontrolling interests nongaap net income attributable noncontrolling interests nongaap net income attributable merck co inc eps assuming dilution reported gaap eps difference nongaap eps assuming dilution estimated tax impact excluded items determined applying statutory rate originating territory nongaap adjustments amount provisional see note consolidated financial statements represents difference calculated gaap eps calculated nongaap eps may different amount calculated dividing impact excluded items weightedaverage shares applicable year acquisition divestiturerelated costs nongaap income nongaap eps exclude impact certain amounts recorded connection business acquisitions divestitures amounts include amortization intangible assets amortization purchase accounting adjustments inventories well intangible asset impairment charges expense income related changes estimated fair value measurement liabilities contingent consideration also excluded integration transaction certain costs associated business acquisitions divestitures restructuring costs nongaap income nongaap eps exclude costs related restructuring actions see note consolidated financial statements amounts include employee separation costs accelerated depreciation associated facilities closed divested accelerated depreciation costs represent difference depreciation expense recognized revised useful life asset based upon anticipated date site closed divested equipment disposed depreciation expense determined utilizing useful table contents life prior restructuring actions restructuring costs also include asset abandonment shutdown related costs well employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation costs certain items nongaap income nongaap eps exclude certain items items adjusted evaluating individual basis considering quantitative qualitative aspects typically consist items unusual nature significant results particular period indicative future operating results excluded nongaap income nongaap eps charge related formation collaboration eisai see note consolidated financial statements charge related termination collaboration agreement samsung insulin glargine see note consolidated financial statements charge acquisition viralytics see note consolidated financial statements measurementperiod adjustments related provisional amounts recorded tcja see note consolidated financial statements excluded nongaap income nongaap eps charge related formation collaboration astrazeneca see note consolidated financial statements well provisional net tax charge related enactment tcja net tax benefit related settlement certain federal income tax issues tax benefit related settlement state income tax issue see note consolidated financial statements excluded nongaap income nongaap eps charge settle worldwide patent litigation related keytruda research development chart reflecting companys current research pipeline february set forth item business research development research development update company currently several candidates regulatory review united states internationally keytruda approved antipd therapy clinical development expanded indications different cancer types february fda accepted granted priority review supplemental bla keytruda combination inlyta axitinib tyrosine kinase inhibitor firstline treatment patients advanced renal cell carcinoma supplemental bla based findings phase keynote trial demonstrated keytruda combination axitinib compared sunitinib significantly improved overall survival os pfs first line treatment advanced renal cell carcinoma data presented american society clinical oncology asco genitourinary cancers symposium february supplemental bla also included supporting data phase b keynote trial fda set pdufa date june merck filed data keynote regulatory authorities worldwide february committee medicinal products human use european medicines agency ema adopted positive opinion recommending keytruda combination carboplatin either paclitaxel nabpaclitaxel firstline treatment metastatic squamous nsclc adults recommendation based results pivotal phase keynote trial enrolled patients regardless pdl tumor expression status trial showed significant improvement os pfs patients taking keytruda combination chemotherapy carboplatin either paclitaxel nabpaclitaxel compared chemotherapy alone approved would mark first approval europe antipd therapy combination chemotherapy adults metastatic squamous nsclc october fda approved keytruda combination carboplatinpaclitaxel nabpaclitaxel firstline treatment metastatic squamous nsclc regardless pdl expression december fda extended action date supplemental bla seeking approval keytruda monotherapy firstline treatment locally advanced metastatic nsclc patients whose tumors express pdl tps without egfr alk genomic tumor aberrations supplemental bla based results phase keynote trial keytruda monotherapy demonstrated significant improvement os compared chemotherapy patient population company submitted additional data analyses table contents fda constituted major amendment extended pdufa date three months april merck continues work closely fda review supplemental bla february fda accepted granted priority review supplemental bla keytruda monotherapy treatment patients advanced sclc whose disease progressed two lines prior therapy supplemental bla seeking accelerated approval new indication based data sclc cohorts phase keynote phase b keynote trials fda set pdufa date june keytruda also studied combination chemotherapy ongoing phase keynote study patients newly diagnosed extensive stage sclc february fda accepted supplemental bla keytruda monotherapy combination platinum fluorouracil chemotherapy firstline treatment patients recurrent metastatic hnscc supplemental bla based part data pivotal phase keynote trial keytruda demonstrated significant improvement os compared standard care monotherapy patients whose tumors expressed pdl combined positive score cps cps combination chemotherapy total patient population data presented european society medical oncology esmo congress fda granted priority review supplemental bla set pdufa date june keynote also serves confirmatory trial keynote phase b study supported previous accelerated approval keytruda monotherapy treatment patients recurrent metastatic hnscc disease progression platinumcontaining chemotherapy november merck announced phase keynote trial investigating keytruda monotherapy secondline treatment advanced metastatic esophageal esophagogastric junction carcinoma met primary endpoint os patients whose tumors expressed pdl cps pivotal study treatment keytruda resulted statistically significant improvement os compared chemotherapy paclitaxel docetaxel irinotecan patients cps regardless histology primary endpoint os also evaluated patients squamous cell histology entire intentionto treat study population directionally favorable statistical significance os met two patient groups per statistical analysis plan key secondary endpoints pfs objective response rate orr formally tested os reached full intentiontotreat study population results presented january asco gastrointestinal cancers symposium submitted regulatory review additionally keytruda received breakthrough therapy designation fda treatment highrisk earlystage triplenegative breast cancer combination neoadjuvant chemotherapy fdas breakthrough therapy designation intended expedite development review candidate planned use alone combination treat serious lifethreatening disease condition preliminary clinical evidence indicates drug may demonstrate substantial improvement existing therapies one clinically significant endpoints october merck announced first presentation results interim analysis keynote phase trial evaluating keytruda previously treated patients highrisk nonmuscle invasive bladder cancer interim analysis studys primary endpoint showed complete response rate nearly three months keytruda patients whose disease unresponsive bacillus calmettegurin therapy current standard care disease ineligible refused undergo radical cystectomy results well study findings presented esmo congress february merck announced pivotal phase keynote trial evaluating keytruda plus best supportive care treatment patients advanced hepatocellular carcinoma previously treated systemic therapy meet coprimary endpoints os pfs compared placebo plus best supportive care final analysis study improvement os patients treated keytruda compared placebo however os results meet statistical significance per prespecified statistical plan results pfs also directionally favorable keytruda arm compared placebo reach statistical significance key secondary endpoint orr formally tested since superiority reached os pfs results presented upcoming medical meeting shared fda discussion table contents keytruda clinical development program consists clinical trials including trials combine keytruda cancer treatments studies encompass cancer types including bladder cervical colorectal esophageal gastric head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma melanoma mesothelioma nasopharyngeal nsclc ovarian pmbcl prostate renal smallcell lung triplenegative breast many currently phase clinical development trials planned cancers lynparza oral parp inhibitor currently approved certain types ovarian breast cancer july merck astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza multiple cancer types see note consolidated financial statements april merck astrazeneca announced ema validated review marketing authorization application lynparza use patients deleterious suspected deleterious brcamutated hernegative metastatic breast cancer previously treated chemotherapy neoadjuvant adjuvant metastatic setting first regulatory submission parp inhibitor breast cancer europe lynparza tablets also review eu maintenance treatment patients newlydiagnosed brcamutated advanced ovarian cancer complete partial response following firstline standard platinumbased chemotherapy submission based positive results pivotal phase solo trial trial showed statisticallysignificant clinicallymeaningful improvement pfs lynparza compared placebo reducing risk disease progression death patients newlydiagnosed brcamutated advanced ovarian cancer complete partial response platinumbased chemotherapy december merck astrazeneca announced positive results randomized openlabel controlled phase solo trial lynparza tablets patients relapsed ovarian cancer two lines treatment trial conducted postapproval commitment agreement fda results trial showed brcamutated advanced ovarian cancer patients treated lynparza following two prior lines chemotherapy demonstrated statistically significant clinically meaningful improvement primary endpoint orr key secondary endpoint pfs compared chemotherapy merck astrazeneca plan discuss results fda mka combination relebactam investigational betalactamase inhibitor imipenemcilastatin approved carbapenem antibiotic february merck announced fda accepted priority review nda mka treatment complicated urinary tract infections complicated intraabdominal infections caused certain susceptible gramnegative bacteria adults limited alternative therapies available pdufa date july april merck announced pivotal phase study mka demonstrated favorable overall response treatment certain imipenemnonsusceptible bacterial infections primary endpoint lower treatmentemergent nephrotoxicity kidney toxicity secondary endpoint compared colistin colistimethate sodium plus imipenemcilastatin regimen fda previously designated combination qualified infectious disease product designated fast track status treatment hospitalacquired bacterial pneumonia ventilatorassociated bacterial pneumonia complicated intraabdominal infections complicated urinary tract infections v rvsvgzebovgp live attenuated investigational ebola zaire disease vaccine candidate studied large scale phase clinical trials december merck announced application emergency use assessment listing eual v accepted review world health organization according eual process designed expedite availability vaccines needed public health emergencies another outbreak ebola decision grant v eual status based data regarding quality safety efficacyeffectiveness well riskbenefit analysis emergency use eual designation allows emergency use vaccine remains investigational yet licensed commercial distribution july merck announced fda granted v breakthrough therapy designation ema granted vaccine candidate prime priority medicines status november merck announced started submission rolling bla fda v rolling submission made pursuant fdas breakthrough therapy designation merck expects rolling submission bla completed company also intends file v ema table contents february merck announced fda accepted priority review supplemental nda zerbaxa treat adult patients nosocomial pneumonia including ventilatorassociated pneumonia caused certain susceptible gramnegative microorganisms pdufa date june zerbaxa also review indication ema zerbaxa currently approved united states treatment adult patients complicated urinary tract infections caused certain susceptible gramnegative microorganisms also indicated combination metronidazole treatment adult patients complicated intraabdominal infections caused certain susceptible gramnegative grampositive microorganisms addition candidates regulatory review company several drug candidates phase clinical development addition keytruda programs discussed mk gefapixant selective nonnarcotic orallyadministered pxreceptor agonist investigated phase trials treatment refractory chronic cough phase trial treatment women endometriosisrelated pain lenvima orally available tyrosine kinase inhibitor currently approved certain types thyroid cancer hepatocellular carcinoma combination certain patients renal cell carcinoma march merck eisai entered strategic collaboration worldwide codevelopment cocommercialization lenvima see note consolidated financial statements agreement merck eisai develop commercialize lenvima jointly monotherapy combination keytruda per agreement companies jointly initiate clinical studies evaluating keytrudalenvima combination support potential indications six types cancer endometrial cancer nsclc hepatocellular carcinoma head neck cancer bladder cancer melanoma well basket trial targeting multiple cancer types fda granted breakthrough therapy designation keytruda combination lenvima potential treatment patients advanced andor metastatic renal cell carcinoma potential treatment certain patients advanced andor metastatic nonmicrosatellite instability highproficient mismatch repair endometrial carcinoma mk vericiguat investigational treatment heart failure studied patients suffering chronic heart failure reduced ejection fracture phase clinical trial chronic heart failure preserved ejection fracture phase clinical trial development vericiguat part worldwide strategic collaboration merck bayer see note consolidated financial statements v investigational polyvalent conjugate vaccine prevention pneumococcal disease june merck initiated first phase study adult population prevention invasive pneumococcal disease currently five phase adult studies ongoing including studies healthy adults years age older adults risk factors pneumococcal disease infected hiv recipients allogeneic hematopoietic stem cell transplant october merck began first phase study pediatric population currently three studies ongoing including studies healthy infants children afflicted sickle cell disease january merck announced v received breakthrough therapy designation fda prevention invasive pneumococcal disease caused vaccine serotypes pediatric patients weeks years age result changes herpes zoster vaccine environment merck ending development v investigational vaccine prevention shingles immunocompromised patients company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources candidates company believes capable providing unambiguous promotable advantages patients payers delivering maximum value approved medicines vaccines new indications new formulations merck pursuing emerging product opportunities independent therapeutic area modality small molecule biologics vaccines building biologics capabilities company committed ensuring externally sourced programs remain important component pipeline strategy focus supplementing internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well access new technologies table contents company also reviews pipeline examine candidates may provide value outlicensing company continues evaluate certain latestage clinical development platform technology assets determine outlicensing sale potential companys clinical pipeline includes candidates multiple disease areas including cancer cardiovascular diseases diabetes infectious diseases neurosciences obesity pain respiratory diseases vaccines acquired inprocess research development connection business acquisitions company recorded fair value inprocess research projects time acquisition yet reached technological feasibility december balance iprd billion iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates time periods receive approvals fda regulatory agencies subject uncertainty significant delays approval process companys failure obtain approval would delay prevent company realizing revenues products additionally certain iprd programs fail abandoned development company realize future cash flows estimated recorded iprd acquisition date company may also recover research development expenditures made since acquisition develop programs circumstances occur companys future operating results could adversely affected company may recognize impairment charges charges could material company recorded iprd impairment charges within research development expenses million million billion respectively see note consolidated financial statements additional research development required remaining programs reach technological feasibility costs complete research projects depend whether projects brought final stages development ultimately submitted fda regulatory agencies approval acquisitions research collaborations license agreements merck continues remain focused pursuing opportunities potential drive near longterm growth certain recent transactions described merck actively monitoring landscape growth opportunities meet companys strategic criteria march merck eisai announced strategic collaboration worldwide codevelopment cocommercialization lenvima orally available tyrosine kinase inhibitor discovered eisai agreement merck eisai develop commercialize lenvima jointly monotherapy combination mercks antipd therapy keytruda agreement merck made upfront payment eisai million make payments million certain option rights million paid march million expected paid million expected paid company recorded charge billion research development expenses related upfront payment future option payments addition agreement provides eisai receive million associated achievement certain clinical regulatory milestones billion achievement milestones associated sales lenvima see note consolidated financial statements june merck acquired viralytics limited viralytics australian publicly traded company focused oncolytic immunotherapy treatments range cancers aud million million transaction provided merck full rights cavatak v formerly cva viralyticss investigational oncolytic immunotherapy cavatak based viralyticss proprietary formulation oncolytic virus coxsackievirus type shown preferentially infect kill cancer cells cavatak currently evaluated multiple phase phase clinical trials intratumoral intravenous agent including combination keytruda previous agreement merck viralytics study investigating use keytruda cavatak combination melanoma prostate lung bladder cancers transaction accounted acquisition asset merck recorded net assets million primarily cash acquisition date research table contents development expenses million related transaction future contingent payments associated acquisition february merck immune design entered definitive agreement merck acquire immune design per share cash approximate value million immune design latestage immunotherapy company employing nextgeneration vivo approaches enable bodys immune system fight disease immune designs proprietary technologies glaas zvex engineered activate immune systems natural ability generate andor expand antigenspecific cytotoxic immune cells fight cancer chronic diseases terms acquisition agreement merck subsidiary initiate tender offer acquire outstanding shares immune design closing tender offer subject certain conditions including tender shares representing least majority total number immune designs outstanding shares expiration waiting period hartscottrodino antitrust improvements act customary conditions transaction expected close early second quarter capital expenditures capital expenditures billion billion billion expenditures united states billion billion billion october company announced plans invest approximately billion new capital projects focus investment primarily increasing manufacturing capacity across mercks key businesses depreciation expense billion billion billion years billion depreciation expense applied locations united states total depreciation expense included accelerated depreciation million million respectively associated restructuring activities see note consolidated financial statements analysis liquidity capital resources mercks strong financial profile enables fund research development focus external alliances support inline products maximize upcoming launches providing significant cash returns shareholders selected data millions working capital total debt total liabilities equity cash provided operations total debt decline working capital compared reflects utilization cash shortterm borrowings fund billion asr agreements billion payment redeem debt connection exercise makewhole provision discussed well million upfront payment related formation collaboration eisai discussed decline working capital compared primarily reflects reclassification billion notes due first half longterm debt shortterm debt billion upfront option payments related formation astrazeneca collaboration discussed well million paid redeem debt connection tender offers discussed cash provided operating activities billion billion billion lower cash provided operating activities reflects billion payment related settlement certain federal income tax issues see note consolidated financial statements payments billion related formation collaboration astrazeneca see note consolidated financial statements million payment made company related previously disclosed settlement worldwide keytruda patent litigation cash provided operating activities continues companys primary source funds finance operating needs capital expenditures treasury stock purchases dividends paid shareholders cash provided investing activities billion compared billion increase cash provided investing activities driven primarily lower purchases securities investments partially offset higher capital expenditures lower proceeds sales securities investments million milestone payment related collaboration bayer see note consolidated financial statements cash provided investing activities billion compared use table contents cash investing activities billion change driven primarily lower purchases securities investments higher proceeds sales securities investments lower use cash acquisitions businesses cash used financing activities billion compared billion increase cash used financing activities driven primarily higher purchases treasury stock largely asr agreements discussed higher payments debt payment contingent consideration related prior year business acquisition partially offset increase shortterm borrowings cash used financing activities billion compared billion increase cash used financing activities driven primarily proceeds issuance debt well higher purchases treasury stock lower proceeds exercise stock options partially offset lower payments debt companys contractual obligations december follows payments due period millions total thereafter purchase obligations loans payable current portion longterm debt longterm debt interest related debt obligations unrecognized tax benefits transition tax related enactment tcja leases includes future inventory purchases company committed connection certain divestitures december companys consolidated balance sheet reflects liabilities unrecognized tax benefits interest penalties billion including million reflected current liability due high degree uncertainty regarding timing future cash outflows liabilities unrecognized tax benefits beyond one year reasonable estimate period cash settlement years beyond made connection enactment tcja company required pay onetime transition tax company elected pay period eight years permitted tcja see note consolidated financial statements purchase obligations enforceable legally binding obligations purchases goods services including minimum inventory contracts research development advertising amounts reflected research development obligations include contingent milestone payments related collaborative arrangements acquisitions contingent milestone payments considered contractual obligations contingent upon successful achievement developmental regulatory approval commercial milestones december company liabilities milestone payments related collaborations astrazeneca eisai bayer see note consolidated financial statements also excluded research development obligations potential future funding commitments approximately million investments research venture capital funds loans payable current portion long term debt reflects million longdated notes subject repayment option holders required funding obligations relating companys pension postretirement benefit plans expected material however company currently anticipates contributing approximately million us pension plans million international pension plans million postretirement benefit plans december company exercised makewhole provision billion notes due repaid debt november company launched tender offers certain outstanding notes debentures company paid million aggregate consideration applicable purchase price together accrued interest redeem million principal amount debt validly tendered connection tender offers november company issued billion principal amount senior unsecured notes consisting million principal amount notes due million principal amount notes due company used net proceeds offering billion general corporate purposes table contents company billion credit facility matures june facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility march company filed securities registration statement us securities exchange commission sec automatic shelf registration process available wellknown seasoned issuers effective three years effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date company continues maintain conservative financial profile company places cash investments instruments meet high credit quality standards specified investment policy guidelines guidelines also limit amount credit exposure one issuer company participate offbalance sheet arrangements involving unconsolidated subsidiaries provide financing potentially expose company unrecorded financial obligations october merck announced board directors approved increase companys quarterly dividend raising per share per share companys outstanding common stock payment made january january board directors declared quarterly dividend per share companys common stock second quarter payable april november mercks board directors authorized purchases billion mercks common stock treasury treasury stock purchase authorization time limit made time openmarket transactions block transactions exchange privately negotiated transactions october mercks board directors authorized additional billion treasury stock purchases time limit completion company entered asr agreements billion discussed company spent billion purchase shares common stock treasury december companys remaining share repurchase authorization billion company purchased billion billion common stock respectively authorized share repurchase programs october company entered asr agreements two thirdparty financial institutions dealers asr agreements merck agreed purchase billion mercks common stock total initial delivery million shares mercks common stock based thencurrent market price made dealers merck payments billion made merck dealers october funded existing cash investments well shortterm borrowings number shares mercks common stock merck may receive may required remit upon final settlement asr agreements based upon average daily volume weightedaverage price mercks common stock term asr program less negotiated discount final settlement transaction asr agreements expected occur first half may occur earlier option dealers later certain circumstances merck obligated make adjustment payments dealers asr agreements merck may elect satisfy obligations cash shares mercks common stock financial instruments market risk disclosures company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates table contents objective revenue hedging program reduce variability caused changes foreign exchange rates would affect us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales forecasted sales expected occur planning cycle typically two years future company layer hedges time increasing portion forecasted sales hedged gets closer expected date forecasted sales portion forecasted sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments company manages anticipated transaction exposure principally purchased local currency put options forward contracts purchased collar options merck principally sells foreign currency revenue hedging program uniform weakening us dollar would yield largest overall potential loss market value hedge instruments market value mercks hedges would declined estimated million million december respectively uniform weakening us dollar market value determined using foreign exchange option pricing model holding factors except exchange rates constant although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows company manages operating activities net asset positions local subsidiary order mitigate effects exchange monetary assets liabilities company also uses balance sheet risk management program mitigate exposure net monetary assets denominated currency subsidiarys functional currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument cash flows contracts reported operating activities consolidated statement cash flows sensitivity analysis changes value us dollar foreign currency denominated derivatives investments monetary assets liabilities indicated us dollar uniformly weakened currency exposures company december income taxes would declined approximately million million respectively company net short payable position relative major foreign currencies consideration forward contracts uniform weakening us dollar yield largest overall potential net loss earnings due exchange measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows economy argentina determined hyperinflationary consequently accordance us gaap company began remeasuring monetary assets liabilities operations earnings impact companys results immaterial company also uses forward exchange contracts hedge net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation company hedges portion net investment certain foreign operations unrealized gains losses contracts recorded foreign currency translation adjustment within comprehensive income loss oci remain accumulated comprehensive income loss aoci either sale complete substantially complete liquidation subsidiary company excludes certain portions change fair value derivative instruments assessment hedge effectiveness excluded component changes fair value excluded components recognized oci accordance new guidance adopted january see note consolidated financial statements company elected recognize earnings initial value excluded component straightline basis life derivative instrument rather table contents using marktomarket approach cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk may four interest rate swaps notional amounts aggregating billion matured swaps effectively converted companys billion fixedrate notes due variable rate debt december connection early repayment debt company settled three interest rate swaps notional amounts aggregating million swaps effectively converted portion companys billion notes due variable rate debt december company party payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes detailed table millions number interest rate total swap notional debt instrument par value debt swaps held amount notes due notes due notes due notes due interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes libor swap rate recorded interest expense along offsetting fair value changes swap contracts cash flows contracts reported operating activities consolidated statement cash flows companys investment portfolio includes cash equivalents shortterm investments market values significantly affected changes interest rates market value companys medium longterm fixedrate investments modestly affected changes us interest rates changes medium longterm us interest rates significant impact market value companys fixedrate borrowings generally longer maturities sensitivity analysis measure potential changes market value mercks investments debt change interest rates indicated one percentage point increase interest rates december would positively affected net aggregate market value instruments billion billion respectively one percentage point decrease december would negatively affected net aggregate market value billion billion respectively fair value mercks debt determined using pricing models reflecting one percentage point shifts appropriate yield curves fair values mercks investments determined using combination pricing duration models table contents critical accounting policies companys consolidated financial statements prepared conformity gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets contingent consideration well subsequent fair value measurements additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities accruals contingent salesbased milestone payments reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates application following accounting policies result accounting estimates potential significant impact financial statements acquisitions dispositions determine whether transactions accounted acquisitions disposals assets businesses company makes certain judgments include assessment inputs processes outputs associated acquired set activities company determines substantially fair value gross assets included transaction concentrated single asset group similar assets assets would represent business considered business assets transaction need include input substantive process together significantly contribute ability create outputs business combination acquisition method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies generally recognized fair value fair value determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date acquisition fair values intangible assets including acquired iprd determined utilizing information available near acquisition date based expectations assumptions deemed reasonable management given considerable judgment involved determining fair values company typically obtains assistance thirdparty valuation specialists significant items amounts allocated acquired iprd capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make separate determination thenuseful life asset generally determined period substantial majority cash flows expected generated begin amortization certain companys business acquisitions involve potential future payment consideration contingent upon achievement performance milestones including product development milestones royalty payments future product sales fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probability weighted cash flows subsequent acquisition date reporting period contingent consideration liability remeasured current fair value changes either expense income recorded earnings changes inputs may result significantly different fair value adjustment judgments made determining estimated fair values assigned assets acquired liabilities assumed business combination well asset lives materially affect companys results operations fair values identifiable intangible assets related currently marketed products product rights primarily determined using income approach fair value estimated based assets table contents discounted projected net cash flows companys estimates market participant net cash flows consider historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles time investment required develop products technologies ability obtain marketing regulatory approvals ability manufacture commercialize products extent timing potential new product introductions companys competitors life assets underlying patent net cash flows probabilityadjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probabilityadjusted future net cash flows product discounted present value utilizing appropriate discount rate fair values identifiable intangible assets related iprd also determined using income approach fair value estimated based assets probabilityadjusted future net cash flows reflect different stages development product associated probability successful completion net cash flows discounted present value using appropriate discount rate company determines transaction accounted acquisition business transaction accounted asset acquisition rather business combination therefore goodwill recorded asset acquisition acquired iprd alternative future use charged expense contingent consideration recognized acquisition date revenue recognition january company adopted new standard revenue recognition see note consolidated financial statements changes companys revenue recognition policy result adopting new guidance described recognition revenue requires evidence contract probable collection sales proceeds completion substantially performance obligations merck acts principal substantially customer arrangements therefore records revenue gross basis majority companys contracts related pharmaceutical animal health segments single performance obligation promise transfer goods shipping considered immaterial context overall customer arrangement damages loss goods transit rare therefore shipping deemed separately recognized performance obligation vast majority revenues sales products recognized point time control goods transferred customer company determined title risks rewards ownership transfer customer company entitled payment certain merck entities including us entities contract terms control goods passes customer upon shipment however either pursuant terms contract business practice merck retains responsibility goods lost damaged transit prior adoption new standard merck would recognize revenue entities upon delivery goods new guidance company recognizing revenue time shipment entities businesses within companys healthcare services segment certain services animal health segment revenue recognized time generally ratably contract term services provided service revenues material nature companys business gives rise several types variable consideration including discounts returns estimated time sale generally using expected value method although likely amount method used prompt pay discounts united states sales discounts issued customers pointofsale intermediary wholesaler known chargebacks form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition revenues recorded net time value money discounts collection accounts receivable expected excess one year us provision aggregate customer discounts covers chargebacks rebates chargebacks discounts occur contracted customer purchases intermediary wholesaler contracted customer generally purchases product wholesaler contracted price plus markup wholesaler turn charges table contents company back difference price initially paid wholesaler contract price paid wholesaler customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product pharmacy benefit plan participant provision rebates based expected patient usage well inventory levels distribution channel determine contractual obligation benefit providers company uses historical customer segment utilization mix sales forecasts changes product mix price inventory levels distribution channel government pricing calculations prior payment history order estimate expected provision amounts accrued aggregate customer discounts evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers federal state agencies customers amounts accrued company continually monitors provision aggregate customer discounts material adjustments estimates associated aggregate customer discount provision summarized information changes aggregate customer discount accrual related us sales follows millions balance january current provision adjustments prior years payments balance december accruals chargebacks reflected direct reduction accounts receivable accruals rebates current liabilities accrued balances relative provisions included accounts receivable accrued current liabilities million billion respectively december million billion respectively december outside united states variable consideration form discounts rebates combination commerciallydriven discounts highly competitive product classes discounts required gain maintain reimbursement legislatively mandated rebates certain european countries legislatively mandated rebates calculated based estimate governments total unbudgeted spending companys specific payback obligation rebates may also required based specific product sales thresholds company applies estimated factor actual invoiced sales represent expected level future discount rebate obligations associated sale company maintains returns policy allows us pharmaceutical customers return product within specified period prior subsequent expiration date generally three six months months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market generic competition changes formularies launch overthecounter products among others product returns provision us pharmaceutical sales percentage us net pharmaceutical sales outside united states returns allowed certain countries limited basis mercks payment terms us pharmaceutical customers typically net days receipt invoice us animal health customers typically net days receipt invoice however certain products including keytruda longer payment terms days outside united states payment terms typically days days although certain markets longer payment terms distribution programs us wholesalers company encourages wholesalers align purchases underlying demand maintain inventories specified levels terms programs allow wholesalers earn fees upon providing visibility inventory levels well achieving certain performance parameters inventory management customer service levels reducing shortage claims reducing table contents product returns information provided wholesaler distribution programs includes items sales trends inventory onhand onorder quantity product returns wholesalers generally provide abovementioned data company regulatory requirement report lot level information manufacturers level information needed determine remaining shelf life original sale date inventory given current wholesaler inventory levels generally less month company believes collection order lot information across wholesale customers would limited use estimating sales discounts returns inventories produced preparation product launches company capitalizes inventories produced preparation product launches sufficient support estimated initial market demand typically capitalization inventory begin related product candidates phase clinical trials considered high probability regulatory approval company monitors status respective product within regulatory approval process however company generally disclose specific timing regulatory approval company aware specific risks contingencies normal regulatory approval process specific issues identified research process relating safety efficacy manufacturing marketing labeling related inventory would generally capitalized expiry dates inventory affected stage completion company manages levels inventory stage optimize shelf life inventory relation anticipated market demand order avoid product expiry issues inventories capitalized anticipated future sales shelf lives support realization inventory value inventory shelf life sufficient meet initial product launch requirements inventories produced preparation product launches capitalized december million million respectively contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well certain additional matters see note consolidated financial statements company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted site investigations feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying accruing costs past merck performed worldwide survey assess sites potential contamination resulting past industrial activities table contents assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated definitive information became available course investigations andor remedial efforts site estimates refined accruals established adjusted accordingly estimates related accruals continue refined annually company believes compliance issues associated applicable environmental laws regulations would material adverse effect company expenditures remediation environmental liabilities million estimated million aggregate years managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year sharebased compensation company expenses sharebased payment awards employees including grants stock options requisite service period based grant date fair value awards company determines fair value certain sharebased awards using blackscholes optionpricing model uses historical current market data estimate fair value method incorporates various assumptions riskfree interest rate expected volatility expected dividend yield expected life options total pretax sharebased compensation expense million million million december million total pretax unrecognized compensation expense related nonvested stock option restricted stock unit performance share unit awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses pensions postretirement benefit plans net periodic benefit cost pension plans totaled million million million net periodic benefit credit postretirement benefit plans million million million pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions including discount rate plan benefit obligations expected rate return plan assets changes net periodic benefit cost year year pension plans largely attributable changes discount rate affecting net loss amortization company reassesses benefit plan assumptions regular basis pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due discount rates companys us pension postretirement benefit plans ranged december compared range december expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid developing expected rate return company considers longterm compound annualized returns historical market data current market conditions actual returns companys plan assets using reference information company develops forwardlooking return expectations asset category weightedaverage expected longterm rate return target portfolio allocated across investment categories expected portfolio performance reflects contribution active management appropriate expected rate return companys us pension postretirement benefit plans range compared range decrease primarily due modest shift asset allocation company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation table contents plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests nonus pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines actuarial assumptions based upon managements best estimates judgment reasonably possible change plus minus basis points discount rate assumption assumptions held constant would estimated million favorable unfavorable impact companys net periodic benefit cost reasonably possible change plus minus basis points expected rate return assumption assumptions held constant would estimated million favorable unfavorable impact mercks net periodic benefit cost required funding obligations relating companys pension postretirement benefit plans expected material preceding hypothetical changes discount rate expected rate return assumptions would impact companys funding requirements net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions recorded component aoci expected returns pension plans based calculated marketrelated value assets methodology asset gainslosses resulting actual returns differ companys expected returns recognized market related value assets ratably fiveyear period also net loss amounts aoci excess certain thresholds amortized net periodic benefit cost average remaining service life employees restructuring costs restructuring costs recorded connection restructuring programs designed streamline companys cost structure result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place accruing termination costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range connection actions management also assesses recoverability longlived assets employed business certain instances asset lives shortened based changes expected useful lives affected assets severance related costs reflected within restructuring costs assetrelated charges reflected within cost sales selling general administrative expenses research development expenses depending upon nature asset impairments longlived assets company assesses changes economic regulatory legal conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets company periodically evaluates whether current facts circumstances indicate carrying values longlived assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows approach goodwill represents excess consideration transferred fair value net assets businesses acquired goodwill assigned reporting units evaluated impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount factors considered assessment include general macroeconomic conditions conditions specific industry market cost factors could significant effect earnings cash flows overall financial performance reporting unit table contents whether sustained declines companys share price company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed carrying value reporting unit greater fair value goodwill impairment charge recorded difference carrying value goodwill acquired intangible assets excluding iprd initially recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives events circumstances warrant review company assess recoverability future operations using pretax undiscounted cash flows derived lowest appropriate asset groupings impairments recognized operating results extent carrying value intangible asset exceeds fair value determined based net present value estimated future cash flows iprd company acquires business combinations represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment project company tests iprd impairment least annually frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value iprd intangible asset less carrying amount company concludes likely fair value less carrying amount quantitative test compares fair value iprd intangible asset carrying value performed impairment testing purposes company may combine separately recorded iprd intangible assets one unit account based relevant facts circumstances generally company combine iprd intangible assets testing purposes operate single asset essentially inseparable fair value less carrying amount impairment loss recognized within companys operating results judgments made evaluating impairment longlived intangibles materially affect companys results operations impairments investments company reviews investments marketable debt securities impairments based determination whether decline market value investment carrying value otherthantemporary company considers available evidence evaluating potential impairments investments marketable debt securities including duration extent fair value less cost changes fair value considered temporary reported net tax oci otherthantemporary impairment occurred company expect recover entire amortized cost basis marketable debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings recorded income expense net limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized oci investments publicly traded equity securities reported fair value determined using quoted market prices active markets identical assets quoted prices similar assets inputs observable corroborated observable market data changes fair value included income expense net investments equity securities without readily determinable fair values recorded cost plus minus subsequent observable price changes orderly transactions identical similar investments minus impairments adjustments recognized income expense net realized gains losses equity securities included income expense net taxes income companys effective tax rate based pretax income statutory tax rates tax planning opportunities available various jurisdictions company operates estimated effective tax rate year applied companys quarterly operating results event significant unusual onetime item recognized expected recognized companys quarterly operating results tax attributable item would separately calculated recorded time unusual onetime item company considers resolution prior year tax matters items significant judgment required determining companys tax provision evaluating tax positions recognition measurement tax position based table contents managements best judgment given facts circumstances information available reporting date company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements likely threshold met period tax position taken company may subsequently recognize benefit tax position tax matter effectively settled statute limitations expires likely threshold met subsequent period see note consolidated financial statements tax regulations require items included tax return different times items reflected financial statements timing differences create deferred tax assets liabilities deferred tax assets generally represent items used tax deduction credit tax return future years company already recorded tax benefit financial statements company establishes valuation allowances deferred tax assets amount expected future taxable income likely support use deduction credit deferred tax liabilities generally represent tax expense recognized financial statements payment deferred expense company already taken deduction tax return yet recognized expense financial statements recently issued accounting standards discussion recently issued accounting standards see note consolidated financial statements cautionary factors may affect future results report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning negative variations foregoing one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement one carefully evaluate statements light factors including risk factors described companys filings securities exchange commission especially forms q k item risk factors annual report company discusses detail various important risk factors could cause actual results differ expected historic results company notes factors investors permitted private securities litigation reform act one understand possible predict identify factors consequently reader consider list complete statement potential risks uncertainties item quantitative qualitative disclosures market risk information required item incorporated reference discussion financial instruments market risk disclosures item managements discussion analysis financial condition results operations table contents item financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income comprehensive income equity cash flows three years period ended december notes consolidated financial statements report dated february pricewaterhousecoopers llp independent registered public accounting firm follows consolidated statement income merck co inc subsidiaries years ended december millions except per share amounts sales costs expenses cost sales selling general administrative research development restructuring costs income expense net income taxes taxes income net income less net loss income attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders consolidated statement comprehensive income merck co inc subsidiaries years ended december millions net income attributable merck co inc comprehensive loss income net taxes net unrealized gain loss derivatives net reclassifications net unrealized loss investments net reclassifications benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment comprehensive income attributable merck co inc accompanying notes integral part consolidated financial statements table contents consolidated balance sheet merck co inc subsidiaries december millions except per share amounts assets current assets cash cash equivalents shortterm investments accounts receivable net allowance doubtful accounts inventories excludes inventories classified assets see note current assets total current assets investments property plant equipment cost land buildings machinery equipment office furnishings construction progress less accumulated depreciation goodwill intangibles net assets liabilities equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable total current liabilities longterm debt deferred income taxes noncurrent liabilities merck co inc stockholders equity common stock par value authorized shares issued shares paidin capital retained earnings accumulated comprehensive loss less treasury stock cost shares shares total merck co inc stockholders equity noncontrolling interests total equity accompanying notes integral part consolidated financial statement table contents consolidated statement equity merck co inc subsidiaries years ended december millions except per share amounts accumulated non common paidin retained comprehensive treasury controlling stock capital earnings loss stock interests total balance january net income attributable merck co inc comprehensive loss net taxes cash dividends declared common stock per share treasury stock shares purchased acquisition staywell company llc net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc comprehensive income net taxes cash dividends declared common stock per share treasury stock shares purchased acquisition valle sa net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc adoption new accounting standards see note comprehensive loss net taxes cash dividends declared common stock per share treasury stock shares purchased net loss attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december accompanying notes integral part consolidated financial statement table contents consolidated statement cash flows merck co inc subsidiaries years ended december millions cash flows operating activities net income adjustments reconcile net income net cash provided operating activities depreciation amortization intangible asset impairment charges charge future payments related collaboration license options provisional charge onetime transition tax related enactment us tax legislation charge related settlement worldwide keytruda patent litigation deferred income taxes sharebased compensation net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities net cash provided operating activities cash flows investing activities capital expenditures purchases securities investments proceeds sales securities investments acquisitions net cash acquired net cash provided used investing activities cash flows financing activities net change shortterm borrowings payments debt proceeds issuance debt purchases treasury stock dividends paid stockholders proceeds exercise stock options net cash used financing activities effect exchange rate changes cash cash equivalents restricted cash net increase decrease cash cash equivalents restricted cash cash cash equivalents restricted cash beginning year includes million restricted cash january included assets cash cash equivalents restricted cash end year includes million restricted cash december included assets accompanying notes integral part consolidated financial statement table contents notes consolidated financial statements merck co inc subsidiaries millions except per share amounts nature operations merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include four operating segments pharmaceutical animal health healthcare services alliances segments pharmaceutical animal health segments reportable segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities december merck sanofi pasteur sa sanofi terminated equallyowned joint venture sanofi pasteur msd spmsd developed marketed vaccines europe merck began recording vaccine sales incurring costs result operating vaccines business european markets previously part spmsd joint venture accounted equity method affiliate animal health segment discovers develops manufactures markets animal health products including pharmaceutical vaccine products prevention treatment control disease major livestock companion animal species company sells veterinarians distributors animal producers healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients alliances segment primarily includes activity companys relationship astrazeneca lp related sales nexium prilosec concluded see note summary accounting policies principles consolidation consolidated financial statements include accounts company subsidiaries controlling interest maintained intercompany balances transactions eliminated controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities majority exposure expected losses residual returns consolidated subsidiaries merck ownership less outside shareholders interests shown noncontrolling interests equity investments affiliates company significant influence controlling interest interests entities owned equally company third party shared control carried equity basis acquisitions business combination acquisition method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies generally recognized fair value fair value determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date acquisition company determines assets acquired meet table contents definition business acquisition method accounting transaction accounted acquisition assets rather business combination therefore goodwill recorded asset acquisition acquired inprocess research development iprd alternative future use charged expense contingent consideration recognized acquisition date foreign currency translation net assets international subsidiaries local currencies determined functional currencies translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation account included accumulated comprehensive income loss aoci reflected separate component equity subsidiaries operate highly inflationary economies subsidiaries us dollar determined functional currency nonmonetary foreign currency assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included income expense net cash equivalents cash equivalents comprised certain highly liquid investments original maturities less three months inventories inventories valued lower cost net realizable value cost substantial majority us pharmaceutical vaccine inventories determined using lastin firstout lifo method financial reporting tax purposes cost inventories determined using firstin firstout fifo method inventories consist currently marketed products well certain inventories produced preparation product launches considered high probability regulatory approval evaluating recoverability inventories produced preparation product launches company considers likelihood revenue obtained future sale related inventory together status product within regulatory approval process investments investments marketable debt securities classified availableforsale reported fair value fair values companys investments marketable debt securities determined using quoted market prices active markets identical assets liabilities quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities changes fair value considered temporary reported net tax comprehensive income oci company considers available evidence evaluating potential impairments investments marketable debt securities including duration extent fair value less cost thantemporary impairment occurred company expect recover entire amortized cost basis marketable debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings recorded income expense net limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized oci realized gains losses debt securities included income expense net investments publicly traded equity securities reported fair value determined using quoted market prices active markets identical assets quoted prices similar assets inputs observable corroborated observable market data changes fair value included income expense net investments equity securities without readily determinable fair values recorded cost plus minus subsequent observable price changes orderly transactions identical similar investments minus impairments adjustments recognized income expense net realized gains losses equity securities included income expense net revenue recognition january company adopted asu revenue contracts customers subsequent amendments asc new guidance using modified retrospective method merck applied new guidance contracts customers within scope standard effect january recognized cumulative effect initially applying new guidance adjustment opening balance retained earnings see recently adopted accounting standards comparative information prior periods restated continues reported accounting standards effect periods table contents new guidance requires entity recognize revenue depict transfer goods services customers amount reflects consideration expects entitled exchange goods services new guidance introduces step model recognize revenue control transferred identify contract customer identify performance obligations contract determine transaction price allocate transaction price performance obligations contract recognize revenue performance obligations satisfied changes companys revenue recognition policy result adopting asc described see note disaggregated revenue disclosures recognition revenue requires evidence contract probable collection sales proceeds completion substantially performance obligations merck acts principal substantially customer arrangements therefore records revenue gross basis majority companys contracts related pharmaceutical animal health segments single performance obligation promise transfer goods shipping considered immaterial context overall customer arrangement damages loss goods transit rare therefore shipping deemed separately recognized performance obligation vast majority revenues sales products recognized point time control goods transferred customer company determined title risks rewards ownership transfer customer company entitled payment certain merck entities including us entities contract terms control goods passes customer upon shipment however either pursuant terms contract business practice merck retains responsibility goods lost damaged transit prior adoption new standard merck would recognize revenue entities upon delivery goods new guidance company recognizing revenue time shipment entities company recognizes revenue sales vaccines federal government placement vaccine stockpiles accordance securities exchange commission sec interpretation commission guidance regarding accounting sales vaccines bioterror countermeasures federal government placement pediatric vaccine stockpile strategic national stockpile interpretation allows companies recognize revenue sales vaccines us government stockpiles even though sales might meet criteria revenue recognition accounting guidance businesses within companys healthcare services segment certain services animal health segment revenue recognized time generally ratably contract term services provided service revenues material nature companys business gives rise several types variable consideration including discounts returns estimated time sale generally using expected value method although likely amount method used prompt pay discounts united states sales discounts issued customers pointofsale intermediary wholesaler known chargebacks form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition revenues recorded net time value money discounts collection accounts receivable expected excess one year us provision aggregate customer discounts covering chargebacks rebates billion billion billion chargebacks discounts occur contracted customer purchases intermediary wholesaler contracted customer generally purchases product wholesaler contracted price plus markup wholesaler turn charges company back difference price initially paid wholesaler contract price paid wholesaler customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product pharmacy benefit plan participant provision rebates based expected patient usage well inventory levels distribution channel determine contractual obligation benefit providers company uses historical customer segment utilization mix sales forecasts changes product mix price inventory levels distribution channel government pricing calculations prior payment history order estimate expected provision amounts accrued aggregate customer discounts table contents evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers federal state agencies customers amounts accrued accrued balances relative provisions chargebacks rebates included accounts receivable accrued current liabilities million billion respectively december million billion respectively december outside united states variable consideration form discounts rebates combination commerciallydriven discounts highly competitive product classes discounts required gain maintain reimbursement legislatively mandated rebates certain european countries legislatively mandated rebates calculated based estimate governments total unbudgeted spending companys specific payback obligation rebates may also required based specific product sales thresholds company applies estimated factor actual invoiced sales represent expected level future discount rebate obligations associated sale company maintains returns policy allows us pharmaceutical customers return product within specified period prior subsequent expiration date generally three six months months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market generic competition changes formularies launch overthecounter products among others outside united states returns allowed certain countries limited basis mercks payment terms us pharmaceutical customers typically net days receipt invoice us animal health customers typically net days receipt invoice however certain products including keytruda longer payment terms days outside united states payment terms typically days days although certain markets longer payment terms following table provides effects adopting asc consolidated statement income amounts without effects adopting adoption asc year ended december reported asc sales cost sales income taxes taxes income net income attributable merck co inc following table provides effects adopting asc consolidated balance sheet amounts without effects adoption asc december reported adopting asc assets accounts receivable inventories liabilities accrued current liabilities income taxes payable equity retained earnings depreciation depreciation provided estimated useful lives assets principally using straightline method tax purposes accelerated tax methods used estimated useful lives primarily range years buildings years machinery equipment office furnishings depreciation expense billion billion billion table contents advertising promotion costs advertising promotion costs expensed incurred company recorded advertising promotion expenses billion billion billion respectively software capitalization company capitalizes certain costs incurred connection obtaining developing internaluse software including external direct costs material services payroll costs employees directly involved software development capitalized software costs included property plant equipment amortized beginning software project substantially complete asset ready intended use capitalized software costs associated projects amortized years including companys ongoing multiyear implementation enterprisewide resource planning system million million net accumulated amortization december respectively capitalized software costs amortized periods ranging years costs incurred preliminary project stage postimplementation stage well maintenance training costs expensed incurred goodwill goodwill represents excess consideration transferred fair value net assets businesses acquired goodwill assigned reporting units evaluated impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed carrying value reporting unit greater fair value goodwill impairment charge recorded difference carrying value goodwill acquired intangibles acquired intangibles include products product rights tradenames patents initially recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives ranging years see note company periodically evaluates whether current facts circumstances indicate carrying values acquired intangibles may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference carrying value intangible asset fair value determined based net present value estimated future cash flows acquired inprocess research development acquired iprd company acquires business combinations represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make determination thenuseful life intangible asset generally determined period substantial majority cash flows expected generated begin amortization company tests iprd impairment least annually frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value iprd intangible asset less carrying amount company concludes likely fair value less carrying amount quantitative test compares fair value iprd intangible asset carrying value performed fair value less carrying amount impairment loss recognized operating results contingent consideration certain companys business acquisitions involve potential future payment consideration contingent upon achievement performance milestones including product development milestones royalty payments future product sales fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probability weighted cash flows subsequent acquisition date reporting period contingent consideration liability remeasured current fair value changes either expense income recorded earnings research development research development expensed incurred nonrefundable advance payments goods services used future research development activities expensed table contents activity performed goods received rather payment made research development expenses include restructuring costs iprd impairment charges addition research development expenses include expense income related changes estimated fair value measurement liabilities contingent consideration research development expenses also include upfront milestone payments related asset acquisitions licensing transactions involving clinical development programs yet received regulatory approval collaborative arrangements merck entered collaborative arrangements provide company varying rights develop produce market products together collaborative partners merck principal sales transactions third parties company recognizes sales cost sales selling general administrative expenses gross basis profit sharing amounts pays collaborative partners recorded within cost sales collaborative partner principal sales transactions third parties company records profit sharing amounts received collaborative partners alliance revenue within sales alliance revenue recorded net cost sales includes adjustment share commercialization costs partners accordance collaboration agreement adjustment determined comparing commercialization costs merck incurred directly reported within selling general administrative expenses costs collaborative partner incurred research development costs merck incurs related collaborations recorded within research development expenses cost reimbursements collaborative partner payments received collaborative partner share costs pursuant terms collaboration agreements recorded increases decreases research development expenses addition terms collaboration agreements may require company make payments based upon achievement certain developmental regulatory approval commercial milestones upfront milestone payments payable merck collaborative partners prior regulatory approval expensed incurred included research development expenses payments due collaborative partners upon subsequent regulatory approval capitalized amortized estimated useful life corresponding intangible asset cost sales provided future cash flows support amounts capitalized salesbased milestones payable merck collaborative partners accrued probable achieved capitalized subject cumulative amortization catchup amortization catchup calculated either time first regulatory approval indications unapproved time collaboration formed time formation collaboration approved products related intangible asset recognized amortized cost sales remaining useful life subject impairment testing sharebased compensation company expenses sharebased payments employees requisite service period based grantdate fair value awards restructuring costs company records liabilities costs associated exit disposal activities period liability incurred accordance existing benefit arrangements employee termination costs accrued restructuring actions probable estimable accruing costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range costs onetime termination benefits employee required render service termination order receive benefits recognized ratably future service period contingencies legal defense costs company records accruals contingencies legal defense costs expected incurred connection loss contingency probable liability incurred amount reasonably estimated taxes income deferred taxes recognized future tax effects temporary differences financial income tax reporting based enacted tax laws rates company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements company recognizes interest table contents penalties associated uncertain tax positions component taxes income consolidated statement income use estimates consolidated financial statements prepared conformity accounting principles generally accepted united states gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets contingent consideration well subsequent fair value measurements additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities accruals contingent salesbased milestone payments reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates reclassifications certain reclassifications made prior year amounts conform current year presentation recently adopted accounting standards may financial accounting standards board fasb issued amended accounting guidance revenue recognition asu applies contracts customers objective new guidance improve comparability revenue recognition practices across entities provide useful information users financial statements improved disclosure requirements new standard permits two methods adoption retrospectively prior reporting period presented full retrospective method retrospectively cumulative effect adopting guidance recognized date initial application modified retrospective method new standard effective january adopted using modified retrospective method company recorded cumulativeeffect adjustment upon adoption increasing retained earnings million january fasb issued revised guidance accounting reporting financial instruments asu issued related technical corrections asu new guidance requires equity investments readily determinable fair values currently classified available sale measured fair value changes fair value recognized net income company elected measure equity investments without readily determinable fair values cost adjusted subsequent observable price changes less impairments recognized net income new guidance also changed certain disclosure requirements asu effective january adopted using modified retrospective approach company recorded cumulativeeffect adjustment upon adoption increasing retained earnings million asu also adopted january prospective basis result additional impacts upon adoption october fasb issued guidance accounting income tax consequences intraentity transfers assets inventory asu new guidance requires recognition income tax consequences intraentity transfer asset exception inventory intraentity transfer occurs replacing prohibition current exception defer recognition tax impact transfer inventory within consolidated entity sold third party remains unaffected new standard effective january adopted using modified retrospective approach company recorded cumulativeeffect adjustment upon adoption increasing retained earnings million corresponding decrease deferred income taxes august fasb issued new guidance hedge accounting asu intended closely align hedge accounting companies risk management strategies simplify application hedge accounting increase transparency scope results hedging programs new guidance makes financial nonfinancial hedging strategies eligible hedge accounting amends presentation disclosure requirements changes companies assess effectiveness company elected early adopt guidance january modified retrospective basis new guidance applied existing hedges adoption date fair value hedges interest rate risk outstanding date adoption company recorded cumulativeeffect adjustment upon adoption basis adjustment hedged item resulting applying benchmark component coupon guidance adjustment decreased retained earnings million also table contents accordance transition provisions asu company required eliminate separate measurement ineffectiveness cash flow hedging instruments existing adoption date cumulativeeffect adjustment retained earnings however amounts de minimis february fasb issued new guidance address narrowscope financial reporting issue arose consequence tax cuts jobs act tcja asu existing guidance requires deferred tax liabilities assets adjusted change tax laws rates effect included income continuing operations reporting period includes enactment date guidance applicable even situations related income tax effects items accumulated comprehensive income originally recognized comprehensive income rather net income amounts related benefit plans hedging activity result tax effects items within accumulated comprehensive income reflect appropriate tax rate difference referred stranded tax effects new guidance allows reclassification stranded tax effects resulting tcja accumulated comprehensive income retained earnings thereby eliminating stranded tax effects company elected early adopt new guidance first quarter reclassified stranded income tax effects tcja increasing accumulated comprehensive loss amount million corresponding increase retained earnings see note companys policy releasing disproportionate income tax effects accumulated comprehensive loss utilize itembyitem approach impact adopting standards follows asu intra entity transfers asu asu asu asu assets derivatives reclassification millions revenue financial instruments inventory hedging certain tax effects total assets increase decrease accounts receivable liabilities increase decrease income taxes payable debt deferred income taxes equity increase decrease retained earnings accumulated comprehensive loss march fasb issued amended guidance retirement benefits asu related net periodic benefit cost defined benefit plans requires entities disaggregate current service cost component components net benefit cost present employee compensation costs income statement within operations subtotal presented present components net benefit cost separately income statement outside income operations capitalize service cost component applicable company adopted new standard january using retrospective transition method requirement separate presentation income statement service costs components prospective transition method requirement limit capitalization benefit costs service cost component company utilized practical expedient permits use amounts disclosed pension postretirement benefit plan note prior comparative periods estimation basis applying retrospective presentation requirements upon adoption net periodic benefit cost credit service cost million million years ended december respectively reclassified income expense net previous classification within cost sales selling general administrative expenses research development expenses see note august fasb issued guidance classification certain cash receipts payments statement cash flows intended reduce diversity practice company adopted new standard effective january using retrospective application changes presentation consolidated statement cash flows previous years presented result adopting new standard table contents november fasb issued guidance requiring amounts generally described restricted cash restricted cash equivalents included cash cash equivalents reconciling beginningofperiod endofperiod total amounts shown statement cash flows new standard effective january adopted using retrospective application adoption new guidance material effect companys consolidated statement cash flows may fasb issued guidance clarifying account change terms conditions sharebased payment award modification new guidance modification accounting required fair value vesting conditions classification award equity liability changes result change terms conditions company adopted new standard effective january apply new guidance future sharebased payment award modifications occur january fasb issued guidance provides elimination step goodwill impairment test new guidance impairment charges recognized extent carrying amount reporting unit exceeds fair value certain limitations company adopted new standard fourth quarter applied new guidance purposes fourth quarter goodwill impairment assessment adoption new guidance immaterial effect consolidated financial statements recently issued accounting standards yet adopted february fasb issued new accounting guidance accounting reporting leases subsequently issued several updates new guidance new guidance requires lessees recognize rightofuse asset lease liability recorded balance sheet leases leases meet definition shortterm lease leases classified either operating finance operating leases result straightline expense income statement similar current operating leases finance leases result expense recognized earlier years lease term similar current capital leases new standard effective january adopted using modified retrospective approach merck elect transition method allows application standard adoption date rather beginning earliest comparative period presented financial statements company intends elect available practical expedients merck implemented lease accounting software application completed data validation companys portfolio leases including assessment potential embedded leases upon adoption company anticipates recognize approximately billion additional assets corresponding liabilities consolidated balance sheet subject finalization june fasb issued amended guidance accounting credit losses financial instruments guidance introduces expected loss model estimating credit losses replacing incurred loss model new guidance also changes impairment model availableforsale debt securities requiring use allowance record estimated credit losses subsequent recoveries new guidance effective interim annual periods beginning earlier application permitted new guidance applied modified retrospective basis cumulativeeffect adjustment directly retained earnings beginning period adoption company currently evaluating impact adoption consolidated financial statements april fasb issued new guidance accounting costs incurred implement cloud computing arrangement considered service arrangement new guidance requires capitalization costs aligning accounting costs associated developing obtaining internaluse software new guidance effective interim annual periods beginning early adoption permitted including adoption interim period prospective adoption eligible costs incurred date adoption retrospective adoption permitted company currently evaluating impact adoption consolidated financial statements may elect early adopt guidance november fasb issued new guidance collaborative arrangements intended reduce diversity practice clarifying whether certain transactions collaborative arrangement participants accounted recently issued guidance revenue recognition asc new guidance effective interim annual periods beginning early adoption permitted including adoption interim period new guidance applied modified retrospective basis cumulativeeffect adjustment directly retained earnings company currently evaluating impact adoption consolidated financial statements table contents acquisitions divestitures research collaborations license agreements company continues pursue acquisition businesses establishment external alliances research collaborations licensing agreements complement internal research capabilities arrangements often include upfront payments well expense reimbursements payments third party milestone royalty profit share arrangements contingent upon occurrence certain future events linked success asset development company also reviews marketed products pipeline examine candidates may provide value outlicensing part portfolio assessment process may also divest certain assets pro forma financial information acquired businesses presented historical financial results acquired entity significant compared companys financial results recently announced transaction december merck privately held antelliq group antelliq signed definitive agreement merck acquire antelliq funds advised bc partners antelliq leader digital animal identification traceability monitoring solutions solutions help veterinarians farmers pet owners gather critical data improve management health wellbeing livestock pets merck make cash payment approximately billion approximately billion based exchange rates time announcement acquire outstanding shares antelliq assume antelliqs debt billion approximately billion intends repay shortly closing acquisition transaction subject clearance antitrust competition law authorities customary closing conditions expected close second quarter transactions company recorded aggregate charge million within cost sales conjunction termination collaboration agreement entered samsung bioepis co ltd samsung insulin glargine charge reflects termination payment million represents reimbursement fees previously paid samsung merck agreement plus interest well release mercks ongoing obligations agreement charge also included fixed asset abandonment charges million inventory writeoffs million well related costs million termination agreement impact companys collaboration samsung june merck acquired viralytics limited viralytics australian publicly traded company focused oncolytic immunotherapy treatments range cancers aud million million transaction provided merck full rights cavatak v formerly cva viralyticss investigational oncolytic immunotherapy cavatak based viralyticss proprietary formulation oncolytic virus coxsackievirus type shown preferentially infect kill cancer cells cavatak currently evaluated multiple phase phase clinical trials intratumoral intravenous agent including combination keytruda previous agreement merck viralytics study investigating use keytruda cavatak combination melanoma prostate lung bladder cancers transaction accounted acquisition asset merck recorded net assets million primarily cash acquisition date research development expenses million related transaction future contingent payments associated acquisition march merck eisai co ltd eisai entered strategic collaboration worldwide codevelopment cocommercialization lenvima orally available tyrosine kinase inhibitor discovered eisai see note transactions october merck acquired rigontec gmbh rigontec rigontec leader accessing retinoic acidinducible gene pathway part innate immune system novel distinct approach cancer immunotherapy induce immediate longterm antitumor immunity rigontecs lead candidate mk formerly rgt currently phase development evaluating treatment patients various tumors terms agreement merck made upfront cash payment million million may make additional contingent payments million million related achievement research milestones regulatory approvals million related achievement commercial targets transaction accounted acquisition asset upfront payment reflected within research development expenses table contents july merck astrazeneca plc astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza multiple cancer types see note march merck acquired controlling interest valle sa valle leading privately held producer animal health products brazil valle extensive portfolio products spanning parasiticides antiinfectives vaccines include products livestock horses companion animals terms agreement merck acquired shares valle million total purchase price million placed escrow pending resolution certain contingent items transaction accounted acquisition business merck recognized intangible assets million related currently marketed products net deferred tax liabilities million net assets million noncontrolling interest million addition company recorded liabilities million contingencies identified acquisition date corresponding indemnification assets million representing amounts reimbursed merck contingent liabilities paid excess consideration transferred fair value net assets acquired million recorded goodwill goodwill allocated animal health segment deductible tax purposes estimated fair values identifiable intangible assets related currently marketed products determined using income approach probabilityadjusted future net cash flows product discounted present value utilizing discount rate actual cash flows likely different assumed intangible assets related currently marketed products amortized estimated useful lives years fourth quarter merck acquired additional interest valle million reduced noncontrolling interest related valle transactions july merck acquired afferent pharmaceuticals afferent privately held pharmaceutical company focused development therapeutic candidates targeting px receptor treatment common poorlymanaged neurogenic conditions afferents lead investigational candidate mk formerly af gefapixant selective nonnarcotic orallyadministered px antagonist evaluated treatment refractory chronic cough treatment endometriosisrelated pain total consideration transferred million included cash paid outstanding afferent shares million well sharebased compensation payments settle equity awards attributable precombination service cash paid transaction costs behalf afferent addition former afferent shareholders eligible receive total additional million contingent upon attainment certain clinical development commercial milestones multiple indications candidates including mk transaction accounted acquisition business company determined fair value contingent consideration million acquisition date utilizing probabilityweighted estimated cash flow stream using appropriate discount rate dependent nature timing milestone payment merck recognized intangible asset iprd million net deferred tax liabilities million net assets million primarily consisting cash acquired excess consideration transferred fair value net assets acquired million recorded goodwill allocated pharmaceutical segment deductible tax purposes fair value identifiable intangible asset related iprd determined using income approach assets probabilityadjusted future net cash flows discounted present value using discount rate actual cash flows likely different assumed result achievement clinical development milestone merck made million payment accrued estimated fair value time acquisition noted contingent consideration liability remeasured current fair value subsequent reporting period payment made see note june merck moderna therapeutics moderna entered strategic collaboration license agreement develop commercialize novel messenger rna mrnabased personalized cancer vaccines development program entail multiple studies several types cancer include evaluation mrnabased personalized cancer vaccines combination mercks keytruda pursuant terms agreement merck made upfront cash payment moderna million recorded research development expenses following human proof concept studies merck right elect make additional payment moderna merck exercises right two companies equally share costs profits worldwide collaboration development personalized cancer vaccines moderna right elect copromote personalized cancer vaccines united states agreement entails exclusivity around combinations keytruda moderna merck ability combine mrnabased personalized cancer vaccines nonpd agents table contents january merck acquired iomet pharma ltd iomet privately held ukbased drug discovery company focused development innovative medicines treatment cancer particular emphasis fields cancer immunotherapy cancer metabolism acquisition provided merck iomets preclinical pipeline ido indoleaminedioxygenase tdo tryptophandioxygenase dualacting idotdo inhibitors transaction accounted acquisition business total purchase consideration transaction included cash payment million future additional milestone payments million contingent upon certain clinical regulatory milestones achieved company determined fair value contingent consideration million acquisition date utilizing probabilityweighted estimated cash flow stream adjusted expected timing payment utilizing discount rate merck recognized intangible assets iprd million net deferred tax assets million excess consideration transferred fair value net assets acquired million recorded goodwill allocated pharmaceutical segment deductible tax purposes fair values identifiable intangible assets related iprd determined using income approach assets probabilityadjusted future net cash flows discounted present value also using discount rate actual cash flows likely different assumed result achievement clinical development milestone merck made million payment accrued estimated fair value time acquisition noted contingent consideration liability remeasured current fair value subsequent reporting period payment made see note remicadesimponi subsidiary scheringplough entered licensing agreement centocor ortho biotech inc centocor johnson johnson jj company market remicade prescribed treatment inflammatory diseases scheringploughs subsidiary exercised option contract centocor license rights develop commercialize simponi fully human monoclonal antibody company marketing rights products throughout europe russia turkey remicade lost market exclusivity major european markets company longer market exclusivity marketing territories company continues market exclusivity simponi marketing territories profits derived mercks distribution two products countries equally divided merck jj collaborative arrangements merck entered collaborative arrangements provide company varying rights develop produce market products together collaborative partners parties arrangements active participants exposed significant risks rewards dependent commercial success activities collaboration mercks significant collaborative arrangements discussed astrazeneca july merck astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza multiple cancer types lynparza oral poly adpribose polymerase parp inhibitor currently approved certain types ovarian breast cancer companies jointly developing commercializing lynparza monotherapy combination trials potential medicines independently merck astrazeneca develop commercialize lynparza combinations respective pd pdl medicines keytruda imfinzi companies also jointly develop commercialize astrazenecas selumetinib oral potent selective inhibitor mek part mitogenactivated protein kinase mapk pathway currently developed multiple indications terms agreement astrazeneca merck share development commercialization costs lynparza selumetinib monotherapy nonpdlpd combination therapy opportunities gross profits lynparza selumetinib product sales generated monotherapies combination therapies shared equally merck fund development commercialization costs keytruda combination lynparza selumetinib astrazeneca fund development commercialization costs imfinzi combination lynparza selumetinib astrazeneca currently principal lynparza sales transactions merck records share lynparza product sales net cost sales commercialization costs alliance revenue within pharmaceutical segment share development costs associated collaboration part research table contents development expenses reimbursements received astrazeneca research development expenses recognized reductions research development costs part agreement merck made upfront payment astrazeneca billion make payments million multiyear period certain license options million paid december million paid december million expected paid company recorded aggregate charge billion research development expenses related upfront payment future license option payments addition agreement provides additional contingent payments merck astrazeneca related successful achievement regulatory salesbased milestones merck determined probable annual sales lynparza future would trigger three salesbased milestone payments merck astrazeneca aggregating million accordingly merck recorded million liabilities corresponding increase intangible asset related lynparza recognized million cumulative amortization expense within cost sales one salesbased milestones triggered resulting million payment astrazeneca merck made additional million salesbased milestone payment accrued company deemed payment probable remaining billion potential future salesbased milestone payments yet accrued deemed company probable time lynparza received approval united states treatment certain patients metastatic breast cancer use firstline maintenance setting advanced ovarian cancer triggering capitalized milestone payments million aggregate merck astrazeneca potential future regulatory milestone payments billion remain agreement asset balance related lynparza includes capitalized salesbased regulatory milestone payments million december included assets consolidated balance sheet amount amortized estimated useful life supported projected future cash flows subject impairment testing summarized information related collaboration follows years ended december alliance revenue cost sales selling general administrative research development december receivables astrazeneca included current assets payables astrazeneca included accrued current liabilities payables astrazeneca included noncurrent liabilities represents amortization capitalized milestone payments amount includes billion related upfront payment future license option payments includes accrued milestone license option payments eisai march merck eisai announced strategic collaboration worldwide codevelopment cocommercialization lenvima orally available tyrosine kinase inhibitor discovered eisai agreement merck eisai develop commercialize lenvima jointly monotherapy combination mercks antipd therapy keytruda eisai records lenvima product sales globally eisai principal lenvima sales transactions merck eisai share gross profits equally merck records share lenvima product sales net cost sales commercialization costs alliance revenue expenses incurred codevelopment including studies evaluating lenvima monotherapy shared equally two companies reflected research development expenses table contents agreement merck made upfront payment eisai million make payments million certain option rights million paid march million expected paid million expected paid company recorded aggregate charge billion research development expenses related upfront payment future option payments addition agreement provides eisai receive million associated achievement certain clinical regulatory milestones billion achievement milestones associated sales lenvima merck determined probable annual sales lenvima future would trigger three salesbased milestone payments merck eisai aggregating million accordingly merck recorded million liabilities corresponding increase intangible asset related lenvima recognized million cumulative amortization expense within cost sales remaining billion potential future salesbased milestone payments yet accrued deemed company probable time lenvima approved treatment patients unresectable hepatocellular carcinoma united states european union japan china triggering capitalized milestone payments eisai million aggregate potential future regulatory milestone payments million remain agreement asset balance related lenvima includes capitalized salesbased regulatory milestone payments million december included assets consolidated balance sheet amount amortized estimated useful life supported projected future cash flows subject impairment testing summarized information related collaboration follows year ended december alliance revenue cost sales selling general administrative research development december receivables eisai included current assets payables eisai included accrued current liabilities payables eisai included noncurrent liabilities represents amortization capitalized milestone payments includes billion related upfront payment future option payments includes accrued milestone option payments bayer ag company entered worldwide clinical development collaboration bayer ag bayer market develop soluble guanylate cyclase sgc modulators including bayers adempas approved treat pulmonary arterial hypertension chronic thromboembolic pulmonary hypertension two companies implemented joint development commercialization strategy collaboration also includes clinical development bayers vericiguat phase trials worsening heart failure well optin rights earlystage sgc compounds development bayer merck turn made available earlystage sgc compounds similar terms agreement bayer leads commercialization adempas americas merck leads commercialization rest world vericiguat potential optin products bayer lead commercialization rest world merck lead americas products candidates included agreement companies share development costs profits sales right copromote territories lead merck began promoting distributing adempas europe transition bayer merck territories including japan continued revenue adempas includes sales mercks marketing territories well mercks share profits sale adempas bayers marketing territories table contents merck determined probable annual worldwide sales adempas future would trigger million salesbased milestone payment merck bayer accordingly merck recorded million noncurrent liability corresponding increase intangible asset related adempas recognized million cumulative amortization expense within cost sales company made million milestone payment bayer accrued merck deemed payment probable additional million potential future salesbased milestone payment yet accrued deemed company probable time intangible asset balance related adempas includes remaining acquired intangible asset balance well capitalized salesbased milestone payments billion december included intangibles net consolidated balance sheet amount amortized estimated useful life supported projected future cash flows subject impairment testing summarized information related collaboration follows years ended december net product sales recorded merck mercks profit share sales bayers marketing territories total sales cost sales selling general administrative research development december receivables bayer included current assets payables bayer included accrued current liabilities payables bayer included noncurrent liabilities includes amortization intangible assets includes accrued milestone payments aggregate amortization expense related capitalized license costs recorded within cost sales million million million estimated aggregate amortization expense next five years follows million million million million million restructuring company commenced actions global restructuring programs designed streamline cost structure actions programs include elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities company also continues reduce global real estate footprint improve efficiency manufacturing supply network company recorded total pretax costs million million billion related restructuring program activities since inception programs december merck recorded total pretax accumulated costs approximately billion eliminated approximately positions comprised employee separations well elimination contractors vacant positions company estimates approximately twothirds cumulative pretax costs cash outlays primarily related employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested company substantially completed actions programs segment reporting restructuring charges unallocated expenses table contents following table summarizes charges related restructuring program activities type cost separation accelerated costs depreciation total year ended december cost sales selling general administrative research development restructuring costs year ended december cost sales selling general administrative research development restructuring costs year ended december cost sales selling general administrative research development restructuring costs separation costs associated actual headcount reductions well headcount reductions probable could reasonably estimated positions eliminated restructuring program activities approximately accelerated depreciation costs primarily relate manufacturing research administrative facilities equipment sold closed part programs accelerated depreciation costs represent difference depreciation expense recognized revised useful life asset based upon anticipated date site closed divested equipment disposed depreciation expense determined utilizing useful life prior restructuring actions sites continue operate respective closure dates since future undiscounted cash flows sufficient recover respective book values merck recording accelerated depreciation revised useful life site assets anticipated site closure dates particularly related manufacturing locations may continue adjusted reflect changes resulting regulatory factors activity includes million million million respectively asset abandonment shutdown related costs additionally activity includes certain employeerelated costs associated pension postretirement benefit plans see note share based compensation activity also reflects net pretax losses resulting sales facilities related assets million following table summarizes charges spending relating restructuring program activities separation accelerated costs depreciation total restructuring reserves january expenses payments receipts net noncash activity restructuring reserves december expenses payments receipts net noncash activity restructuring reserves december remaining cash outlays expected substantially completed end table contents financial instruments derivative instruments hedging activities company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce variability caused changes foreign exchange rates would affect us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales forecasted sales expected occur planning cycle typically two years future company layer hedges time increasing portion forecasted sales hedged gets closer expected date forecasted sales portion forecasted sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments company manages anticipated transaction exposure principally purchased local currency put options forward contracts purchased collar options fair values derivative contracts recorded either assets gain positions liabilities loss positions consolidated balance sheet changes fair value derivative contracts recorded period either current earnings oci depending whether derivative designated part hedge transaction type hedge transaction derivatives designated cash flow hedges unrealized gains losses contracts recorded aoci reclassified sales hedged anticipated revenue recognized derivatives designated cash flow hedges serve economic hedges forecasted sales unrealized gains losses recorded sales period cash flows designated nondesignated contracts reported operating activities consolidated statement cash flows company enter derivatives trading speculative purposes company manages operating activities net asset positions local subsidiary order mitigate effects exchange monetary assets liabilities company also uses balance sheet risk management program mitigate exposure net monetary assets denominated currency subsidiarys functional currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument cash flows contracts reported operating activities consolidated statement cash flows monetary assets liabilities denominated currency functional currency given subsidiary remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less one year table contents company also uses forward exchange contracts hedge net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation company hedges portion net investment certain foreign operations unrealized gains losses contracts recorded foreign currency translation adjustment within oci remain aoci either sale complete substantially complete liquidation subsidiary company excludes certain portions change fair value derivative instruments assessment hedge effectiveness excluded component changes fair value excluded components recognized oci accordance new guidance adopted january see note company elected recognize earnings initial value excluded component straightline basis life derivative instrument rather using marktomarket approach cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci effects companys net investment hedges oci consolidated statement income shown amount pretax gain loss recognized amount pretax gain loss recognized income expense net amounts excluded comprehensive income effectiveness testing years ended december net investment hedging relationships foreign exchange contracts eurodenominated notes amounts reclassified aoci income related sale subsidiary interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk may four interest rate swaps notional amounts aggregating billion matured swaps effectively converted companys billion fixedrate notes due variable rate debt december connection early repayment debt company settled three interest rate swaps notional amounts aggregating million swaps effectively converted portion companys billion notes due variable rate debt december company party payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes detailed table number interest rate total swap notional debt instrument par value debt swaps held amount notes due notes due notes due notes due interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes libor swap rate recorded interest expense along offsetting fair value changes swap contracts cash flows contracts reported operating activities consolidated statement cash flows table contents table presents location amounts recorded consolidated balance sheet related cumulative basis adjustments fair value hedges december cumulative amount fair value hedging adjustment increase decrease included carrying amount hedged liabilities carrying amount balance sheet line item hedged item included loans payable current portion longterm debt longterm debt amounts include hedging adjustment gains related discontinued hedging relationships million december presented table fair value derivatives gross basis segregated derivatives designated hedging instruments designated hedging instruments december fair value fair value derivative derivative us dollar us dollar balance sheet caption asset liability notional asset liability notional derivatives designated hedging instruments interest rate swap contracts assets interest rate swap contracts accrued current liabilities interest rate swap contracts noncurrent liabilities foreign exchange contracts current assets foreign exchange contracts assets foreign exchange contracts accrued current liabilities foreign exchange contracts noncurrent liabilities derivatives designated hedging instruments foreign exchange contracts current assets foreign exchange contracts accrued current liabilities noted company records derivatives gross basis consolidated balance sheet company master netting agreements several financial institution counterparties see concentrations credit risk following table provides information companys derivative positions subject master netting arrangements presented net basis allowing right offset counterparty cash collateral exchanged per master agreements related credit support annexes december asset liability asset liability gross amounts recognized consolidated balance sheet gross amount subject offset master netting arrangements offset consolidated balance sheet cash collateral received net amounts table contents table provides information regarding location amount pretax gains losses derivatives designated fair value cash flow hedging relationships sales income expense net comprehensive income loss years ended december financial statement line items effects fair value cash flow hedges recorded gain loss fair value hedging relationships interest rate swap contracts hedged items derivatives designated hedging instruments impact cash flow hedging relationships foreign exchange contracts amount gain loss recognized oci derivatives decrease increase sales result aoci reclassifications interest expense component income expense net table provides information regarding income statement effects derivatives designated hedging instruments amount derivative pretax gain loss recognized income years ended december income statement caption derivatives designated hedging instruments foreign exchange contracts income expense net foreign exchange contracts sales derivative contracts mitigate changes value remeasured foreign currency denominated monetary assets liabilities attributable changes foreign currency exchange rates derivative contracts serve economic hedges forecasted transactions december company estimates million pretax net unrealized gains derivatives maturing within next months hedge foreign currency denominated sales period reclassified aoci sales amount ultimately reclassified sales may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity table contents investments debt equity securities information investments debt equity securities december follows gross unrealized gross unrealized fair amortized fair amortized value cost gains losses value cost gains losses corporate notes bonds assetbacked securities us government agency securities foreign government bonds mortgagebacked securities commercial paper total debt securities publicly traded equity securities total debt publicly traded equity securities pursuant adoption asu see note beginning january changes fair value publicly traded equity securities recognized net income unrealized net losses million recognized income expense net equity securities still held december december company also million equity investments without readily determinable fair values included assets company recognized unrealized gains million income expense net certain equity investments based favorable observable price changes transactions involving similar investments investee addition company recognized unrealized losses million income expense net related certain investments based unfavorable observable price changes availableforsale debt securities included shortterm investments totaled million december remaining debt securities billion mature within five years december debt securities pledged collateral fair value measurements fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date company uses fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets liabilities whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well assets liabilities determination fair value requires significant judgment estimation inputs used measure financial assets liabilities fall within one level described categorization based lowest level input significant fair value measurement instrument table contents financial assets liabilities measured fair value recurring basis financial assets liabilities measured fair value recurring basis december summarized fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total assets investments corporate notes bonds assetbacked securities us government agency securities foreign government bonds mortgagebacked securities commercial paper publicly traded equity securities assets us government agency securities corporate notes bonds assetbacked securities mortgagebacked securities foreign government bonds publicly traded equity securities derivative assets forward exchange contracts purchased currency options interest rate swaps total assets liabilities liabilities contingent consideration derivative liabilities interest rate swaps forward exchange contracts written currency options total liabilities primarily assetbacked securities highlyrated standard poors rating aaa moodys investors service rating aaa secured primarily auto loan credit card student loan receivables weightedaverage lives primarily years less investments included assets restricted use primarily payment benefits employee benefit plans fair value determination derivatives includes impact credit risk counterparties derivatives companys credit risk effects significant transfers level level december cash cash equivalents billion include billion cash equivalents would considered level fair value hierarchy table contents contingent consideration summarized information changes liabilities contingent consideration follows fair value january changes estimated fair value additions payments fair value december recorded research development expenses cost sales income expense net includes cumulative translation adjustments balance december includes million recorded current liability amounts expected paid within next months changes estimated fair value liabilities contingent consideration largely attributable increases liabilities recorded connection termination spmsd joint venture see note partially offset reversal liability related discontinuation program obtained connection acquisition smartcells see note changes estimated fair value liabilities contingent consideration primarily relate increases liabilities recorded connection termination spmsd joint venture clinical progression program related afferent acquisition payments contingent consideration include million related achievement clinical milestone connection acquisition afferent see note remaining payments relate liabilities recorded connection termination spmsd joint venture payments contingent consideration relate achievement clinical milestone connection acquisition iomet see note fair value measurements companys financial instruments cash cash equivalents receivables payables reflected balance sheet carrying value approximates fair value due shortterm nature estimated fair value loans payable longterm debt including current portion december billion compared carrying value billion december billion compared carrying value billion fair value estimated using recent observable market prices would considered level fair value hierarchy concentrations credit risk ongoing basis company monitors concentrations credit risk associated corporate government issuers securities financial institutions conducts business credit exposure limits established limit concentration single issuer institution cash investments placed instruments meet high credit quality standards specified companys investment policy guidelines majority companys accounts receivable arise product sales united states europe primarily due drug wholesalers retailers hospitals government agencies managed health care providers pharmacy benefit managers company monitors financial performance creditworthiness customers properly assess respond changes credit profile company also continues monitor global economic conditions including volatility associated international sovereign economies associated impacts financial markets business companys customers largest accounts receivable balances mckesson corporation amerisourcebergen corporation cardinal health inc represented aggregate approximately total accounts receivable december company monitors creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral security support credit sales derivative financial instruments executed international swaps derivatives association master agreements master agreements several companys financial institution counterparties also include credit support annexes annexes contain provisions require collateral exchanged depending value derivative assets liabilities companys credit rating credit rating counterparty cash collateral received company various counterparties million million december table contents respectively obligation return collateral recorded accrued current liabilities cash collateral advanced company counterparties december inventories inventories december consisted finished goods raw materials work process supplies total approximates current cost increase lifo costs recognized inventories assets inventories valued lifo method comprised approximately billion billion december respectively amounts recognized assets comprised almost entirely raw materials work process inventories december amounts included billion billion respectively inventories expected sold within one year addition amounts included million million december respectively inventories produced preparation product launches goodwill intangibles following table summarizes goodwill activity segment pharmaceutical animal health total balance january acquisitions impairments balance december acquisitions impairments balance december includes cumulative translation adjustments goodwill balances certain adjustments accumulated goodwill impairment losses december million million respectively additions goodwill within animal health segment primarily relate acquisition valle see note impairments goodwill within nonreportable segments relate certain businesses within healthcare services segment table contents intangibles december consisted gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net products product rights iprd tradenames acquired intangibles include products product rights tradenames patents initially recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives companys significant acquired intangibles related marketed products included products product rights december include zerbaxa billion sivextro million implanonnexplanon million dificid million gardasilgardasil million bridion million simponi million company intangible asset related adempas result collaboration bayer see note carrying value billion december reflected table company recorded impairment charges related marketed products intangibles million million respectively within cost sales company recorded intangible asset impairment charge million related intron treatment certain types cancers sales intron adversely affected availability new therapeutic options sales intron united states eroded rapidly previously anticipated company led changes cash flow assumptions intron revisions cash flows indicated intron intangible asset value fully recoverable undiscounted cash flows basis company utilized market participant assumptions determine best estimate fair value intangible asset related intron compared related carrying value resulted impairment charge noted remaining charges relate impairment customer relationship tradename developed technology intangibles certain businesses healthcare services segment company lowered cash flow projections zontivity product reduction thrombotic cardiovascular events patients history myocardial infarction peripheral arterial disease following several business decisions reduced sales expectations zontivity united states europe company utilized market participant assumptions considered several different scenarios determine fair value intangible asset related zontivity compared related carrying value resulted impairment charge million also company wroteoff million capitalized connection inlicensed products grastek ragwitek allergy immunotherapy tablets business reasons company returned licensor iprd company acquires business combinations represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized iprd accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project company make separate determination useful life asset begin amortization company recorded million iprd impairment charges within research development expenses amount million relates writeoff remaining intangible asset balance program obtained connection smartcells acquisition following decision terminate program due product development issues company previously recorded impairment charge programs obtained connection acquisition smartcells described discontinuation clinical development program resulted reversal related liability contingent consideration million see note company recorded million iprd impairment charges amount million resulted strategic decision discontinue development investigational combination regimens table contents mkb grazoprevirruzasviruprifosbuvir mkc ruzasviruprifosbuvir treatment chronic hepatitis c virus hcv infection decision made based review available phase efficacy data consideration evolving marketplace growing number treatment options available patients chronic hcv infection including zepatier marketed company treatment adult patients chronic hcv infection result decision company recorded iprd impairment charge writeoff remaining intangible asset related uprifosbuvir company previously recorded impairment charge uprifosbuvir described iprd impairment charges also include charge million writeoff intangible asset related verubecestat investigational small molecule inhibitor betasite amyloid precursor protein cleaving enzyme bace resulting decision february stop phase study evaluating verubecestat people prodromal alzheimers disease decision stop study followed recommendation external data monitoring committee edmc assessed overall benefitrisk interim safety analysis edmc concluded unlikely positive benefitrisk could established trial continued company recorded billion iprd impairment charges amount billion related clinical development program uprifosbuvir nucleotide prodrug evaluated treatment hcv company determined changes product profile well changes mercks expectations pricing market opportunity taken together constituted triggering event required company evaluate uprifosbuvir intangible asset impairment utilizing market participant assumptions considering different scenarios company concluded best estimate fair value intangible asset related uprifosbuvir million resulting recognition impairment charge noted iprd impairment charges also included charges million million related discontinuation programs obtained connection acquisitions ccam biotherapeutics ltd oncoethix respectively resulting unfavorable efficacy data additional million related programs obtained connection smartcells acquisition following decision terminate lead compound due lack efficacy pursue backup compound reduced projected future cash flows iprd impairment charges also included million related inlicensed program house dust mite allergies business reasons returned licensor remaining iprd impairment charges primarily related deprioritized pipeline programs deemed alternative use period including million impairment charge investigational candidate contraception discontinuation delay certain clinical development programs resulted reduction related liabilities contingent consideration iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates company may recognize additional noncash impairment charges future related marketed products pipeline programs charges could material aggregate amortization expense primarily recorded within cost sales billion billion billion estimated aggregate amortization expense next five years follows billion billion billion billion billion joint ventures equity method affiliates sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur sa established equallyowned joint venture spmsd market vaccines europe collaborate development combination vaccines distribution europe joint venture vaccine sales billion table contents december merck sanofi pasteur sanofi terminated spmsd ended joint vaccines operations europe terms termination merck acquired sanofis interest spmsd exchange consideration million comprised cash well future royalties net sales merck products previously sold joint venture december company determined fair value million date termination company accounted transaction step acquisition required merck remeasure ownership interest previously accounted equity method investment fair value acquisition date merck turn sold sanofi intellectual property rights held spmsd exchange consideration million comprised cash future royalties net sales sanofi products previously sold joint venture december company determined fair value million date termination excluded arrangement sales vaxelis jointly developed pediatric hexavalent combination vaccine approved european commission us food drug administration european marketing rights vaxelis transferred separate equallyowned joint venture sanofi merck net impact termination spmsd joint venture follows products product rights year useful life accounts receivable income taxes payable deferred income tax liabilities net net assets acquired consideration payable sanofi net derecognition mercks previously held equity investment spmsd increase net assets mercks share restructuring costs related termination net gain termination spmsd joint venture recorded income expense net estimated fair values identifiable intangible assets related products product rights determined using income approach fair value estimated based market participant expectations assets projected net cash flows projected net cash flows discounted present value utilizing discount rate actual cash flows likely different assumed amount recorded products product rights million related gardasilgardasil fair value liabilities contingent consideration related mercks future royalty payments sanofi million reflected consideration payable sanofi net table determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows riskadjusted discount rate used present value cash flows changes inputs could result different fair value measurement based existing accounting policy election merck record million estimated fair value contingent future royalties received sanofi sale sanofi products rather recognizing amounts sales occur royalties earned company incurred million transaction costs related termination spmsd included selling general administrative expenses pro forma financial information transaction presented results significant compared companys financial results table contents astrazeneca lp merck entered agreement astra ab astra develop market astra products royaltybearing license mercks total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami merck astra owned share joint venture formed developed marketed astras new prescription medicines united states merck astra completed restructuring ownership operations joint venture whereby merck acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc became exclusive distributor products kbi retained rights merck earned revenue based sales kbi products earned certain partnership returns azlp june astrazeneca exercised option purchase mercks interest kbi redeem mercks remaining interest azlp portion exercise price remained subject trueup based actual sales nexium prilosec closing june deferred recognized income contingency eliminated sales occurred deferred income amount fully recognized company began recognizing income corresponding receivable amounts would due merck astrazeneca based sales performance nexium prilosec subject trueup june company recognized income million million million including million remaining deferred income income expense net related amounts january company received million astrazeneca settlement amounts concludes transactions related termination companys relationship azlp loans payable longterm debt commitments loans payable december included billion commercial paper million longdated notes subject repayment option holders loans payable december included billion notes due million longdated notes subject repayment option holders weightedaverage interest rate commercial paper borrowings years ended december respectively table contents longterm debt december consisted notes due notes due notes due notes due notes due notes due eurodenominated notes due notes due eurodenominated notes due notes due notes due floatingrate notes due eurodenominated notes due eurodenominated notes due eurodenominated notes due notes due notes due notes due debentures due notes due debentures due debentures due notes due presented table includes million million december respectively borrowings variable rates resulted effective interest rates respectively exception debentures due notes listed table redeemable whole part mercks option time varying redemption prices december company exercised makewhole provision billion notes due repaid debt november company launched tender offers certain outstanding notes debentures company paid million aggregate consideration applicable purchase price together accrued interest redeem million principal amount debt validly tendered connection tender offers recognized loss extinguishment debt million effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date certain companys borrowings require merck comply covenants december company compliance covenants aggregate maturities longterm debt next five years follows maturities billion billion billion billion table contents company billion credit facility matures june facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility rental expense operating leases net sublease income million million million minimum aggregate rental commitments noncancellable leases follows million million million million million thereafter million company significant capital leases contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well certain additional matters including governmental environmental matters opinion company unlikely resolution matters material companys financial position results operations cash flows given nature litigation discussed complexities involved matters company unable reasonably estimate possible loss range possible loss matters company knows among factors claims survive dispositive motion practice ii extent claims including size potential class particularly damages specified indeterminate iii discovery process affect litigation iv settlement posture parties litigation v factors may material effect litigation company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance product liabilities effective august product liability litigation fosamax previously disclosed merck defendant product liability lawsuits united states involving fosamax fosamax litigation december approximately cases filed either pending conditionally dismissed noted merck either federal state court plaintiffs vast majority cases generally allege sustained femur fractures andor bone injuries femur fractures association use fosamax march merck submitted motion transfer judicial panel multidistrict litigation jpml seeking federal cases alleging femur fractures consolidated one multidistrict litigation coordinated pretrial proceedings federal cases involving allegations femur fracture transferred multidistrict litigation district new jersey femur fracture mdl bellwether case tried date femur fracture mdl glynn v merck jury returned verdict mercks favor addition june femur fracture mdl court granted mercks motion judgment matter law glynn case held plaintiffs failure warn claim preempted federal law august femur fracture mdl court entered order requiring plaintiffs femur fracture mdl show cause cases asserting claims femur fracture injury took place prior september dismissed based courts preemption decision glynn case pursuant show cause order march femur fracture mdl court dismissed prejudice approximately cases preemption grounds plaintiffs approximately cases appealed decision us court appeals third circuit third circuit march third circuit issued decision reversing femur fracture mdl table contents courts preemption ruling remanding appealed cases back femur fracture mdl court merck filed petition writ certiorari us supreme court august seeking review third circuits decision december supreme court invited solicitor general file brief case expressing views united states may solicitor general submitted brief stating third circuits decision wrongly decided recommended supreme court grant mercks cert petition supreme court granted mercks petition june oral argument supreme court held january final decision femur fracture mdl courts preemption ruling pending supreme court accordingly december nine cases actively pending femur fracture mdl approximately cases either dismissed without prejudice administratively closed pending final resolution supreme court appeal femur fracture mdl courts preemption order december approximately cases alleging femur fractures filed new jersey state court pending judge james hyland middlesex county parties selected initial group cases reviewed fact discovery two additional groups cases reviewed fact discovery selected november march respectively group cases reviewed fact discovery selected merck july merck continued select additional cases reviewed fact discovery present december approximately cases alleging femur fractures filed pending california state court femur fracture cases filed california state court coordinated single judge orange county california march court directed group discovery pool cases reviewed fact discovery subsequently scheduled galper v merck case plaintiffs selected first trial galper trial began february jury returned verdict mercks favor april plaintiff appealed verdict california appellate court april california appellate court issued decision affirming lower courts judgment favor merck next femur fracture trial california scheduled begin april stayed plaintiffs request new trial date set additionally four femur fracture cases pending state courts discovery ongoing femur fracture mdl state courts femur fracture cases pending company intends defend lawsuits januviajanumet previously disclosed merck defendant product liability lawsuits united states involving januvia andor janumet december merck aware approximately product users alleging januvia andor janumet caused development pancreatic cancer injuries claims filed multidistrict litigation us district court southern district california mdl outside mdl majority claims filed coordinated proceedings superior court california county los angeles california state court november mdl california state courtin separate opinionsgranted summary judgment defendants grounds federal preemption plaintiffs appealed forums november us court appeals ninth circuit vacated judgment remanded discovery ongoing november california state appellate court reversed remanded similar grounds december eight product users claims pending merck state courts california including illinois june illinois trial court denied mercks motion summary judgment based federal preemption merck appealed illinois appellate court affirmed december merck intends appeal ruling addition claims noted company agreed toll statute limitations approximately additional claims company intends continue defending lawsuits table contents vioxx previously disclosed merck defendant lawsuit brought attorney general utah alleging merck misrepresented safety vioxx lawsuit pending utah state court utah seeks damages penalties utah false claims act bench trial matter currently scheduled july propeciaproscar previously disclosed merck defendant product liability lawsuits united states involving propecia andor proscar lawsuits filed various federal courts state court new jersey federal lawsuits consolidated pretrial purposes federal multidistrict litigation judge brian cogan eastern district new york matters pending state court new jersey consolidated judge hyland middlesex county nj coordinated proceedings previously disclosed april merck plaintiffs executive committee propecia mdl plaintiffs liaison counsel nj coordinated proceedings entered agreement resolve mentioned propeciaproscar lawsuits aggregate amount million settlement subject certain contingencies including plaintiff participation per plaintiff clawback participation rate less contingencies satisfied settlement agreement finalized settlement fewer cases remain pending united states company intends defend remaining unsettled lawsuits governmental proceedings previously disclosed company learned prosecution office milan italy investigating interactions companys italian subsidiary certain employees subsidiary certain italian health care providers company understands part larger investigation involving engagements various health care companies health care providers company cooperating investigation previously disclosed united kingdom uk competition markets authority cma issued statement objections company msd sharp dohme limited msd uk may statement objections cma alleges msd uk abused dominant position discount program remicade period march february company msd uk contesting cmas allegations previously disclosed company received investigative subpoena california insurance commissioners fraud bureau bureau seeking information january present related pricing promotion cubicin bureau investigating whether cubist pharmaceuticals inc company acquired unlawfully induced presentation false claims cubicin private insurers california insurance code false claims act company cooperating investigation previously disclosed companys subsidiaries china received may continue receive inquiries regarding operations various chinese governmental agencies inquiries may related matters involving multinational pharmaceutical companies well chinese entities business companies companys policy cooperate authorities provide responses appropriate previously disclosed time time company receives inquiries subject preliminary investigation activities competition governmental authorities markets outside united states authorities may include regulators administrative authorities law enforcement similar officials preliminary investigation activities may include site visits formal informal requests demands documents materials inquiries interviews similar matters certain preliminary inquiries activities may lead commencement formal proceedings proceedings determined adversely company monetary fines andor remedial undertakings may required table contents commercial litigation zetia antitrust litigation previously disclosed merck msd schering corporation msp singapore company llc collectively merck defendants defendants putative class action optout lawsuits filed behalf direct indirect purchasers zetia alleging violations federal state antitrust laws well state statutory common law causes action cases consolidated pretrial purposes federal multidistrict litigation judge rebecca beach smith eastern district virginia december court denied merck defendants motions dismiss stay direct purchaser putative class actions pending bilateral arbitration february magistrate judge issued report recommendation recommending district judge grant part deny part defendants motions dismiss nonarbitration issues february defendants retailer optout plaintiffs filed objections report recommendation responses filed parties await decision district judge rotavirus vaccines antitrust litigation previously disclosed msd defendant putative class action lawsuits filed behalf direct purchasers rotateq alleging violations federal antitrust laws cases consolidated eastern district pennsylvania january court denied msds motions compel arbitration dismiss consolidated complaint february msd appealed courts order arbitration third circuit february court granted msds motion vacate existing deadlines district court light appeal sales force litigation previously disclosed may ms kelli smith filed complaint company us district court district new jersey behalf putative class female sales representatives putative subclass female sales representatives children claiming discriminatory policies practices selection promotion advancement b disparate pay c differential treatment hostile work environment e retaliation federal state discrimination laws january plaintiffs filed amended complaint adding four additional named plaintiffs october court denied companys motion dismiss strike class claims premature september plaintiffs filed additional motions including motion conditional certification equal pay act motion amend pleadings seeking add erisa constructive discharge claims company subsidiary named defendant motion equitable relief merck filed papers opposition motions april court granted plaintiffs motion conditional certification denied plaintiffs motions extend liability period equal pay act claims back june april magistrate judge granted plaintiffs request amend complaint add following company subsidiary corporate defendant ii erisa claim iii individual constructive discharge claim one named plaintiffs approximately individuals optedin action optin period closed august plaintiffs filed motion class certification motion sought certify title vii pay discrimination class also sought final collective action certification plaintiffs equal pay act claim october parties entered agreement fully resolve smith sales force litigation part settlement exchange full general release individual class claims company agreed pay million settlement agreement contains optout clause allowing merck pull agreement individuals opt subject court approval december plaintiffs filed motion court seeking preliminary approval settlement qui tam litigation previously disclosed june us district court eastern district pennsylvania unsealed complaint filed company federal false claims act two former employees alleging among things company defrauded us government falsifying data connection clinical study conducted mumps component companys mmr ii vaccine complaint alleges fraud took place us government right participate take prosecution lawsuit notified court declined exercise right two former employees pursuing lawsuit without involvement us government addition previously disclosed two putative class action lawsuits behalf direct purchasers mmr ii vaccine charge company misrepresented efficacy mmr ii vaccine violation federal antitrust laws various state consumer table contents protection laws pending eastern district pennsylvania september court denied mercks motion dismiss false claims act suit granted part denied part motion dismiss thenpending antitrust suit result false claims act suit antitrust suits proceeded discovery ongoing company continues defend lawsuits merck kgaa litigation previously disclosed january protect longestablished brand rights united states company filed lawsuit merck kgaa darmstadt germany kgaa historically operating emd group united states alleging improperly uses name merck united states kgaa filed suit company france uk germany switzerland mexico india australia singapore hong kong china alleging among things unfair competition trademark infringement andor corporate name infringement uk australia singapore hong kong india kgaa also alleges breach parties coexistence agreement december paris court first instance issued judgment finding certain activities company directed towards france constitute trademark infringement unfair competition activities found infringe constitute unfair competition company kgaa appealed decision appeal heard may june french appeals court held certain activities company directed france constituted unfair competition trademark infringement december company decided pursue appeal january uk high court issued judgment finding company breached coexistence agreement infringed kgaas trademark rights result certain activities directed towards uk based use word merck promotional information activity noted uk decision finding based companys use sign merck connection sale products material pharmaceutical business transacted uk company kgaa appealed decision appeal heard june november uk court appeals affirmed decision coexistence agreement remitted rehearing issues trademark infringement scope kgaas uk trademarks pharmaceutical products relief kgaa would entitled rehearing held decision handed november district court hamburg germany dismissed kgaas claims concerning kgaas eu trademark respect territory eu accordance judgment court justice eu delivered october district court hamburg held jurisdiction claim kgaa insofar claim related territory uk kgaa appealed decision decisions district court hamburg germany connection claims concerning kgaas eu trademark german trademark trade name rights well unfair competition law respect territory germany expected february january mexican trademark office issued decision kgaas action court found trademark infringement company dismissed kgaas claims trademark infringement court ruled company kgaas unfair competition claim kgaa company appealed decision patent litigation time time generic manufacturers pharmaceutical products file abbreviated ndas fda seeking market generic forms companys products prior expiration relevant patents owned company protect patent rights company may file patent infringement lawsuits generic companies similar lawsuits defending companys patent rights may exist countries company intends vigorously defend patents believes valid infringement companies attempting market products prior expiration patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products respect products acquired acquisitions potentially significant intangible asset impairment charges inegy patents protecting inegy europe expired supplemental protection certificates spcs granted company many european countries expire april multiple challenges spcs related inegy throughout europe generic products launched austria france italy ireland spain portugal germany netherlands company filed preliminary injunctions many countries still pending decision preliminary injunctions presently force austria czech republic greece norway portugal slovakia preliminary injunctions denied revoked germany ireland netherlands spain company appealing decisions france belgium preliminary injunctions granted companies denied others appeals pending spc held valid table contents merits proceedings portugal france company filed continue file actions patent infringement seeking damages companies launch generic products april noxafil august company filed lawsuit actavis laboratories fl inc actavis united states respect companys application fda seeking prepatent expiry approval sell generic version noxafil october district court held patent valid infringed actavis appealed decision appeal pending parties reached settlement subject certain terms agreement met whereby actavis launch generic version prior expiry patent pediatric exclusivity certain conditions march company filed lawsuit roxane laboratories inc roxane united states respect companys application fda seeking prepatent expiry approval sell generic version noxafil november parties reached settlement whereby roxane launch generic version prior expiry patent certain conditions february company filed lawsuit par sterile products llc par pharmaceutical inc par pharmaceutical companies inc par pharmaceutical holdings inc collectively par united states respect companys application fda seeking prepatent expiry approval sell generic version noxafil injection october parties reached settlement whereby par launch generic version january earlier certain conditions february company filed lawsuit fresenius kabi usa llc fresenius united states respect companys application fda seeking prepatent expiry approval sell generic version noxafil november company reached settlement fresenius whereby fresenius launch generic version intravenous product prior expiry patent certain conditions march company filed lawsuit mylan laboratories limited united states respect companys application fda seeking prepatent expiry approval sell generic version noxafil nasonex nasonex lost market exclusivity united states prior april company filed patent infringement lawsuit apotex inc apotex corp apotex respect apotexs marketed product company believed infringing january company apotex settled matter apotex agreeing pay company million plus certain consideration januvia janumet janumet xr february par pharmaceutical inc par pharmaceutical filed suit company us district court district new jersey seeking declaratory judgment invalidity patent owned company covering certain salt polymorphic forms sitagliptin expires judgment favor may allow par pharmaceutical bring market generic version janumet xr following expiration key patent protection prior expiration latergranted patent challenging response company filed patent infringement lawsuit us district court district delaware par pharmaceutical additional companies also indicated intent market generic versions januvia janumet janumet xr following expiration key patent protection prior expiration latergranted patent owned company covering certain salt polymorphic forms sitagliptin expires later granted patent owned company covering janumet formulation expires schedule cases set court gilead patent litigation opposition company idenix pharmaceuticals inc subsidiary pending litigation gilead united states germany france based different patent estates would infringed gileads sales two products sovaldi harvoni gilead opposed european patent european patent office epo trial united states held december jury returned verdict company awarding damages billion company submitted posttrial motions including issues enhanced damages future royalties gilead submitted posttrial motions judgment matter law hearing motions held september also september court denied companys motion enhanced damages granted motion prejudgment interest deferred motion future royalties february court granted gileads motion judgment matter law found patent invalid lack enablement company appealed decision appellate briefing completed company waiting oral argument scheduled epo opposition division revoked european patent company appealed decision cases france germany stayed pending final decision epo table contents litigation various pending legal proceedings involving company principally product liability intellectual property lawsuits feasible predict outcome proceedings opinion company either likelihood loss remote reasonably possible loss associated resolution proceedings expected material companys financial position results operations cash flows either individually aggregate legal defense reserves legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate environmental matters previously disclosed mercks facilities oss netherlands inspected province brabant province pursuant dutch hazards major accidents decree sites environmental permits province issued penalties alleged violations regulations governing preventing managing accidents hazardous substances government also issued fine alleged environmental violations one oss facilities together totaled thousand company subsequently advised criminal investigation initiated based upon certain issues formed basis administrative enforcement action province previously disclosed matter settled without admission liability aggregate payment thousand company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others final costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial position results operations liquidity capital resources company company taken active role identifying accruing costs amounts include reduction anticipated recoveries cleanup costs former site owners operators recalcitrant potentially responsible parties managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued table contents exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year equity merck certificate incorporation authorizes shares common stock shares preferred stock capital stock summary common stock treasury stock transactions shares millions follows common treasury common treasury common treasury stock stock stock stock stock stock balance january purchases treasury stock issuances balance december issuances primarily reflect activity sharebased compensation plans october company entered accelerated share repurchase asr agreements two thirdparty financial institutions dealers asr agreements merck agreed purchase billion mercks common stock total initial delivery million shares mercks common stock based thencurrent market price made dealers merck payments billion made merck dealers october funded existing cash investments well shortterm borrowings payments dealers recorded reductions shareholders equity consisting billion increase treasury stock reflects value initial million shares received october billion decrease otherpaidin capital reflects value stock held back dealers pending final settlement number shares mercks common stock merck may receive may required remit upon final settlement asr agreements based upon average daily volume weightedaverage price mercks common stock term asr program less negotiated discount final settlement transaction asr agreements expected occur first half may occur earlier option dealers later certain circumstances merck obligated make adjustment payments dealers asr agreements merck may elect satisfy obligations cash shares mercks common stock sharebased compensation plans company sharebased compensation plans company grants restricted stock units rsus performance share units psus certain management level employees addition employees nonemployee directors may granted options purchase shares company common stock fair market value time grant plans approved companys shareholders december million shares collectively authorized future grants companys sharebased compensation plans awards settled primarily treasury shares employee stock options granted purchase shares company stock fair market value time grant awards generally vest one third year threeyear period contractual term years rsus stock awards granted employees entitle holder shares common stock awards vest fair value stock option rsu awards determined fixed grant date based companys stock price psus stock awards ultimate number shares issued contingent companys performance preset objective set objectives fair value psu determined date grant based companys stock price rsus psus dividends declared vesting period payable employees upon vesting psu performance period number shares stock expected issued adjusted based probability achievement performance target final compensation expense recognized based ultimate number shares issued rsu psu table contents distributions shares company stock end vesting performance period subject terms applicable awards psu awards generally vest three years prior rsu awards generally vested three years beginning awards granted rsu awards generally vest one third year threeyear period total pretax sharebased compensation cost recorded million million million respectively related income tax benefits million million million respectively company uses blackscholes option pricing model determining fair value option grants applying model company uses historical data current market data estimate fair value options blackscholes model requires several assumptions including expected dividend yield riskfree interest rate volatility term options expected dividend yield based historical patterns dividend payments riskfree rate based rate grant date zerocoupon us treasury notes term equal expected term option expected volatility estimated using blend historical implied volatility historical component based historical monthly price changes implied volatility obtained market data companys traded options expected life represents amount time options granted expected outstanding based historical forecasted exercise behavior weighted average exercise price options granted per option respectively weighted average fair value options granted per option respectively determined using following assumptions years ended december expected dividend yield riskfree interest rate expected volatility expected life years summarized information relative stock option plan activity options thousands follows weighted weighted average average remaining aggregate number exercise contractual intrinsic options price term years value outstanding january granted exercised forfeited outstanding december exercisable december additional information pertaining stock option plans provided table years ended december total intrinsic value stock options exercised fair value stock options vested cash received exercise stock options table contents summary nonvested rsu psu activity shares thousands follows rsus psus weighted weighted average average number grant date number grant date shares fair value shares fair value nonvested january granted vested forfeited nonvested december december million total pretax unrecognized compensation expense related nonvested stock options rsu psu awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses pension postretirement benefit plans company defined benefit pension plans covering eligible employees united states certain international subsidiaries addition company provides medical benefits principally eligible us retirees dependents postretirement benefit plans company uses december yearend measurement date pension plans postretirement benefit plans net periodic benefit cost net periodic benefit cost credit pension postretirement benefit plans consisted following components pension benefits us international postretirement benefits years ended december service cost interest cost expected return plan assets amortization unrecognized prior service cost net loss amortization termination benefits curtailments settlements net periodic benefit cost credit changes net periodic benefit cost credit year year pension plans largely attributable changes discount rate affecting net loss amortization connection restructuring actions see note termination charges recorded pension postretirement benefit plans related expanded eligibility certain employees exiting merck also connection restructuring activities curtailments recorded pension postretirement benefit plans settlements recorded certain us international pension plans reflected table components net periodic benefit cost credit service cost component included income expense net see note exception certain amounts termination benefits curtailments settlements recorded restructuring costs event giving rise termination benefits curtailment settlement related restructuring actions noted table contents obligations funded status summarized information changes plan assets benefit obligations funded status amounts recorded december follows pension benefits postretirement us international benefits fair value plan assets january actual return plan assets company contributions net effects exchange rate changes benefits paid settlements fair value plan assets december benefit obligation january service cost interest cost actuarial gains losses benefits paid effects exchange rate changes plan amendments curtailments termination benefits settlements benefit obligation december funded status december recognized assets accrued current liabilities noncurrent liabilities actuarial gains losses primarily reflect changes discount rates december accumulated benefit obligation billion billion respectively pension plans billion billion respectively related us pension plans table contents information related funded status selected pension plans december follows us international pension plans projected benefit obligation excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligation excess plan assets accumulated benefit obligation fair value plan assets plan assets entities required use fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well instruments determination fair value requires significant judgment estimation december million million respectively approximately respectively companys pension investments categorized level assets inputs used measure financial assets fall within one level described categorization based lowest level input significant fair value measurement instrument table contents fair values companys pension plan assets december asset category follows fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total us pension plans assets cash cash equivalents investment funds developed markets equities emerging markets equities equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments net assets fair value hierarchy investments measured nav plan assets fair value international pension plans assets cash cash equivalents investment funds developed markets equities emerging markets equities government agency obligations corporate obligations fixed income obligations real estate equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments insurance contracts net assets fair value hierarchy investments measured nav plan assets fair value certain investments measured net asset value nav per share equivalent practical expedient classified fair value hierarchy fair value amounts presented table intended permit reconciliation fair value hierarchy fair value plan assets december plans level investments real estate funds generally valued market appraisals underlying investments funds plans level investments insurance contracts generally valued using crediting rate approximates market returns invest underlying securities whose market values unobservable determined using pricing models discounted cash flow methodologies similar techniques table contents table provides summary changes fair value including transfers andor financial assets measured fair value using significant unobservable inputs level companys pension plan assets insurance real insurance real contracts estate total contracts estate total us pension plans balance january actual return plan assets relating assets still held december relating assets sold year purchases sales net balance december international pension plans balance january actual return plan assets relating assets still held december purchases sales net transfers level balance december fair values companys postretirement benefit plan assets december asset category follows fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total assets cash cash equivalents investment funds developed markets equities emerging markets equities government agency obligations equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities net assets fair value hierarchy investments measured nav plan assets fair value certain investments measured net asset value nav per share equivalent practical expedient classified fair value hierarchy fair value amounts presented table intended permit reconciliation fair value hierarchy fair value plan assets december company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation table contents plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests international pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines expected contributions expected contributions approximately million us pension plans approximately million international pension plans approximately million postretirement benefit plans expected benefit payments expected benefit payments follows international pension postretirement us pension benefits benefits benefits expected benefit payments based assumptions used measure benefit obligations include estimated future employee service amounts recognized comprehensive income net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions net loss amounts excess certain thresholds amortized net periodic benefit cost average remaining service life employees following amounts reflected components oci pension plans postretirement us international benefit plans years ended december net loss gain arising period prior service cost credit arising period net loss amortization included benefit cost prior service credit cost amortization included benefit cost estimated net loss gain prior service cost credit amounts amortized aoci net periodic benefit cost million million respectively pension plans million million respectively relates us pension plans million million respectively postretirement benefit plans table contents actuarial assumptions company reassesses benefit plan assumptions regular basis weighted average assumptions used determining us pension postretirement benefit plan international pension plan information follows us pension postretirement benefit plans international pension plans december net periodic benefit cost discount rate expected rate return plan assets salary growth rate benefit obligation discount rate salary growth rate pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid determined plan basis expected rate return within plan developed considering longterm historical returns data current market conditions actual returns plan assets using reference information longterm return expectations asset category weighted average expected return plans target portfolio developed according allocation among investment categories expected portfolio performance reflects contribution active management appropriate expected rate return companys us pension postretirement benefit plans range compared range decrease primarily due modest shift asset allocation change weightedaverage expected return us pension postretirement benefit plan assets due relative weighting referenced plans assets health care cost trend rate assumptions postretirement benefit plans follows december health care cost trend rate assumed next year rate cost trend rate assumed decline year trend rate reaches ultimate trend rate one percentage point change health care cost trend rate would following effects one percentage point increase decrease effect total service interest cost components effect benefit obligation savings plans company also maintains defined contribution savings plans united states company matches percentage employees contributions consistent provisions plan employee eligible total employer contributions plans million million million respectively table contents income expense net income expense net consisted years ended december interest income interest expense exchange losses gains income investments equity securities net net periodic defined benefit plan credit cost service cost net includes net realized unrealized gains losses investments equity securities either owned directly ownership interests investment funds income investments equity securities net reflects recognition unrealized net gains pursuant prospective adoption asu january see note increase income investments equity securities net driven primarily higher realized gains sales net presented table includes gain million related settlement certain patent litigation see note income million related astrazenecas option exercise see note gain million resulting receipt milestone payment outlicensed migraine clinical development program net also includes million goodwill impairment charges related certain businesses healthcare services segment see note well million charges related writedown assets held sale fair value anticipation dissolution companys joint venture supera farma laboratorios sa brazil net includes income million related astrazenecas option exercise million loss extinguishment debt see note net includes charge million related previously disclosed settlement worldwide patent litigation related keytruda gain million related settlement patent litigation gains million resulting receipt milestone payments outlicensed migraine clinical development programs million income related astrazenecas option exercise interest paid million million million table contents taxes income reconciliation effective tax rate us statutory rate follows amount tax rate amount tax rate amount tax rate us statutory rate applied income taxes differential arising impact tcja valuation allowances impact purchase accounting adjustments including amortization state taxes restructuring foreign earnings rd tax credit tax settlements includes tax effects losses foreign subsidiaries miscellaneous items companys effective tax rate reflected provisional impact tax cuts jobs act tcja enacted december among provisions tcja reduced us federal corporate statutory tax rate effective january requires companies pay onetime transition tax undistributed earnings certain foreign subsidiaries creates new taxes certain foreign sourced earnings company reflected impact tcja financial statements however since application certain provisions tcja remained subject interpretation certain instances company made reasonable estimates effects tcja amounts finalized described onetime transition tax based companys post undistributed earnings profits ep substantial portion undistributed ep company previously provided deferred taxes earnings deemed merck retained indefinitely subsidiary companies reinvestment company recorded provisional amount onetime transition tax liability billion provisional amount reduced reversal billion deferred taxes previously recorded connection merger scheringplough corporation certain undistributed foreign ep basis revised calculations post undistributed foreign ep finalization amounts held cash specified assets company recognized measurementperiod adjustment million related transition tax obligation corresponding adjustment income tax expense period resulting revised transition tax obligation billion company anticipates able utilize certain foreign tax credits partially reduce transition tax payment permitted tcja company elected pay onetime transition tax period eight years payment amount due remaining transition tax liability december billion million included income taxes payable remainder billion included noncurrent liabilities result tcja company made determination longer indefinitely reinvested respect undistributed earnings foreign subsidiaries provided deferred tax liability withholding tax would apply company remeasured deferred tax assets liabilities new federal statutory tax rate resulted provisional deferred tax benefit million basis clarifications deferred tax benefit calculation company recorded measurementperiod adjustments million related deferred income taxes beginning tcja includes tax global intangible lowtaxed income gilti defined tcja company made accounting policy election account tax effects gilti tax income tax provision future periods tax arises table contents foreign earnings tax rate differentials tax rate reconciliation primarily reflect impacts operations jurisdictions different tax rates united states particularly ireland switzerland well singapore puerto rico operate tax incentive grants begin expire earnings indefinitely reinvested thereby yielding favorable impact effective tax rate compared us statutory rate foreign earnings tax rate differentials include impact intangible asset impairment charges amortization purchase accounting adjustments restructuring costs items presented separately represent significant separately disclosed pretax cost charge substantial portion items relates jurisdictions lower tax rates united states therefore impact recording expense items lower tax rate jurisdictions unfavorable impact effective tax rate compared us statutory rate income taxes consisted years ended december domestic foreign taxes income consisted years ended december current provision federal foreign state deferred provision federal foreign state table contents deferred income taxes december consisted assets liabilities assets liabilities product intangibles licenses inventory related accelerated depreciation pensions postretirement benefits compensation related unrecognized tax benefits net operating losses tax credit carryforwards subtotal valuation allowance total deferred taxes net deferred income taxes recognized assets deferred income taxes company net operating loss nol carryforwards several jurisdictions december million deferred taxes nol carryforwards relate foreign jurisdictions valuation allowances billion established foreign nol carryforwards foreign deferred tax assets company nol carryforwards relating us jurisdictions income taxes paid billion billion billion respectively tax benefits relating stock option exercises million million million reconciliation beginning ending amount unrecognized tax benefits follows balance january additions related current year positions additions related prior year positions reductions tax positions prior years settlements lapse statute limitations balance december amounts reflect settlements irs discussed company recognize unrecognized tax benefits billion december income tax provision would reflect favorable net impact billion company examination numerous tax authorities various jurisdictions globally company believes reasonably possible total amount unrecognized tax benefits december could decrease approximately million next months result various audit closures settlements expiration statute limitations ultimate finalization companys examinations relevant taxing authorities include formal administrative legal proceedings could significant impact timing reversal unrecognized tax benefits company believes reserves uncertain tax positions adequate cover existing risks exposures expenses interest penalties associated uncertain tax positions amounted million million million amounts reflect beneficial impacts various tax settlements including discussed liabilities accrued interest penalties million million december respectively table contents internal revenue service irs concluded examinations mercks us federal income tax returns result company required make payment approximately billion companys reserves unrecognized tax benefits years examination exceeded adjustments relating examination period therefore company recorded net million tax benefit net benefit reflects reductions reserves unrecognized tax benefits tax positions relating years examination partially offset additional reserves tax positions previously reserved well adjustments reserves unrecognized tax benefits relating years remain open examination affected settlement irs currently conducting examinations companys tax returns years addition various state foreign tax examinations progress jurisdictions companys income tax returns open examination period earnings per share calculations earnings per share shares millions follows years ended december net income attributable merck co inc average common shares outstanding common shares issuable average common shares outstanding assuming dilution basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders issuable primarily sharebased compensation plans million million million respectively common shares issuable sharebased compensation plans excluded computation earnings per common share assuming dilution effect would antidilutive table contents comprehensive income loss changes aoci component follows employee cumulative accumulated benefit translation comprehensive derivatives investments plans adjustment income loss balance january net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes adoption asu see note adoption asu see note balance december net taxes relates foreign currency cash flow hedges reclassified aoci sales represents net realized gains losses sales availableforsale investments reclassified aoci income expense net amounts included investments debt equity securities however result adoption asu see note amounts relate investments available forsale debt securities includes net amortization prior service cost actuarial gains losses included net periodic benefit cost see note includes pension plan net loss billion billion december respectively postretirement benefit plan net gain loss million million december respectively well pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december respectively table contents segment reporting companys operations principally managed products basis include four operating segments pharmaceutical animal health healthcare services alliances segments pharmaceutical animal health segments reportable segments animal health segment met criteria separate reporting became reportable segment pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities large component pediatric adolescent vaccine sales made us centers disease control prevention vaccines children program funded us government additionally company sells vaccines federal government placement vaccine stockpiles sales vaccines major european markets marketed companys spmsd joint venture termination december see note animal health segment discovers develops manufactures markets animal health products including pharmaceutical vaccine products prevention treatment control disease major livestock companion animal species company sells veterinarians distributors animal producers healthcare services segment provides services solutions focus engagement health analytics clinical services improve value care delivered patients alliances segment primarily includes activity companys relationship astrazeneca lp related sales nexium prilosec concluded see note table contents sales companys products follows years ended december us intl total us intl total us intl total pharmaceutical oncology keytruda emend temodar alliance revenue lynparza alliance revenue lenvima vaccines gardasilgardasil proquadmmr iivarivax pneumovax rotateq zostavax hospital acute care bridion noxafil invanz cubicin cancidas primaxin immunology simponi remicade neuroscience belsomra virology isentressisentress hd zepatier cardiovascular zetia vytorin atozet adempas diabetes januvia janumet womens health nuvaring implanonnexplanon diversified brands singulair cozaarhyzaar nasonex arcoxia follistim aq dulera fosamax pharmaceutical total pharmaceutical segment sales animal health livestock companion animals total animal health segment sales segment sales total segment sales us plus international may equal total due rounding december merck sanofi terminated equallyowned joint venture spmsd marketed vaccines major european markets see note accordingly vaccine sales include sales european markets previously part spmsd amounts include sales vaccines sold spmsd results reflected equity income affiliates included income expense net amounts however include supply sales spmsd pharmaceutical primarily reflects sales human health pharmaceutical products including products within franchises listed separately represents nonreportable segments healthcare services alliances primarily comprised miscellaneous corporate revenues including revenue hedging activities well thirdparty manufacturing sales also includes approximately million million million respectively related sale marketing rights certain products table contents consolidated revenues geographic area derived follows years ended december united states europe middle east africa japan asia pacific japan china latin america china reconciliation segment profits income taxes follows years ended december segment profits pharmaceutical segment animal health segment segments total segment profits profits unallocated interest income interest expense depreciation amortization research development amortization purchase accounting adjustments restructuring costs charge related termination collaboration agreement samsung loss extinguishment debt gain sale certain migraine clinical development programs charge related settlement worldwide keytruda patent litigation unallocated net pharmaceutical segment profits comprised segment sales less standard costs well selling general administrative expenses research development costs directly incurred segment animal health segment profits comprised segment sales less cost sales well selling general administrative expenses research development costs directly incurred segment internal management reporting presented chief operating decision maker merck allocate remaining cost sales included segment profits described research development expenses incurred merck research laboratories companys research development division focuses human healthrelated activities general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits addition costs related restructuring activities well amortization purchase accounting adjustments allocated segments profits primarily comprised miscellaneous corporate profits well operating profits related thirdparty manufacturing sales table contents unallocated net includes expenses corporate manufacturing cost centers goodwill intangible asset impairment charges gains losses sales businesses expense income related changes estimated fair value liabilities contingent consideration miscellaneous income expense items company adopted new accounting standard related classification certain defined benefit plan costs see note resulted change measurement segment profits net periodic benefit cost credit service cost longer included component segment profits prior period amounts recast conform new presentation equity income loss affiliates depreciation amortization included segment profits follows pharmaceutical animal health total year ended december included segment profits equity income loss affiliates depreciation amortization year ended december included segment profits equity income loss affiliates depreciation amortization year ended december included segment profits equity income loss affiliates depreciation amortization property plant equipment net geographic area located follows december united states europe middle east africa asia pacific japan china latin america china japan company disaggregate assets products services basis internal management reporting therefore information presented table contents report independent registered public accounting firm board directors stockholders merck co inc opinions financial statements internal control financial reporting audited accompanying consolidated balance sheets merck co inc subsidiaries company december related consolidated statements income comprehensive income equity cash flows three years period ended december including related notes collectively referred consolidated financial statements also audited company 's internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso opinion consolidated financial statements referred present fairly material respects financial position company december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued coso change accounting principle discussed note consolidated financial statements company changed manner accounts retirement benefits basis opinions companys management responsible consolidated financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included managements report internal control financial reporting appearing item responsibility express opinions companys consolidated financial statements company 's internal control financial reporting based audits public accounting firm registered public company accounting oversight board united states pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audits obtain reasonable assurance whether consolidated financial statements free material misstatement whether due error fraud whether effective internal control financial reporting maintained material respects audits consolidated financial statements included performing procedures assess risks material misstatement consolidated financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures consolidated financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation consolidated financial statements audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions table contents definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecoopers llp florham park new jersey february served companys auditor since table contents b supplementary data selected quarterly financial data contained condensed interim financial data table condensed interim financial data unaudited millions except per share amounts th q rd q nd q st q sales cost sales selling general administrative research development restructuring costs income expense net income taxes net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders sales cost sales selling general administrative research development restructuring costs income expense net income taxes net loss income attributable merck co inc basic loss earnings per common share attributable merck co inc common shareholders loss earnings per common share assuming dilution attributable merck co inc common shareholders amounts include provisional net tax charge related enactment us tax legislation see note amounts include charge related formation collaboration astrazeneca see note amounts include charge related formation collaboration eisai see note amounts reflect acquisition divestiturerelated costs see note impact restructuring actions see note amounts recast result adoption january new accounting standard related classification certain defined benefit plan costs impact net income result adopting new accounting standard see note table contents item changes disagreements accountants accounting financial disclosure applicable item controls procedures management company participation chief executive officer chief financial officer evaluated effectiveness companys disclosure controls procedures based evaluation end period covered companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ae de securities exchange act amended act effective fourth quarter changes internal control financial reporting materially affected reasonably likely materially affect companys internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af act management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december pricewaterhousecoopers llp independent registered public accounting firm performed assessment effectiveness companys internal control financial reporting attestation report included filing managements report managements responsibility financial statements responsibility integrity objectivity companys financial statements rests management financial statements report managements stewardship company assets statements prepared conformity generally accepted accounting principles accordingly include amounts based managements best estimates judgments nonfinancial information included annual report also prepared management consistent financial statements assure financial information reliable assets safeguarded management maintains effective system internal controls procedures important elements include careful selection training development operating financial managers organization provides appropriate division responsibility communications aimed assuring company policies procedures understood throughout organization staff internal auditors regularly monitors adequacy application internal controls worldwide basis ensure personnel continue understand system internal controls procedures policies concerning good prudent business practices annually employees company required complete code conduct training training reinforces importance understanding internal controls reviewing key corporate policies procedures systems addition company compliance programs including ethical business practices program reinforce companys longstanding commitment high ethical standards conduct business financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows formal certification securities exchange commission included filing managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af securities exchange act companys internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states america management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued table contents committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december inherent limitations internal control financial reporting may prevent detect misstatements projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein kenneth c frazier robert davis chairman president executive vice president global services chief executive officer chief financial officer item b information none table contents part iii item directors executive officers corporate governance required information directors nominees incorporated reference discussion proposal election directors companys proxy statement annual meeting shareholders held may information executive officers set forth part document required information compliance section securities exchange act incorporated reference discussion heading section beneficial ownership reporting compliance companys proxy statement annual meeting shareholders held may company code conduct values standards applicable employees including principal executive officer principal financial officer principal accounting officer controller code conduct available companys website wwwmerckcomaboutcodeofconductpdf company intends disclose future amendments certain provisions code conduct waivers code conduct granted executive officers directors website within four business days following date amendment waiver every merck employee responsible adhering business practices accordance law ethical principles reflect highest standards corporate individual behavior required information identification audit committee audit committee financial expert incorporated reference discussion heading board meetings committees companys proxy statement annual meeting shareholders held may item executive compensation information required executive compensation incorporated reference discussion headings compensation discussion analysis summary compensation table compensation table grants planbased awards table outstanding equity awards table option exercises stock vested table pension benefits table nonqualified deferred compensation table potential payments upon termination change control including discussion subheadings separation change control well footnote information various tables companys proxy statement annual meeting shareholders held may required information director compensation incorporated reference discussion heading director compensation related director compensation table schedule director fees table companys proxy statement annual meeting shareholders held may required information headings compensation benefits committee interlocks insider participation compensation benefits committee report incorporated reference companys proxy statement annual meeting shareholders held may table contents item security ownership certain beneficial owners management related stockholder matters information respect security ownership certain beneficial owners management incorporated reference discussion heading stock ownership information companys proxy statement annual meeting shareholders held may equity compensation plan information following table summarizes information options warrants rights equity compensation companys equity compensation plans close business december table include information tax qualified plans merck us savings plan number number securities remaining securities available future issued upon weightedaverage issuance equity exercise exercise price compensation plans outstanding outstanding excluding options warrants options warrants securities rights rights reflected column plan category b c equity compensation plans approved security holders equity compensation plans approved security holders total includes options purchase shares company common stock rights following shareholderapproved plans merck sharp dohme incentive stock plans merck co inc nonemployee directors stock option plans merck co inc scheringplough stock incentive plans excludes approximately shares restricted stock units performance share units assuming maximum payouts merck sharp dohme incentive stock plans also excludes shares phantom stock deferred msd employee deferral program shares phantom stock deferred merck co inc plan deferred payment directors compensation item certain relationships related transactions director independence required information transactions related persons incorporated reference discussion heading related person transactions companys proxy statement annual meeting shareholders held may required information director independence incorporated reference discussion heading independence directors companys proxy statement annual meeting shareholders held may item principal accountant fees services information required item incorporated reference discussion proposal ratification appointment independent registered public accounting firm beginning caption preapproval policy services independent registered public accounting firm fees services provided independent registered public accounting firm companys proxy statement annual meeting shareholders held may table contents part iv item